

Assessment of Radiologic Progression in Rheumatoid Arthritis: A Randomized, Controlled Trial <i>James F. Fries, Daniel A. Bloch, John T. Sharp, Dennis J. McShane, Patricia Spitz, Gilbert B. Bluhm, Deborah Forrester, Harry Genant, Philip Gofton, Steven Richman, Barbara Weissman, and Frederick Wolfe</i> .....	1
Distal Interphalangeal Joint Involvement in Rheumatoid Arthritis <i>Janel Jacob, David Sartoris, Sevil Kursunoglu, Deborah Pate, Carlos J. Pineda, Richard M. Braun, Donald Resnick, and Michael H. Weisman</i> .....	10
Lymphoid Irradiation in Intractable Rheumatoid Arthritis: A Double-Blind, Randomized Study Comparing 750-Rad Treatment with 2,000-Rad Treatment <i>John G. Hanly, Jaythoon Hassan, Michael Moriarty, Ciaran Barry, Jack Molony, Eoin Casey, Alex Whelan, Conleth Feighery, and Barry Bresnihan</i> .....	16
Effect of Total Lymphoid Irradiation on Levels of Serum Autoantibodies in Systemic Lupus Erythematosus and in Rheumatoid Arthritis <i>Amir Tanay, Gerald Schiffman, and Samuel Strober</i> .....	26
Methylprednisolone Infusion Therapy in Rheumatoid Arthritis Patients: The Effect on Synovial Fluid Lymphocyte Subsets and Inflammatory Indices <i>James V. Bertouch, Peter J. Roberts-Thomson, Malcolm D. Smith, Timothy G. Woodruff, Peter M. Brooks, and John Bradley</i> .....	32
IgM Anti-Histone H-3 Antibody Associated with Undifferentiated Rheumatic Disease Syndromes <i>Daniel P. Molden, Gary L. Klipple, Carol L. Peebles, Robert L. Rubin, Robert M. Nakamura, and Eng M. Tan</i> .....	39
The Value of Biopsy in Patients with Monarticular Juvenile Rheumatoid Arthritis of Recent Onset <i>Yrjö T. Konttinen, Ville Bergroth, Ilkka Kunnamo, and Jarkko Haapasaari</i> .....	47
Persistence of Scleroderma-Like Phenotype in Normal Fibroblasts After Prolonged Exposure to Soluble Mediators From Mononuclear Cells <i>Jennifer G. Worrall, Theresa L. Whiteside, Robert K. Prince, Robert B. Buckingham, Irene Stachura, and Gerald P. Rodnan</i> .....	54
Rheumatic Diseases in an Inuit Population <i>Kiem Oen, Brian Postl, Ian M. Chalmers, Norma Ling, Maria Louise Schroeder, Fletcher D. Baragar, Liam Martin, Martin Reed, and Paul Major</i> .....	65
Alterations in Macrophage Collagenase Secretion Induced by Gold Sodium Thiomalate <i>David M. Spalding, Walter L. Darby, III, and Louis W. Heck</i> .....	75
The Allopurinol Hypersensitivity Syndrome: Unnecessary Morbidity and Mortality <i>Joyce Z. Singer and Stanley L. Wallace</i> .....	82
Composition and Glycosaminoglycan Metabolism of Articular Cartilage From Habitually Loaded and Habitually Unloaded Sites <i>Sally D. Slowman and Kenneth D. Brandt</i> .....	88
Articular Cartilage Proteoglycans From Normal and Osteoarthritic Mice <i>Katherine S. Rostand, John R. Baker, Bruce Caterson, and James E. Christner</i> .....	95
Homologous Type II Collagen Induces Chronic and Progressive Arthritis in Mice <i>Rikard Holmdahl, Liselott Jansson, Erik Larsson, Kristofer Rubin, and Lars Klareskog</i> .....	106
Hereditary Joint Disorder in Progressive Ankylosis (ank/ank) Mice. II. Effect of High-Dose Hydrocortisone Treatment on Inflammation and Intraarticular Calcium Hydroxyapatite Deposits <i>Frances T. Hakim, Kenneth S. Brown, and Joost J. Oppenheim</i> .....	114
Brief Reports Systemic Sclerosis (Scleroderma) and Multiple Sclerosis <i>David C. Trostle, David Helfrich, and Thomas A. Medsger, Jr.</i> .....	124

Assessment of Radiologic Progression in Rheumatoid Arthritis: A Randomized, Controlled Trial <i>James F. Fries, Daniel A. Bloch, John T. Sharp, Dennis J. McShane, Patricia Spitz, Gilbert B. Bluhm, Deborah Forrester, Harry Genant, Philip Gofton, Steven Richman, Barbara Weissman, and Frederick Wolfe</i> .....	1
Distal Interphalangeal Joint Involvement in Rheumatoid Arthritis <i>Janel Jacob, David Sartoris, Sevil Kursunoglu, Deborah Pate, Carlos J. Pineda, Richard M. Braun, Donald Resnick, and Michael H. Weisman</i> .....	10
Lymphoid Irradiation in Intractable Rheumatoid Arthritis: A Double-Blind, Randomized Study Comparing 750-Rad Treatment with 2,000-Rad Treatment <i>John G. Hanly, Jaythoon Hassan, Michael Moriarty, Ciaran Barry, Jack Molony, Eoin Casey, Alex Whelan, Conleth Feighery, and Barry Bresnihan</i> .....	16
Effect of Total Lymphoid Irradiation on Levels of Serum Autoantibodies in Systemic Lupus Erythematosus and in Rheumatoid Arthritis <i>Amir Tanay, Gerald Schiffman, and Samuel Strober</i> .....	26
Methylprednisolone Infusion Therapy in Rheumatoid Arthritis Patients: The Effect on Synovial Fluid Lymphocyte Subsets and Inflammatory Indices <i>James V. Bertouch, Peter J. Roberts-Thomson, Malcolm D. Smith, Timothy G. Woodruff, Peter M. Brooks, and John Bradley</i> .....	32
IgM Anti-Histone H-3 Antibody Associated with Undifferentiated Rheumatic Disease Syndromes <i>Daniel P. Molden, Gary L. Klipple, Carol L. Peebles, Robert L. Rubin, Robert M. Nakamura, and Eng M. Tan</i> .....	39
The Value of Biopsy in Patients with Monarticular Juvenile Rheumatoid Arthritis of Recent Onset <i>Yrjö T. Konttinen, Ville Bergroth, Ilkka Kunnamo, and Jarkko Haapasaari</i> .....	47
Persistence of Scleroderma-Like Phenotype in Normal Fibroblasts After Prolonged Exposure to Soluble Mediators From Mononuclear Cells <i>Jennifer G. Worrall, Theresa L. Whiteside, Robert K. Prince, Robert B. Buckingham, Irene Stachura, and Gerald P. Rodnan</i> .....	54
Rheumatic Diseases in an Inuit Population <i>Kiem Oen, Brian Postl, Ian M. Chalmers, Norma Ling, Maria Louise Schroeder, Fletcher D. Baragar, Liam Martin, Martin Reed, and Paul Major</i> .....	65
Alterations in Macrophage Collagenase Secretion Induced by Gold Sodium Thiomalate <i>David M. Spalding, Walter L. Darby, III, and Louis W. Heck</i> .....	75
The Allopurinol Hypersensitivity Syndrome: Unnecessary Morbidity and Mortality <i>Joyce Z. Singer and Stanley L. Wallace</i> .....	82
Composition and Glycosaminoglycan Metabolism of Articular Cartilage From Habitually Loaded and Habitually Unloaded Sites <i>Sally D. Slowman and Kenneth D. Brandt</i> .....	88
Articular Cartilage Proteoglycans From Normal and Osteoarthritic Mice <i>Katherine S. Rostand, John R. Baker, Bruce Caterson, and James E. Christner</i> .....	95
Homologous Type II Collagen Induces Chronic and Progressive Arthritis in Mice <i>Rikard Holmdahl, Liselott Jansson, Erik Larsson, Kristofer Rubin, and Lars Klareskog</i> .....	106
Hereditary Joint Disorder in Progressive Ankylosis (ank/ank) Mice. II. Effect of High-Dose Hydrocortisone Treatment on Inflammation and Intraarticular Calcium Hydroxyapatite Deposits <i>Frances T. Hakim, Kenneth S. Brown, and Joost J. Oppenheim</i> .....	114
Brief Reports Systemic Sclerosis (Scleroderma) and Multiple Sclerosis <i>David C. Trostle, David Helfrich, and Thomas A. Medsger, Jr.</i> .....	124

Ultrastructural Evidence for Persistent Gold in the Bone Marrow of a Patient with Aplastic Anemia <i>Bruce D. Cheson, Daniel O. Clegg, and Farhad Moatamed</i> .....	128
Megaloblastic Pancytopenia in a Patient Receiving Concurrent Methotrexate and Trimethoprim-Sulfamethoxazole Treatment <i>Michael Maricic, Mark Davis, and Eric P. Gall</i> .....	133
Pseudoaneurysm of the Vertebral Artery: A Complication of Rheumatoid Cervical Spine Disease <i>F. Alexander Fedele, George Ho, Jr., and Brian A. Dorman</i> .....	136
Anticentriole Antibody in a Patient with Progressive Systemic Sclerosis <i>Thomas G. Osborn, Jan S. Ryerse, Nancy E. Bauer, Jesse M. Urhahn, Dana Blair, and Terry L. Moore</i> .....	142
<b>Letters</b>	
Accelerated Hypertension Associated with Lupus Anticoagulant and False-Positive VDRL in Systemic Lupus Erythematosus <i>J. Jouquan, Y. Pennec, D. Mottier, P. Youinou, J. Cledes, J. P. Leroy, and G. Le Menn</i> .....	147
Antihistone Antibodies and Drug-Induced Lupus Erythematosus <i>J. B. Peter and R. L. Dawkins</i> .....	148
Reply <i>Alan Epstein and Peter Barland</i> .....	148
Subsets of Rheumatoid Arthritis in the Aged <i>L. A. Healey</i> .....	149
Juxtaarticular Osteoporosis <i>Howard Duncan and Jeanne M. Riddle</i> .....	149
Reply <i>Shunichi Shiozawa and Shinichi Shimizu</i> .....	150
DR2 Positivity and Response to Methotrexate in Rheumatoid Arthritis <i>Graciela S. Alarcón, Jean M. Guyton, Ronald T. Acton, Bruce O. Barger, and William J. Koopman</i> ...	151
Doctor Yvan: The Father of Reiter's Syndrome <i>P. Seror</i> .....	152
<b>ARA Announcements</b> .....	A15

<b>VOLUME 29</b>	<b>JANUARY SUPPLEMENT</b>	<b>NO. 1</b>
------------------	---------------------------	--------------

1985 Regional Meetings of the American Rheumatism Association .....	S1
---	----

<b>VOLUME 29</b>	<b>FEBRUARY</b>	<b>NO. 2</b>
------------------	-----------------	--------------

Treatment of Rheumatoid Synovitis of the Knee with Intraarticular Injection of Dysprosium 165-Ferric Hydroxide Macroaggregates <i>Clement B. Sledge, Joseph D. Zuckerman, Michael R. Zalutsky, Robert W. Atcher, Sonya Shortkroff, David R. Lionberger, Howard A. Rose, Brian J. Hurson, Peter A. Lankenner, Jr., Ronald J. Anderson, and William A. Bloomer</i> .....	153
Histamine Stimulates Prostaglandin E Production by Rheumatoid Synovial Cells and Human Articular Chondrocytes in Culture <i>David J. Taylor, Joan R. Yoffe, Diane M. Brown, and David E. Woolley</i> .....	160
Phagocytosis and Intracellular Killing of <i>Staphylococcus Aureus</i> by Polymorphonuclear Cells From Synovial Fluid of Patients with Rheumatoid Arthritis <i>Ferdinand C. Breedveld, Geertruida J. M. LaFeber, Maria T. van den Barselaar, Jaap T. van Dissel, and Peter C. J. Leijh</i> .....	166
Collagen Antibodies in Rheumatoid Arthritis: Significance of Antibodies to Denatured Collagen and Their Association with HLA-DR4 <i>Merrill Rowley, Brian Tait, Ian R. Mackay, Tim Cunningham, and Brian Phillips</i> .....	174
Type C Retroviruses of the Human T Cell Leukemia Family are Not Evident in Patients with Systemic Lupus Erythematosus <i>D. T. Boumpas, M. Popovic, D. L. Mann, J. E. Balow, and G. C. Tsokos</i> .....	185
Nailfold Capillary Microscopy in Mixed Connective Tissue Disease: Comparison with Systemic Sclerosis and Systemic Lupus Erythematosus <i>Françoise Granier, Michel Vayssairat, Pascal Priollet, and Edward Housset</i> .....	189

<b>Anti-Ro (SS-A) and Anti-La (SS-B) in Patients with Sjögren's Syndrome</b> <i>John B. Harley, Elaine L. Alexander, Wilma B. Bias, Owen F. Fox, Thomas T. Provost, Morris Reichlin, Hajime Yamagata, and Frank C. Arnett</i> .....	196
<b>Immunofluorescence Studies of Florid Rheumatic Aschoff Lesions</b> <i>Gunnar Husby, Ramesh Arora, Ralph C. Williams, Jr., Ban An Khaw, Edgar Haber, and Cooley Butler</i> .....	207
<b>Abnormal B Cell Function in Patients with Behçet's Disease</b> <i>Noboru Suzuki, Tsuyoshi Sakane, Yuji Ueda, and Tokugoro Tsunematsu</i> .....	212
<b>Food-Induced (Allergic) Arthritis: Inflammatory Arthritis Exacerbated By Milk</b> <i>Richard S. Panush, Robert M. Stroud, and Ella M. Webster</i> .....	220
<b>Infectious Arthritis in Renal Transplant Patients</b> <i>John S. Bomalaski, Paul K. Williamson, and Carl S. Goldstein</i> .....	227
<b>POEMS Syndrome: Study of a Patient with Proteinuria, Microangiopathic Glomerulopathy, and Renal Enlargement</b> <i>Adel G. Fam, Joel D. Rubenstein, and Donald H. Cowan</i> .....	233
<b>Naturally Occurring Antibody Response to DNA is Associated with the Response to Retroviral gp70 in Autoimmune New Zealand Mice</b> <i>Toshikazu Shirai, Kiyoe Ohta, Atsushi Kohno, Fukumi Furukawa, Haruyoshi Yoshida, Naoki Maruyama, and Sachiko Hirose</i> .....	242
<b>Experimental Osteoarthritis Induced by Selective Myectomy and Tendotomy</b> <i>Christiane L. Arsever and Giles G. Bole</i> .....	251
<b>Inhibition by Cyclosporin A of Streptococcal Cell Wall-Induced Arthritis and Hepatic Granulomas in Rats</b> <i>David E. Yocum, Janice B. Allen, Sharon M. Wahl, Gary B. Calandra, and Ronald L. Wilder</i> .....	262
<b>A Study of Classification Criteria For a Diagnosis of Juvenile Rheumatoid Arthritis</b> <i>J. T. Cassidy, J. E. Levinson, J. C. Bass, J. Baum, E. J. Brewer, Jr., C. W. Fink, V. Hanson, J. C. Jacobs, A. T. Masi, J. G. Schaller, J. F. Fries, D. McShane, and D. Young</i> .....	274
<b>Brief Reports</b>	
Colonic Telangiectasias in a Patient with Progressive Systemic Sclerosis <i>Murray Baron and Herbert Srolovitz</i> .....	282
Light and Electron Microscopic Findings in POEMS, or Japanese Multisystem Syndrome <i>Elliott L. Semble, Venkata R. Challa, David A. Holt, and Edward J. Pisko</i> .....	286
Secretion of Higher Levels of Active Proteoglycanases From Human Osteoarthritic Chondrocytes <i>Takayuki Nojima, Christine A. Towle, Henry J. Mankin, and Benjamin V. Treadwell</i> .....	292
Immune Complex Arthritis in a Patient with <i>Schistosoma mansoni</i> Infection <i>David I. Greenfield, William S. Hughes, Terry M. Phillips, and Werner F. Barth</i> .....	296
<b>Letters</b>	
C3b Receptor (CR1) on Erythrocytes and the HLA-DR3 Antigen <i>M. Malaise, A. Desoroux, P. Mahieu, and P. Franchimont</i> .....	300
Destructive Spondylarthropathy in Hemodialyzed Patients: Possible Role of Amyloidosis <i>Jean-Luc Sebert, Patrice Fardellone, Annick Marie, Hervé Deramond, Guy Lambrey, Daniel Legars, Pierre Galibert, André Smajda, and Albert Fournier</i> .....	301
HLA-Bw35 and Mucocutaneous Toxicity in Rheumatoid Arthritis Patients Treated with Gold <i>Jan Tore Gran and Gunnar Husby</i> .....	303
Explaining the Term "Arthritis" <i>Irving Kushner</i> .....	303
Water-Soluble Gels in Narrowfield Nailfold Capillary Microscopy <i>Fergus Eoin McKiernan</i> .....	304
<b>ARA Announcements</b> .....	A41

VOLUME 29

MARCH

NO. 3

<b>Immunomodulatory Effects of Treatment with Naproxen in Patients with Rheumatic Disease</b> <i>Jan L. Ceuppens, Geert Robaey, Wilfried Verdict, Simonne Vertessen, Hans Deckmyn, and Jan Dequeker</i> .....	305
<b>Enhanced Phospholipase Activity in Peripheral Blood Monocytes from Patients with Rheumatoid Arthritis</b> <i>John S. Bomalaski, Mike A. Clark, and Robert B. Zurier</i> .....	312



$\alpha_2$ -Macroglobulin-Proteinase Complexes as Correlated with $\alpha_1$ -Proteinase Inhibitor-Elastase Complexes in Synovial Fluids of Rheumatoid Arthritis Patients <i>Wolfgang Borth, Attila Dunky, and Knut Kleesiek</i> .....	319
Immunoglobulin from Systemic Lupus Erythematosus Serum Induces Interferon Release by Normal Mononuclear Cells <i>Francisco Ramirez, Ralph C. Williams, Jr., Wilmer L. Sibbitt, Jr., and Robert P. Searles</i> .....	326
Progressive Multifocal Leukoencephalopathy Complicating Systemic Lupus Erythematosus <i>P. Newton, R. D. Aldridge, A. M. Lessells, and P. V. Best</i> .....	337
Effect of Warfarin Sodium Therapy on Excretion of 4-Carboxy-L-Glutamic Acid in Scleroderma, Dermatomyositis, and Myositis Ossificans Progressiva <i>Sterling E. Moore, Adrien A. Jump, and J. Donald Smiley</i> .....	344
Anti-HLA-B27 Antibodies in Sera from Patients with Gram-Negative Bacterial Infections <i>Druie Cavender and Morris Ziff</i> .....	352
Normal Anti-Klebsiella Lymphocytotoxicity in Ankylosing Spondylitis <i>T. Douglas Kinsella, Marvin J. Fritzler, and Raymond M. Lewkonja</i> .....	358
Low Density Lipoprotein Inhibits the Physical Interaction of Phlogistic Crystals and Inflammatory Cells <i>Robert Terkeltaub, Dianne Smeltzer, Linda K. Curtiss, and Mark H. Ginsberg</i> .....	363
Analysis of Interleukin-2 Activity in Patients with Behçet's Disease: Ability of T Cells to Produce and Respond to Interleukin-2 <i>Tsuyoshi Sakane, Noboru Suzuki, Yuji Ueda, Shinsuke Takada, Yohko Murakawa, Takashi Hoshino, Yukie Niwa, and Tokugoro Tsunematsu</i> .....	371
Oxygen Radicals as Effectors of Cartilage Destruction: Direct Degradative Effect on Matrix Components and Indirect Action Via Activation of Latent Collagenase from Polymorphonuclear Leukocytes <i>H. Burkhardt, M. Schwingel, H. Menninger, H. W. Macartney, and H. Tschesche</i> .....	379
Evaluation of Arthritis Self-Management Courses Led by Laypersons and by Professionals <i>Judith L. Cohen, Suzanne van Houten Sauter, Robert F. DeVellis, and Brenda McEvoy DeVellis</i> ...	388
Fibronectin in Acute and Chronic Inflammation <i>Vera J. Stecher, John E. Kaplan, Kevin Connolly, Zigmund Mielens, and Jeffrey K. Saelens</i> .....	394
Characterization of the Antibody Response in Mice with Type II Collagen-Induced Arthritis, Using Monoclonal Anti-Type II Collagen Antibodies <i>Rikard Holmdahl, Kristofer Rubin, Lars Klareskog, Erik Larsson, and Hans Wigzell</i> .....	400
Progesterone Secretion in the Rat in Response to an Adjuvant Arthritis Challenge <i>Neal S. Latman, Vimal Kishore, and Brent Bruot</i> .....	411
Adult-Onset Still's Disease: Disease Course and HLA Associations <i>Jacques M. G. W. Wouters, Paul Reekers, and Levinus B. A. van de Putte</i> .....	415
<b>Brief Reports</b>	
Handedness in Systemic Lupus Erythematosus <i>Peter H. Schur</i> .....	419
Concurrence of Subacute Cutaneous Lupus Erythematosus and Rheumatoid Arthritis <i>Stanley Cohen, Peter Stastny, and Richard D. Sontheimer</i> .....	421
Treatment of Gold-Induced Thrombocytopenia by High-Dose Intravenous Gamma Globulin <i>Rose Goldstein, Victor S. Blanchette, Lothar B. Huebsch, and Robert J. R. McKendry</i> .....	426
Reversible Cause of Back Pain and Sciatica in Rheumatoid Arthritis: An Apophyseal Joint Cyst <i>Janel R. Jacob, Michael H. Weisman, Jerrold H. Mink, Allan L. Metzger, Gary R. Feldman, Howard D. Dorfman, Elliott E. Blinderman, and Donald Resnick</i> .....	431
A Familial Syndrome of Pericarditis, Arthritis, Camptodactyly, and Coxa Vara <i>Gülstan Bulutlar, Hasan Yazici, Huri Özdoğan, and Ieke Schreuder</i> .....	436
The Camptodactyly-Arthropathy-Pericarditis Syndrome: Case Report and Literature Review <i>Ronald M. Laxer, Bonnie J. Cameron, David Chaisson, Charles R. Smith, and Leonard D. Stein</i> ...	439
Scalloped Pupils in Familial Amyloid Polyneuropathy <i>Alan Rubinow and Alan S. Cohen</i> .....	445
Long-Term Colchicine Administration Leading to Colchicine Toxicity and Death <i>Michael N. Neuss, Rex M. McCallum, Wayne D. Brenckman, and Harold R. Silberman</i> .....	448
<b>Letters</b>	
D-Penicillamine as a Treatment for Toxic Reactions to Gold Therapy <i>Majda I. Khoury</i> .....	450
Poor Clearance of Gold Using Peritoneal Dialysis for the Treatment of Gold Toxicity <i>Jeffery S. Garland, K. J. Sheth, and Dorothy W. Wortmann</i> .....	450

Nailfold Capillary Abnormalities and Organ Involvement in Scleroderma	
Nella M. Houtman, Cees G. M. Kallenberg, and Aaktje A. Wouda.....	451
Reply	
Hildegard R. Maricq .....	452
Juvenile Primary Fibromyalgia Syndrome	
John J. Calabro and Robert F. Perry .....	452
Reply	
Muhammad B. Yunus and Alfonse T. Masi .....	453
Synovial Amyloidosis and $\beta_2$ -Microglobulin in Patients Undergoing Long-Term Hemodialysis	
T. Bardin, D. Kurtz, J. Zingraff, L. H. Noel, D. Droz, T. Drueke, J. L. Funck-Brentano, P. Lucas, J. Vantelon, P. Hiermaux, and C. Barbanel .....	453
Pressure Erosions: Rheumatoid Arthritis or Calcium Pyrophosphate Dihydrate Crystal Deposition Disease?	
Daniel J. McCarty .....	454
Reply	
William A. Murphy and Barbara Monsees .....	454
Book Reviews.....	455
ARA Announcements.....	A24

## VOLUME 29

## APRIL

## NO. 4

Current Comment: The Lupus Autoantigens and the Pathogenesis of Systemic Lupus Erythematosus	
John A. Hardin .....	457
Interleukin-1 Lymphocyte Chemotactic Activity in Rheumatoid Arthritis Synovial Fluid	
Pierre Miossec, Charles A. Dinarello, and Morris Ziff .....	461
Stimulation of Neovascularization by Human Rheumatoid Synovial Tissue Macrophages	
Alisa E. Koch, Peter J. Poverini, and S. Joseph Leibovich .....	471
Effects of Gold Therapy on the Synthesis and Quantity of Serum and Synovial Fluid IgM, IgG, and IgA	
Rheumatoid Factors in Rheumatoid Arthritis Patients	
John G. Hanly, Jaythoon Hassan, Alex Whelan, Conleth Feighery, and Barry Bresnihan .....	480
A Multicenter Study of Annual Health Service Utilization and Costs in Rheumatoid Arthritis	
Deborah P. Lubeck, Patricia W. Spitz, James F. Fries, Frederick Wolfe, Donald M. Mitchell, and Sanford H. Roth.....	488
The Development of Disability in Rheumatoid Arthritis	
Yvonne S. Sherrer, Daniel A. Bloch, Donald M. Mitchell, Donald Y. Young, and James F. Fries ...	494
Induction of Lupus Inclusions by Sera from Patients with Systemic Lupus Erythematosus	
Steven A. Rich, Timothy R. Owens, M. Cristina Anzola, and Lee E. Bartholomew .....	501
Further Evidence for the Lack of Association Between Acetylator Phenotype and Systemic Lupus Erythematosus	
Alan N. Baer, Raymond L. Woosley, and Theodore Pincus .....	508
Pulmonary Hypertension in the CREST Syndrome Variant of Systemic Sclerosis	
Angela M. Stupi, Virginia D. Steen, Gregory R. Owens, E. Leon Barnes, Gerald P. Rodnan, and Thomas A. Medsger, Jr. ....	515
Interstitial Lung Disease in Scleroderma: Immune Complexes in Sera and Bronchoalveolar Lavage Fluid	
Richard M. Silver, John F. Metcalf, and E. Carwile LeRoy .....	525
An Experimental Model for Hydrogen Peroxide-Induced Tissue Damage: Effects of a Single Inflammatory Mediator on (Peri)articular Tissues	
Joost Schalkwijk, Wim B. van den Berg, Levinus B. A. van de Putte, and Leo A. B. Joosten .....	532
Dietary Fish Oil Reduces Progression of Established Renal Disease in (NZB $\times$ NZW) $F_1$ Mice and Delays Renal Disease in BXSB and MRL/l Strains	
Dwight R. Robinson, James D. Prickett, Gregory T. Makoul, Alfred D. Steinberg, and Robert B. Colvin .....	539
Suppressive Effects of <i>Escherichia Coli</i> on Adjuvant-Induced Arthritis in Germ-Free Rats	
Osamu Kohashi, Yukiko Kohashi, Tokutaro Takahashi, Atsushi Ozawa, and Nobuaki Shigematsu .	547
Special Article: Winners of the 1985 Slide Competition	
Sidney Block and the Audiovisual Aids Subcommittee of the ARA Education Committee .....	554

## Brief Reports

- Bronchiolitis in a Rheumatoid Arthritis Patient Receiving Auranofin  
*J. Desmond O'Duffy, Harvinder S. Luthra, K. Krishnan Unni, and Robert E. Hyatt*..... 556
- D-Penicillamine-Induced Polymyositis in Patients with Rheumatoid Arthritis  
*Koki Takahashi, Tadaatsu Ogita, Hirokazu Okudaira, Sadayoshi Yoshino, Hisayoshi Yoshizawa, and Terumasa Miyamoto* ..... 560
- Necrotizing Systemic Vasculitis with Features of Both Wegener's Granulomatosis and Churg-Strauss Vasculitis  
*Stuart Henochowicz, Diane Eggensperger, Leslie Pierce, and Werner F. Barth*..... 565
- Acute Gout Presenting in the Manubriosternal Joint  
*G. Wallace Kernodle, Jr. and Nancy B. Allen* ..... 570

## Letters

- The Negative Charge of Articular Cartilage Surfaces  
*Ritta Stanesco and S. J. Leibovich* ..... 573
- Cyclosporin A is Effective, But Not Safe, in the Management of Beçhet's Disease  
*B. Wechsler, E. B. Mertani, P. le Hoang, F. de Groc, J. C. Piette, H. Beaufils, B. Aupetit, H. le Minh, and J. Rottembourg* ..... 574
- Reply  
*Robert B. Nussenblatt and Alan G. Palestine* ..... 574
- Human Parvovirus Arthropathy  
*Maxime Dougados, Bernard Amor, Jean Jacques Lefrere, and Anne Marie Courouze* ..... 575
- Do Spray Coolant Anesthetics Contaminate an Aseptic Field?  
*Micha Abeles and Peggy Garjian* ..... 576

ARA Announcements..... A13

## VOLUME 29

## APRIL SUPPLEMENT

## NO. 4

- 50th Annual Meeting of the American Rheumatism Association ..... S1
- 21st Annual Meeting of the Arthritis Health Professions Association ..... S140

## VOLUME 29

## MAY

## NO. 5

- Current Comment: Sjögren's Syndrome: Proposed Criteria for Classification  
*Robert I. Fox, Charles A. Robinson, John G. Curd, Franklin Kozin, and Francis V. Howell* ..... 577
- Alpha<sub>1</sub>-Antitrypsin Phenotypes, Including M Subtypes, in Pulmonary Disease Associated with Rheumatoid Arthritis and Systemic Sclerosis  
*Joseph P. Michalski, Candace C. McCombs, Eve Scopelitis, Joseph J. Biundo, Jr., and Thomas A. Medsger, Jr.* ..... 586
- Serum Amino-Terminal Type III Procollagen Peptide in Rheumatoid Arthritis: Relationship to Disease Activity, Treatment, and Development of Joint Erosions  
*Kim Hørslev-Petersen, Kirsten D. Bentsen, Peter Junker, and Ib Lorenzen* ..... 592
- Electron Microscopic Study of HLA-DR and Monocyte/Macrophage Staining Cells in the Rheumatoid Synovial Membrane  
*Tetsuhiro Iguchi, Masahiro Kurosaka, and Morris Ziff*..... 600
- A Multicenter Study of Hospitalization in Rheumatoid Arthritis: Frequency, Medical-Surgical Admissions, and Charges  
*Frederick Wolfe, Sue M. Kleinheksel, Patricia W. Spitz, Deborah P. Lubeck, James F. Fries, Donald Y. Young, Donald Mitchell, and Sanford Roth*..... 614
- Impact of Specific Therapy upon Rheumatoid Arthritis  
*James F. Fries, Patricia W. Spitz, Donald M. Mitchell, Sanford H. Roth, Frederick Wolfe, and Daniel A. Bloch*..... 620

Rehabilitation for Rheumatoid Arthritis Patients: A Controlled Trial <i>Jane Sinden Spiegel, Timothy M. Spiegel, Nancy B. Ward, Harold E. Paulus, Barbara Leake, and Robert L. Kane</i> .....	628
Effects of Lupus-Inducing Drugs on the B to Z Transition of Synthetic DNA <i>T. J. Thomas and Ronald P. Messner</i> .....	638
Effect of Anti-T Cell Autoantibodies from Systemic Lupus Erythematosus Sera upon T Lymphocyte Functions <i>Leonard P. Goldschmidt, Thomas F. Kresina, and Gary M. Kammer</i> .....	646
Evaluation of Amitriptyline in Primary Fibrositis: A Double-Blind, Placebo-Controlled Study <i>Simon Carette, Glenn A. McCain, David A. Bell, and Adel G. Fam</i> .....	655
The Effect of Sodium Selenite on Chondrocytes in Monolayer Culture <i>Xiqin Wei, George C. Wright, Jr., and Leon Sokoloff</i> .....	660
Flare of Antigen-Induced Arthritis in Mice after Intravenous Challenge: Kinetics of Antigen in the Circulation and Localization of Antigen in the Arthritic and Noninflamed Joint <i>Jan Willem Lens, Wim B. van den Berg, Levinus B. A. van de Putte, and Wil A. Zwartz</i> .....	665
Brief Reports	
Characterization of an Expanded Subpopulation of Large Granular Lymphocytes in a Patient with Rheumatoid Arthritis <i>Bernard Combe, Monique Andary, Jean Caraux, Pierre Baldet, Françoise Barchechath, Jacques Clot, and Jacques Sany</i> .....	675
Pulmonary Amyloidosis Associated with Systemic Lupus Erythematosus <i>Shigeo Nomura, Naoki Kumagai, Tadashi Kanoh, Haruto Uchino, and Jiro Kurihara</i> .....	680
Treatment of AL Amyloidosis with Melphalan, Prednisone, and Colchicine <i>Merrill D. Benson</i> .....	683
Adult Sporadic Hypophosphatemic Osteomalacia Presenting as Regional Migratory Osteoporosis <i>Jean-C. Gerster, Philippe Jaeger, Charles Gobelet, and Georges Boivin</i> .....	688
Letters	
Influence of the Menopausal State on the Effect of Low-Dose Glucocorticoid on Bone Mass in Rheumatoid Arthritis Patients <i>Charles Nagant de Deuxchaisnes, Jean-Pierre Devogelaer, Jean-Pierre Huaux, and Walter Esselinckx</i> .....	693
Reply to Nagant de Deuxchaisnes <i>Anders Gotfredsen, Orla Skibsted Als, and Claus Christiansen</i> .....	694
Reply to Nagant de Deuxchaisnes <i>Thomas R. Dykman</i> .....	695
The Striking Association Between Lupus Anticoagulant and Fetal Loss in Systemic Lupus Erythematosus Patients <i>R. H. W. M. Derksen, B. N. Bouma, and L. Kater</i> .....	695
ARA Announcements .....	A11

## VOLUME 29

## JUNE

## NO. 6

Current Comment: Idiotype and Autoimmunity <i>Dennis Marc Klinman and Alfred David Steinberg</i> .....	697
Survival, Prognosis, and Causes of Death in Rheumatoid Arthritis <i>Donald M. Mitchell, Patricia W. Spitz, Donald Y. Young, Daniel A. Bloch, Dennis J. McShane, and James F. Fries</i> .....	706
Complement Activation in Rheumatoid Arthritis Evaluated by C3dg and the Terminal Complement Complex <i>Tom E. Mollnes, Tor Lea, Ove J. Mellbye, Jan Pahle, Øyvind Grand, and Morten Harboe</i> .....	715
Estimation of the Relative Avidity of 19S IgM Rheumatoid Factor Secreted by Rheumatoid Synovial Cells for Human IgG Subclasses <i>Dick L. Robbins, Jeffrey Skilling, William F. Benisek, and Richard Wistar, Jr.</i> .....	722
Reactivity of Monoclonal Anti-Type II Collagen Antibodies with Cartilage and Synovial Tissue in Rheumatoid Arthritis and Osteoarthritis <i>Lars Klareskog, Olof Johnell, Anders Hulth, Rikard Holmdahl, and Kristofer Rubin</i> .....	730



Decreased Expression of the C3b/C4b Receptor (CR1) and the C3d Receptor (CR2) on B Lymphocytes and of CR1 on Neutrophils of Patients with Systemic Lupus Erythematosus <i>James G. Wilson, William D. Ratnoff, Peter H. Schur, and Douglas T. Fearon</i> .....	739
Complement-Activating Abilities of Defined Antinuclear Antibodies <i>Yoshiharu Kanayama, Carol Peebles, Eng M. Tan, and John G. Curd</i> .....	748
Increased Proto-Oncogene Expression in Peripheral Blood Lymphocytes from Patients with Systemic Lupus Erythematosus and Other Autoimmune Diseases <i>D. T. Boumpas, G. C. Tsokos, D. L. Mann, E. G. Eleftheriades, C. C. Harris, and G. E. Mark</i> .....	755
Proliferative Responses of Mononuclear Cells in Lyme Disease: Reactivity to <i>Borrelia burgdorferi</i> Antigens is Greater in Joint Fluid Than in Blood <i>Leonard H. Sigal, Allen C. Steere, Daniel H. Freeman, and John M. Dwyer</i> .....	761
Reproducibility of Synovial Fluid Analyses: A Study Among Four Laboratories <i>H. Ralph Schumacher, Jr., Marie S. Sieck, Susan Rothfuss, Gilda M. Clayburne, Dorothy F. Baumgarten, Bonnie S. Mochan, and Jeffrey A. Kant</i> .....	770
Comparison of Pain Properties in Fibromyalgia Patients and Rheumatoid Arthritis Patients <i>Frank Leavitt, Robert S. Katz, Harvey E. Golden, Paul B. Glickman, and Lawrence F. Layfer</i> .....	775
An Animal Model of Antibody Binding in Cutaneous Lupus <i>Lela A. Lee, William L. Weston, Gerald G. Krueger, Mansoor Emam, Morris Reichlin, James O. Stevens, Sandra K. Surbrugg, Adriana Vasil, and David A. Norris</i> .....	782
Brief Reports	
Binding of Normal Human Mononuclear Cells to Blood Vessels in Rheumatoid Arthritis Synovial Membrane <i>Nancy Oppenheimer-Marks and Morris Ziff</i> .....	789
Association of Cerebrospinal Fluid IgM Index with Central Nervous System Involvement in Behçet's Disease <i>Shunsei Hirohata, Akiteru Takeuchi, and Terumasa Miyamoto</i> .....	793
The Relationship Between Ocular and Articular Disease Activity in Children with Juvenile Rheumatoid Arthritis and Associated Uveitis <i>Alan M. Rosenberg and Kiem G. Oen</i> .....	797
Methotrexate Therapy in Juvenile Rheumatoid Arthritis: A Retrospective Study <i>H. Truckenbrodt and R. Häfner</i> .....	801
Arthropathy Associated with Factor XIII Deficiency <i>Suman Thakker, William McGehee, and Francisco P. Quismorio, Jr.</i> .....	808
Letters	
Destructive Arthritis in a Patient with Cutaneous Polyarteritis Nodosa <i>Malcolm M. Steven, J. J. F. Belch, and R. D. Sturrock</i> .....	812
Anserine Bursitis <i>Micha Abeles</i> .....	812
Chondrosarcoma Coexistent with Dermatomyositis <i>M. J. Th. Mol, A. F. H. Stalenhoef, and A. M. Th. Boerbooms</i> .....	813
Rheumatoid Arthritis: Clinical Onset, Seropositivity, and a Possible Cause <i>Valerie E. Jones, R. K. Jacoby, Alison H. Puttick, and B. J. Cohen</i> .....	814
Book Reviews .....	816
ARA Announcements .....	A16

## VOLUME 29

## JULY

## NO. 7

Reduced High-Energy Phosphate Levels in the Painful Muscles of Patients with Primary Fibromyalgia <i>Ann Bengtsson, K. G. Henriksson, and Jörgen Larsson</i> .....	817
The Safety and Efficacy of the Use of Methotrexate in Long-Term Therapy for Rheumatoid Arthritis <i>Joel M. Kremer and Joong Kil Lee</i> .....	822
Methotrexate Metabolism Analysis in Blood and Liver of Rheumatoid Arthritis Patients: Association with Hepatic Folate Deficiency and Formation of Polyglutamates <i>Joel M. Kremer, John Galivan, Anita Streckfuss, and Barton Kamen</i> .....	832

Formation of a Synovial-Like Membrane at the Bone-Cement Interface: Its Role in Bone Resorption and Implant Loosening after Total Hip Replacement <i>Steven R. Goldring, Murali Jasty, Merrilee S. Roelke, Carolyn M. Rourke, F. Richard Bringhurst, and William H. Harris</i> .....	836
Altered Distribution of Debrisoquine Oxidation Phenotypes in Patients with Systemic Lupus Erythematosus <i>Alan N. Baer, C. B. McAllister, Grant R. Wilkinson, Raymond L. Woosley, and Theodore Pincus</i> .....	843
Inhibition of Excessive Scleroderma Fibroblast Collagen Production by Recombinant $\gamma$ -Interferon: Association with a Coordinate Decrease in Types I and III Procollagen Messenger RNA Levels <i>Joel Rosenbloom, George Feldman, Bruce Freundlich, and Sergio A. Jimenez</i> .....	851
Complement C3b Receptors on Erythrocytes, Circulating Immune Complexes, and Complement C3 Split Products in Patients with Primary Sjögren's Syndrome <i>Bjarne S. Thomsen, Peter Oxholm, Rolf Manthorpe, and Henrik Nielsen</i> .....	857
Analysis of Osteoarthritic Cartilage Using Monoclonal Antibodies Reactive with Rabbit Proteoglycan <i>Thomas F. Kresina, Charles J. Malemud, and Roland W. Moskowitz</i> .....	863
The Impact of Childhood Rheumatic Diseases on the Family <i>Marie C. McCormick, Margaret M. Stemmler, and Balu H. Athreya</i> .....	872
Phosphoribosylpyrophosphate Synthetase Superactivity: A Study of Five Patients with Catalytic Defects in the Enzyme <i>Michael A. Becker, Michele J. Losman, Alan L. Rosenberg, Ira Mehlman, Dennis J. Levinson, and Edward W. Holmes</i> .....	880
Liposome-Induced Synovitis in Rabbits: Light and Electron Microscopic Studies <i>Sung Jae Choi, H. Ralph Schumacher, Jr., Gilda Clayburne, M. Susan Rothfuss, and Marie Sieck</i> .....	889
The Neurotoxic Effect of Gold Sodium Thiomalate on the Peripheral Nerves of the Rat: Insights into the Antiinflammatory Actions of Gold Therapy <i>Jon D. Levine, Joshua Goldstine, Margaret Mayes, Michael A. Moskowitz, and Allan I. Basbaum</i> .....	897
<b>Brief Reports</b>	
Treatment of Felty's Syndrome with Low-Dose Oral Methotrexate <i>Lisa Sherbin Allen and Gerald Groff</i> .....	902
The Face Scale: A Brief, Nonverbal Method for Assessing Patient Mood <i>Christopher D. Lorish and Richard Maisiak</i> .....	906
Aseptic Arthritis in a Man with Toxic Shock Syndrome <i>Elie Gertner and Robert D. Inman</i> .....	910
Scleromyxedema with Systemic Involvement Mimics Rheumatic Diseases <i>Edward J. Fudman, Joseph Golbus, and Robert W. Ike</i> .....	913
Reflex Sympathetic Dystrophy Syndrome: An Unusual Mode of Presentation of Osteomalacia <i>J. P. Huaux, J. Malghem, B. Maldague, J. P. Devogelaer, W. Esselinckx, H. Withofs, and C. Nagant de Deuxchaisnes</i> .....	918
Adult-Type Osteopetrosis Presenting as Carpal Tunnel Syndrome <i>Milovan Rakic, Abdelmonen Elhousseiny, Farouk Ramadan, Radha Iyer, Rudolph G. Howard, and Ludwig Gross</i> .....	926
<b>Special Article: International League Against Rheumatism: A Brief History and Update</b> <i>Ephraim P. Engleman</i> .....	929
<b>Letters</b>	
B $\beta$ Polymorphisms in Systemic Lupus Erythematosus Patients of Spanish Descent <i>Manuel Martin-Villa, Antonio Arnaiz Villena, Luis Linares, and Juan Gomez-Reino</i> .....	932
Systemic Lupus Erythematosus Occurring in a Patient with Multiple Myeloma <i>Eric Solary, Denis Caillot, Henri Guy, Nils-Olivier Olsson, Yves Tanter, and Jean-Marc Chalopin</i> .....	933
Patients' Knowledge of Their Antirheumatic Drugs <i>Murray Friedberg, John J. Nicholas, Wallace Christy, and Floyd H. Taylor</i> .....	934
Diagnosis of Xerostomia: The Beck Test <i>C. D. Burda</i> .....	936
<b>Book Review</b> .....	936
<b>ARA Announcements</b> .....	A20

VOLUME 29

AUGUST

NO. 8

**Cost-Effectiveness of Total Joint Arthroplasty in Osteoarthritis**

<i>Matthew H. Liang, Karen E. Cullen, Martin G. Larson, Mark S. Thompson, Julie A. Schwartz, Anne H. Fossel, William N. Roberts, and Clement B. Sledge</i> .....	937
--	-----

Characterization and Functional Studies of Rheumatoid Synovial Mast Cells: Activation by Secretagogues, Anti-IgE, and a Histamine-Releasing Lymphokine <i>Barry Gruber, Mark Poznansky, Eleonore Boss, Jacqueline Partin, Peter Gorevic, and Allen P. Kaplan</i> .....	944
Mast Cell Numbers and Histamine Levels in Synovial Fluids from Patients with Diverse Arthritides <i>Daniel G. Malone, Anne-Marie Irani, Lawrence B. Schwartz, Kim E. Barrett, and Dean D. Metcalfe</i> .....	956
Correlation Between the Presence of Antibodies to the Epstein-Barr Virus Nuclear Antigen Type 2 and Antibodies to the Rheumatoid Arthritis Nuclear Antigen in Patients with Rheumatoid Arthritis <i>Thomas B. Sculley, John H. Pope, and Ron A. Hazelton</i> .....	964
Influence of Age, Gender, and Obesity on Salicylate Kinetics Following Single Doses of Aspirin <i>David J. Greenblatt, Darrell R. Abernethy, Harold G. Boxenbaum, Rita Matlis, Hermann R. Ochs, Jerold S. Harmatz, and Richard I. Shader</i> .....	971
Clinical and Serologic Associations of the Antiribosomal P Protein Antibody <i>Eloisa Bonfa and Keith B. Elkon</i> .....	981
The Use of Immunoblotting and Immunoprecipitation of (U) Small Nuclear Ribonucleoproteins in the Analysis of Sera of Patients with Mixed Connective Tissue Disease and Systemic Lupus Erythematosus: A Cross-Sectional, Longitudinal Study <i>Ingvar Pettersson, Grace Wang, Elaine I. Smith, Hans Wigzell, Eva Hedfors, John Horn, and Gordon C. Sharp</i> .....	986
Intraarticular Triamcinolone Hexacetonide in the Management of Chronic Arthritis in Children <i>R. C. Allen, K. R. Gross, R. M. Laxer, P. N. Malleson, R. D. Beauchamp, and R. E. Petty</i> .....	997
Increased Calcification of Growth Plate Cartilage as a Result of Compressive Force In Vitro <i>J. Klein-Nulend, J. P. Veldhuijzen, and E. H. Burger</i> .....	1002
In Vitro Cell Proliferation and Proteoglycan Synthesis of Rabbit Meniscal Fibrochondrocytes as a Function of Age and Sex <i>Richard J. Webber, Teresa Zitaglio, and Aubrey J. Hough, Jr.</i> .....	1010
The Contribution of Pain to Disability in Experimentally Induced Arthritis <i>Samuel J. Dardick, Allan I. Basbaum, and Jon D. Levine</i> .....	1017
Brief Reports	
Systemic Lupus Erythematosus is Not Genetically Linked to the Beta Chain of the T Cell Receptor <i>Zdenka Froncek, Daniel Lentz, Nancy Berliner, Allan D. Duby, Karen A. Klein, J. G. Seidman, and Peter H. Schur</i> .....	1023
Cryoglobulinemia and Hepatitis B Markers in North African Jews with Raynaud's Disease <i>Jacob Horowitz, Mordechai Klein, and Shaul Sukenik</i> .....	1026
Psoriatic Arthritis Affecting the Manubriosternal Joint <i>Nancy J. Becker, Arthur A. De Smet, William Cathcart-Rake, and Daniel J. Stechschulte</i> .....	1029
Idiopathic Familial Acroosteolysis: Histomorphometric Study of Bone and Literature Review of the Hajdu-Cheney Syndrome <i>James Udell, H. Ralph Schumacher, Jr., Frederick Kaplan, and Michael D. Falon</i> .....	1032
Special Article: Development of Criteria for the Classification and Reporting of Osteoarthritis: Classification of Osteoarthritis of the Knee <i>R. Altman, E. Asch, D. Bloch, G. Bole, D. Borenstein, K. Brandt, W. Christy, T. D. Cooke, R. Greenwald, M. Hochberg, D. Howell, D. Kaplan, W. Koopman, S. Longley, III, H. Mankin, D. J. McShane, T. Medsger, Jr., R. Meenan, W. Mikkelsen, R. Moskowitz, W. Murphy, B. Rothschild, M. Segal, L. Sokoloff, and F. Wolfe</i> .....	1039
Letters	
Amyloid Lymphadenopathy in a Patient with Mixed (Type II) Cryoglobulinemia <i>Tadashi Kanoh and Hiroshi Okada</i> .....	1050
Simultaneous Occurrence of Darier's Disease and Primary Sjögren's Syndrome <i>Annemette Oxholm, Flemming da Cunha Bang, and Peter Oxholm</i> .....	1052
Anticardiolipin Antibodies in Systemic Sclerosis <i>James R. Seibold, Peter J. Knight, and James B. Peter</i> .....	1052
Nifedipine Treatment for Progressive Systemic Sclerosis <i>L. Cziráj and Gy. Szegedi</i> .....	1053
Effects of Diltiazem Versus Nifedipine on Lower Esophageal Sphincter Pressure in Patients with Progressive Systemic Sclerosis <i>F. Jean, A. Aubert, F. Bloch, J. P. Petite, P. Priollet, J. N. Fiessinger, J. M. Husson, and E. Billaud</i> .....	1054
Successful Treatment of Raynaud's Phenomenon with Pentoxifylline <i>Jerry Goldberg and Andrea Dlesk</i> .....	1055
Book Review .....	1056
ARA Announcements .....	A7

HLA-DP Antigens in Patients with Pauciarticular Juvenile Rheumatoid Arthritis <i>Robert W. Hoffman, Stephen Shaw, Lynn C. Francis, Martin G. Larson, Robert A. Petersen, Leo T. Chylack, and David N. Glass</i> .....	1057
Urinary Neopterin Reflects Clinical Activity in Patients with Rheumatoid Arthritis <i>Gilbert Reibnegger, Dietmar Egg, Dietmar Fuchs, Robert Günther, Arno Hausen, Ernst R. Werner, and Helmut Wachter</i> .....	1063
Production of a Glycosaminoglycan Stimulatory Factor by Cloned Human T Lymphocytes Activated In Vitro <i>Min Tsao, Adriana Zeevi, and Theresa L. Whiteside</i> .....	1071
Evidence That Interleukin-1 Induction of Synovial Cell Plasminogen Activator is Mediated Via Prostaglandin E <sub>2</sub> and cAMP <i>Eugene Mochan, Joanne Uhl, and Robert Newton</i> .....	1078
Complement Activation During Systemic Lupus Erythematosus: C3a and C5a Anaphylatoxins Circulate During Exacerbations of Disease <i>H. Michael Belmont, Patricia Hopkins, Henry S. Edelson, Howard B. Kaplan, Rocio Ludewig, Gerald Weissmann, and Steven Abramson</i> .....	1085
Autoantibodies in the Cerebrospinal Fluid of Patients with Systemic Lupus Erythematosus <i>Steven J. Golombek, Francesc Graus, and Keith B. Elkon</i> .....	1090
Cryoglobulinemia in Autoimmune Rheumatic Diseases: Evidence of Circulating Monoclonal Cryoglobulins in Patients with Primary Sjögren's Syndrome <i>A. G. Tzioufas, M. N. Manoussakis, R. Costello, M. Silis, N. M. Papadopoulos, and H. M. Moutsopoulos</i> .....	1098
Expression of Histocompatibility Antigen HLA-DR by Salivary Gland Epithelial Cells in Sjögren's Syndrome <i>Robert I. Fox, Thomas Bumol, Richard Fantozzi, Robert Bone, and Robert Schreiber</i> .....	1105
Neutral Proteases in Human Osteoarthritic Synovium <i>J. Martel-Pelletier, J. M. Cloutier, and J. P. Pelletier</i> .....	1112
Macrophage Activation in Rat Models of Inflammation and Arthritis: Systemic Activation Precedes Arthritis Induction and Progression <i>William J. Johnson, Katharine A. Muirhead, Paul C. Meunier, Bart J. Votta, Thomas C. Schmitt, Michael J. DiMartino, and Nabil Hanna</i> .....	1122
Murine Type II Collagen Arthritis: Association of an Acute-Phase Response with Clinical Course <i>Marcia L. Bliven, Paul H. Wooley, Mark B. Pepys, and Ivan G. Otterness</i> .....	1131
Detection of Native and Denatured DNA Antibody Forming Cells by the Enzyme-Linked Immunospot Assay: A Clinical Study of (New Zealand black × New Zealand white)F <sub>1</sub> Mice <i>Dale G. Ando, Fanny M. Ebling, and Bevra H. Hahn</i> .....	1139
Brief Reports	
Eosinophilic Synovitis: Clinical Observations on a Newly Recognized Subset of Patients with Dermatographism <i>Jacques P. Brown, Marek Rola-Pleszczynski, and Henri-A. Ménard</i> .....	1147
Retinopathy in Systemic Lupus Erythematosus: Relationship to Disease Activity <i>Alice V. Klinkhoff, Craig W. Beattie, and Andrew Chalmers</i> .....	1152
Wegener's Granulomatosis in the Elderly <i>Steven R. Weiner, Harold E. Paulus, and Richard H. Weisbart</i> .....	1157
Development of Severe Limited Scleroderma in Complicated Raynaud's Phenomenon After Limb Immobilization: Report of Two Cases and Study of Collagen Biosynthesis <i>John Varga and Sergio A. Jimenez</i> .....	1160
Lipid Microspherule-Associated Acute Monarticular Arthritis <i>David C. Trostle, H. Ralph Schumacher, Jr., Thomas A. Medsger, Jr., and Wishwa N. Kapoor</i> .....	1166
Letters	
Dialysis-Related Amyloid is Amyloid of Beta-2-Microglobulin (AM <sub>β2M</sub> ) Origin <i>Terence T. Casey, William J. Stone, Carol R. DiRaimondo, David L. Page, and Peter D. Gorevic</i> .....	1170
Carpal Tunnel Syndrome and Type of Dialysis Membrane Used in Patients Undergoing Long-Term Hemodialysis <i>Jacques Chanard, Sylvie Lavaud, Olivier Toupance, Haycam Roujouleh, and Jean-Pierre Melin</i> ....	1170
Early Radiologic Manifestations of Destructive Spondylarthropathy in Hemodialyzed Patients <i>José Muñoz Gómez and Pilar Estrada-Laza</i> .....	1171



Preliminary Evidence for the Presence of an Inhibitor on the Surface of Natural Monosodium Urate Crystals	
<i>Thomas P. Gordon and Peter J. Roberts-Thomson</i> .....	1172
Eosinophilic Vasculitic Neuropathy in the Churg-Strauss Syndrome	
<i>Shin J. Oh, Guillermo A. Herrera, and David M. Spalding</i> .....	1173
Adverse Drug Reactions: Working Toward More Appropriate Monitoring Models	
<i>Sanford H. Roth</i> .....	1175
Book Review .....	1176
ARA Announcements .....	A7

## VOLUME 29

## OCTOBER

## NO. 10

The Early Diagnosis of Ischemic Necrosis of Bone	
<i>T. M. Zizic, C. Marcoux, D. S. Hungerford, and M. B. Stevens</i> .....	1177
Intraarticular Ferritin-Bound Iron in Rheumatoid Arthritis: A Factor that Increases Oxygen Free Radical-Induced Tissue Destruction	
<i>Pieter Biemond, Antonius J. G. Swaak, Henk G. van Eijk, and Johan F. Koster</i> .....	1187
Molecular Forms of IgA Rheumatoid Factor in Serum and Synovial Fluid of Patients with Rheumatoid Arthritis	
<i>Ralph E. Schrohenloher, William J. Koopman, and Graciela S. Alarcón</i> .....	1194
Group Therapies for Rheumatoid Arthritis: A Controlled Study of Two Approaches	
<i>Gordon D. Strauss, Jane Sinden Spiegel, Marcia Daniels, Timothy Spiegel, John Landsverk, Peter Roy-Byrne, Carole Edelstein, Johanna Ehhardt, Roberta Falke, Lee Hindin, and Les Zackler</i> ...	1203
Deficient $\gamma$ -Interferon Production in Patients with Systemic Lupus Erythematosus	
<i>George C. Tsokos, Dimitri T. Boumpas, Paula L. Smith, Julie Y. Djeu, James E. Balow, and Alain H. Rook</i> .....	1210
DNA-Daunorubicin Complexes Specifically Suppress In Vitro Spontaneous Anti-DNA Antibody Production in Lymphocytes of Patients with Systemic Lupus Erythematosus	
<i>Tsutomu Takeuchi, Jun Koide, Osamu Hosono, Koichi Amano, Mitsuo Homma, Yasuhiko Masuho, Chikao Morimoto, Makoto Takano, and Tohru Abe</i> .....	1216
Evidence of an Immunopathogenic Basis for Central Nervous System Disease in Primary Sjögren's Syndrome	
<i>Elaine L. Alexander, Jane E. Lijewski, Myles S. Jerdan, and Garrett E. Alexander</i> .....	1223
Incidence of Arthritis in Urban Finnish Children: A Prospective Study	
<i>Ilkka Kunnamo, Pentti Kallio, and Pirkko Pelkonen</i> .....	1232
Heterogeneity of Proteoglycans Extracted Before and After Collagenase Treatment of Human Articular Cartilage. I. Physical Properties Related to Age	
<i>Rob J. van de Stadt, Roel Kuijer, G. P. Jos van Kampen, Margret H. M. T. de Koning, Els van de Voorde-Vissers, and Jan K. van der Korst</i> .....	1239
Heterogeneity of Proteoglycans Extracted Before and After Collagenase Treatment of Human Articular Cartilage. II. Variations in Composition with Age and Tissue Source	
<i>Roel Kuijer, Rob J. van de Stadt, G. P. Jos van Kampen, Margret H. M. T. de Koning, Els van de Voorde-Vissers, and Jan K. van der Korst</i> .....	1248
Metabolism of Cartilage Matrix Glycoprotein in Normal and Osteoarthritic Canine Articular Cartilage	
<i>Rose S. Fife, Marshall J. Palmoski, and Kenneth D. Brandt</i> .....	1256
Rat Cytomegalovirus Infection Enhances Type II Collagen Arthritis in Rats	
<i>Charles B. Smith, Marie M. Griffiths, and Lian S. Wei</i> .....	1263
Brief Reports	
Anti-SS-A Antibodies and Fetal Outcome in Maternal Systemic Lupus Erythematosus	
<i>Rosalind Ramsey-Goldman, David Hom, Jau-Shyong Deng, Gayle Casterline Ziegler, Leslie E. Kahl, Virginia D. Steen, Ronald E. LaPorte, and Thomas A. Medsger, Jr.</i> .....	1269
A Strong Association Between Null Alleles at the C4A Locus in the Major Histocompatibility Complex and Systemic Sclerosis	
<i>David C. Briggs, Ken Welsh, R. Scott Pereira, and Carol M. Black</i> .....	1274
Rheumatoid Nodulosis: Report of a Case with Evidence of Intraosseous Rheumatoid Granuloma	
<i>Antonio Morales-Piga, Angel Elena-Ibañez, Antonio C. Zea-Mendoza, Antonio Rocamora-Ripoll, and Juan Beltrán-Gutiérrez</i> .....	1278

Unusual Metacarpophalangeal Osteoarthritis in a Jackhammer Operator <i>Adel G. Fam and Arnost Kolin</i> .....	1284
Government Affairs: FDA Arthritis Advisory Committee Meeting: Methotrexate; <i>Guidelines for the Clinical Evaluation of Antiinflammatory Drugs</i> ; DMSO in Scleroderma <i>Harold E. Paulus</i> .....	1289
Letters	
Lupus Vasculitis with Tibial Artery Thrombosis and Gangrene <i>Jeffrey L. Kaufman, Edita Bancilla, and John Slade</i> .....	1291
Myocardial Infarction in Systemic Lupus Erythematosus and "Lupus-Like" Disease <i>Ronald A. Asherson, Nigel Harris, Azzudin Gharavi, and Graham R. V. Hughes</i> .....	1292
Antibodies to Cardiolipin and Vascular Complications in Women Taking Oral Contraceptives <i>C. Bruneau, L. Intrator, A. Sobel, V. Beaumont, and A. Billecocq</i> .....	1294
Discordant Effects of Prednisone on Anticardiolipin Antibodies and the Lupus Anticoagulant <i>R. H. W. M. Derksen, D. Biesma, B. N. Bouma, F. H. J. Gmelig Meyling, and L. Kater</i> .....	1295
Thalidomide Neurotoxicity and Rheumatoid Arthritis <i>Nicholas J. Sheehan</i> .....	1296
ARA Announcements .....	A11

## VOLUME 29

## NOVEMBER

## NO. 11

ARA Presidential Address: Wanted: Catalysts for Growth <i>Edward D. Harris, Jr.</i> .....	1297
Characterization of Rabbit Genes for Synovial Cell Collagenase <i>M. Elizabeth Fini, Robert H. Gross, and Constance E. Brinckerhoff</i> .....	1301
Assessment of the Potential Pathogenicity of Type II Collagen Autoantibodies in Patients with Rheumatoid Arthritis: Evidence of Restricted IgG3 Subclass Expression and Activation of Complement C5 to C5a <i>W. C. Watson, M. A. Cremer, P. H. Wooley, and A. S. Townes</i> .....	1316
Work Disability Among Persons with Musculoskeletal Conditions <i>Edward H. Yelin, Curtis J. Henke, and Wallace V. Epstein</i> .....	1322
Low Density Neutrophils in Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Acute Rheumatic Fever <i>Elisa Hacbarth and Andre Kajdacsy-Balla</i> .....	1334
In Vitro Production of Autoantibodies to U1 Ribonucleoproteins by Peripheral Blood Mononuclear Cells from Patients with Connective Tissue Diseases <i>Yasuo Ohosone, Masashi Akizuki, Michito Hirakata, Minoru Satoh, Hajime Yamagata, and Mitsuo Homma</i> .....	1343
Cytoskeletal Binding of Monoclonal Anti-DNA Antibodies Derived from Tonsillar Lymphoid Cells of a Normal Subject <i>Ewa Cairns, Ronald Komar, and David A. Bell</i> .....	1351
Complement Activation in Synovial Fluid and Tissue from Patients with Juvenile Rheumatoid Arthritis <i>Tom Eirik Mollnes and Albert Paus</i> .....	1359
Prevalence of Coxsackie B Virus Antibodies in Patients with Juvenile Dermatomyositis <i>Mary L. Christensen, Lauren M. Pachman, Richard Schneiderman, Devendrakumar C. Patel, and Jan M. Friedman</i> .....	1365
A Randomized, Controlled Trial of Amitriptyline and Naproxen in the Treatment of Patients with Fibromyalgia <i>Don L. Goldenberg, David T. Felson, and Hal Dinerman</i> .....	1371
Bacterial Arthritis: A Staphylococcal Proteoglycan-Releasing Factor <i>R. Lane Smith and David J. Schurman</i> .....	1378
Arthropathy and Cutaneous Calcinosi in Hemodialysis Oxalosis <i>Antonio J. Reginato, Jose Luis Ferreira Seoane, Ceferino Barbazan Alvarez, Jorge Mitja Piferrer, Lino Vidal Meijon, Raul Pascual Turon, Fernando Vasconez, Exequiel R. Rivera, Gilda Clayburne, and Susan Rothfuss</i> .....	1387
Brief Reports	
Human Synovial Fibroblasts Produce Urokinase-Type Plasminogen Activator <i>Robert L. Medcalf and John A. Hamilton</i> .....	1397

Congenital Cytomegalovirus Infection and Maternal Systemic Lupus Erythematosus: A Case Report <i>Mary M. Jones, Martin D. Lidsky, Earl J. Brewer, Martha D. Yow, and W. Daniel Williamson</i> .....	1402
Successful Treatment of Autoimmunity in MRL/l Mice with LS-2616, A New Immunomodulator <i>A. Tarkowski, K. Gunnarsson, L.-Å. Nilsson, L. Lindholm, and T. Stålhandske</i> .....	1405
Editorial: Work Disability and Musculoskeletal Disease <i>Nortin M. Hadler</i> .....	1410
<b>Letters</b>	
Acetylator Phenotype in Patients with Systemic Lupus Erythematosus <i>Semra Sardas, Ali Esat Karakaya, and Orhan Seyfi Sardas</i> .....	1412
Response to Paolaggi et al: Bridging the Communications Gap <i>J. G. Jones</i> .....	1413
"Chorée Fibrillaire de Morvan" followed by Guillain-Barré Syndrome in a Patient Receiving Gold Therapy <i>D. Vernay, J. J. Dubost, J. P. Thevenet, B. Sauvezie, and S. Rampon</i> .....	1413
Paget's Disease and Osteoarthritis <i>Sharad Lakhanpal and J. Desmond O'Duffy</i> .....	1414
Book Review .....	1416
ARA Announcements.....	A19

## VOLUME 29

## DECEMBER

## NO. 12

Current Comment: Antibodies to DNA: A Perspective <i>Woodruff Emlen, David S. Pisetsky, and Ronald P. Taylor</i> .....	1417
Sulfasalazine in Rheumatoid Arthritis: A Double-Blind, Placebo-Controlled Trial <i>Robert S. Pinals, Stanley B. Kaplan, Jeffrey G. Lawson, and Bonnie Hepburn</i> .....	1427
Modulation of Spontaneous Immunoglobulin Production by Natural Killer Cells in Rheumatoid Arthritis <i>Zair Tovar, Richard M. Pope, and Norman Talal</i> .....	1435
In Vitro Synthesis of IgM Rheumatoid Factor in Response to <i>Staphylococcus Aureus</i> by Lymphocytes from Healthy Adults <i>Rose Goldstein and Jacob Karsh</i> .....	1440
Abnormal Immunoglobulin and Rheumatoid Factor Synthesis by Blood Lymphocytes in Patients with Primary Sjögren's Syndrome <i>Martin A. Rodriguez, Miren L. Baroja, Matilde Leon-Ponte, and Isaac Abadi</i> .....	1446
Elevated MMPI Scores for Hypochondriasis, Depression, and Hysteria in Patients with Rheumatoid Arthritis Reflect Disease Rather than Psychological Status <i>Theodore Pincus, Leigh F. Callahan, Laurence A. Bradley, William K. Vaughn, and Frederick Wolfe</i> .....	1456
Hypocomplementemia with Low C1s-C1 Inhibitor Complex in Systemic Lupus Erythematosus <i>M. D. Lockshin, Tasneem Qamar, Patricia Redecha, and P. C. Harpel</i> .....	1467
Products of Polymorphonuclear Cell Injury Inhibit IgG Enhancement of Monosodium Urate-Induced Superoxide Production <i>Michael S. Rosen, Daniel G. Baker, H. Ralph Schumacher, Jr., and Plammoottil V. Cherian</i> .....	1473
Monosodium Urate Crystals in the Knee Joints of Patients with Asymptomatic Nontophaceous Gout <i>John S. Bomalaski, Geronimo Lluberas, and H. Ralph Schumacher, Jr.</i> .....	1480
Inorganic Pyrophosphate Release by Rabbit Articular Chondrocytes in Vitro <i>A. Pieter A. Prins, Erno Kiljan, Rob J. van de Stadt, and Jan K. van der Korst</i> .....	1485
Alterations in a Cartilage Matrix Glycoprotein in Canine Osteoarthritis <i>Rose S. Fife</i> .....	1493
Female Sex Hormones Suppress Development of Collagen-Induced Arthritis in Mice <i>Rikard Holmdahl, Liselott Jansson, and Mikael Andersson</i> .....	1501
<b>Brief Reports</b>	
Ankylosing Spondylitis in Families with Two Distinct B27 Haplotypes: A Selective Association <i>Maria E. Suarez-Almazor, Anthony S. Russell, and Sharon LeClercq</i> .....	1510
HLA-DR Antigens in Gold-Induced Neutropenia <i>Stephen Aaron, Paul Davis, and James Bertouch</i> .....	1515

Association Between HLA and Sjögren's Syndrome in Japanese Patients <i>Junko Moriuchi, Yukinobu Ichikawa, Masatoshi Takaya, Hiroaki Shimizu, Mitsuaki Uchiyama, Kaoru Sato, Kimiyoshi Tsuji, and Shigeru Arimori</i> .....	1518
The Natural History of Fibromyalgia <i>David T. Felson and Don L. Goldenberg</i> .....	1522
Multiple Unusual Manifestations of Wegener's Granulomatosis: Breast Mass, Microangiopathic Hemolytic Anemia, Consumptive Coagulopathy, and Low Erythrocyte Sedimentation Rate <i>Joanne M. Jordan, Michael Manning, and Nancy Bates Allen</i> .....	1527
<b>Letters</b>	
Sjögren-Like Syndrome in K Chain Deficiency <i>Carlomaurizio Montecucco, Enrico L. Chérier-Lignière, Renato Rosso, Matteo Longhi, and Alberto Riccardi</i> .....	1532
Rheumatoid Arthritis and Human T Cell Lymphotropic Retroviruses <i>M. Galeazzi, T. Tuzi, C. Amici, and A. Benedetto</i> .....	1533
Takatsuki Syndrome: A Reversible Multisystem Plasma Cell Dyscrasia <i>W. Pruzanski</i> .....	1534
Systemic Lupus Erythematosus, Antiphospholipid Antibodies, Chorea, and Oral Contraceptives <i>Ronald A. Asherson, Nigel E. Harris, Azzudin E. Gharavi, and Graham R. V. Hughes</i> .....	1535
<b>Reviewers</b> .....	1537
<b>Contents Volume 29, 1986</b> .....	1540
<b>Indexes</b> .....	1555
<b>ARA Announcements</b> .....	A23







# AUTHOR INDEX

*Arthritis and Rheumatism*, Volume 29, Numbers 1 through 12, 1986

## A

Aaron S, 1515  
Abadi I, 1446  
Abe T, 1216  
Abeles M, 576, 812  
Abernethy DR, 971  
Abramson S, 1085  
Acton RT, 151  
Akizuki M, 1343  
Alarcón GS, 151, 1194  
Aldridge RD, 337  
Alexander EL, 196, 1223  
Alexander GE, 1223  
Allen JB, 262  
Allen LS, 902  
Allen NB, 570, 1527  
Allen RC, 997  
Als OS, 694  
Altman R, 1039  
Alvarez CB, 1387  
Amano K, 1216  
Amici C, 1533  
Amor B, 575  
Andary M, 675  
Anderson RJ, 153  
Andersson M, 1501  
Ando DG, 1139  
Anzola MC, 501  
Arimori S, 1518  
Arnett FC, 196  
Arora R, 207  
Arsever CL, 251  
Asch E, 1039  
Asherson RA, 1292, 1535  
Atcher RW, 153  
Athreya BH, 872  
Aubert A, 1054  
Aupetit B, 574

## B

Baer AN, 508, 843  
Baker DG, 1473  
Baker JR, 95  
Baldet P, 675  
Balow JE, 185, 1210  
Bancilla E, 1291  
Baragar FD, 65  
Barbanel C, 453  
Barchechath F, 675  
Bardin T, 453  
Barger BO, 151  
Barland P, 148  
Barnes EL, 515  
Baroja ML, 1446  
Baron M, 282  
Barrett KE, 956  
Barry C, 16  
Barth WF, 296, 565  
Bartholomew LE, 501  
Basbaum AI, 897, 1017  
Bass JC, 274  
Bauer NE, 142  
Baum J, 274  
Baumgarten DF, 770  
Beattie CW, 1152  
Beauchamp RD, 997  
Beaufils H, 574  
Beaumont V, 1294  
Becker MA, 880  
Becker NJ, 1029  
Belch JF, 812  
Bell DA, 655, 1351  
Belmont HM, 1085  
Beltrán-Gutiérrez J, 1278  
Benedetto A, 1533  
Bengtsson A, 817  
Benisek WF, 722  
Benson MD, 683  
Bentsen KD, 592  
Bergroth V, 47  
Berliner N, 1023  
Bertouch JV, 32, 1515  
Best PV, 337  
Bias WB, 196  
Biemond P, 1187  
Biesma D, 1295  
Billaud E, 1054  
Billecocq A, 1294  
Biundo JJ Jr, 586  
Black CM, 1274  
Blair D, 142  
Blanchette VS, 426  
Blinderman EE, 431  
Bliven ML, 1131  
Bloch DA, 1, 494, 620, 706, 1039  
Bloch F, 1054  
Block S, 554  
Bloomer WA, 153  
Bluestone R, 455  
Bluhm GB, 1  
Boerbooms AMT, 813  
Boivin G, 688  
Bole GG, 251, 1039  
Bomalaski JS, 227, 312, 1480  
Bone R, 1105  
Bonfa E, 981  
Borenstein D, 1039  
Borth W, 319  
Boss E, 944

Bouma BN, 695, 1295  
Boumpas DT, 185, 755, 1210  
Boxenbaum HG, 971  
Bradley J, 32  
Bradley LA, 1456  
Brandt KD, 88, 1039, 1256  
Braun RM, 10  
Breedveld FC, 166  
Brenckman WD, 448  
Bresnihan B, 16, 480  
Brewer EJ Jr, 274, 1402  
Briggs DC, 1274  
Brinckerhoff CE, 1301  
Bringham FR, 836  
Brooks PM, 32  
Brown DM, 160  
Brown JP, 1147  
Brown KS, 114  
Bruneau C, 1294  
Bruot B, 411  
Buckingham RB, 54  
Bulutlar G, 436  
Bumol T, 1105  
Burda CD, 936  
Burger EH, 1002  
Burkhardt H, 379  
Butler C, 207

## C

Caillot D, 933  
Cairns E, 1351  
Calabro JJ, 452  
Calandra GB, 262  
Calkins E, 1416  
Callahan LF, 1456  
Cameron BJ, 439  
Carauz J, 675  
Carette S, 655  
Casey E, 16  
Casey TT, 1170  
Cassidy JT, 274  
Catterson B, 95  
Cathcart-Rake W, 1029  
Cavender D, 352  
Ceuppens JL, 305  
Chaisson D, 439  
Challa VR, 286  
Chalmers A, 1152  
Chalmers IM, 65  
Chalopin J-M, 933  
Chanard J, 1170  
Cherian PV, 1473  
Chérié-Lignière EL, 1532  
Cheson BD, 128

Choi SJ, 889  
Christensen ML, 1365  
Christiansen C, 694  
Christner JE, 95  
Christy W, 934, 1039  
Chylack LT, 1057  
Clark MA, 312  
Clayburne GM, 770, 889, 1387  
Cledes J, 147  
Clegg DO, 128  
Clot J, 675  
Cloutier JM, 1112  
Cohen AS, 445  
Cohen BJ, 814  
Cohen JL, 388  
Cohen S, 421  
Colvin RB, 539  
Combe B, 675  
Connolly K, 394  
Cooke TD, 1039  
Costello R, 1098  
Courouce AM, 575  
Cowan DH, 233  
Cremer MA, 1316  
Cullen KE, 937  
Cunningham T, 174  
Curd JG, 577, 748  
Curtiss LK, 363  
Czirják L, 1053

## D

da Cunha Bang F, 1052  
Daniels M, 1203  
Darby WL III, 75  
Dardick SJ, 1017  
Davis JS IV, 816  
Davis M, 133  
Davis P, 1515  
Dawkins RL, 148  
Deckmyn H, 305  
de Groc F, 574  
de Koning MGMT, 1239, 1248  
Deng J-S, 1269  
Dequeker J, 305  
Deramond H, 301  
Derksen RHW, 695, 1295  
De Smet AA, 1029  
Desoroux A, 300  
DeVellis BM, 388  
DeVellis RF, 388  
Devogelaer J-P, 693, 918  
DiMartino MJ, 1122  
Dinarello CA, 461

Dinerman H, 1371  
DiRaimondo CR, 1170  
Djeu JY, 1210  
Dlesk A, 1055  
Dorfman HD, 431  
Dorman BA, 136  
Dougados M, 575  
Droz D, 453  
Drueke T, 453  
Dubost JJ, 1413  
Duby AD, 1023  
Duncan H, 149  
Dunky A, 319  
Dwyer JM, 761  
Dykman TR, 695

## E

Ebling FM, 1139  
Edelson HS, 1085  
Edelstein C, 1203  
Egg D, 1063  
Eggensperger D, 565  
Ehlhardt J, 1203  
Eleftheriades EG, 755  
Elena-Ibeñez A, 1278  
Elhosseiny A, 926  
Elkon KB, 981, 1090  
Emam M, 782  
Emlen W, 1417  
Engleman EP, 929  
Epstein A, 148  
Epstein WV, 1322  
Esselinckx W, 693, 918  
Estrada-Laza P, 1171

## F

Falke R, 1203  
Fallon MD, 1032  
Fam AG, 233, 655, 1284  
Fantozzi R, 1105  
Fardellone P, 301  
Fearon DT, 739  
Fedele FA, 136  
Feighery C, 16, 480  
Feldman G, 851  
Feldman GR, 431  
Felson DT, 1371, 1522  
Fiessinger JN, 1054  
Fife RS, 1256, 1493  
Fini ME, 1301  
Fink CW, 274  
Forrester D, 1  
Fossel AH, 937  
Fournier A, 301  
Fox OF, 196  
Fox RI, 577, 1105  
Franchimont P, 300  
Francis LC, 1057  
Freeman DH, 761  
Freundlich B, 851

Friedberg M, 934  
Friedman JM, 1365  
Fries JF, 1, 274, 438, 494, 614, 620, 706  
Fritzler MJ, 358  
Fronek Z, 1023  
Fuchs D, 1063  
Fudman EJ, 913  
Funck-Brentano JL, 453  
Furukawa F, 242

## G

Galeazzi M, 1533  
Galibert P, 301  
Galivan J, 832  
Gall EP, 133  
Garjian P, 576  
Garland JS, 450  
Genant H, 1  
Gerster J-C, 688  
Gertner E, 910  
Gharavi AE, 1292, 1535  
Ginsberg MH, 363  
Glass DN, 1057  
Glickman PB, 775  
Gobelet C, 688  
Gofton P, 1  
Golbus J, 913  
Goldberg J, 1055  
Golden HE, 775  
Goldenberg DL, 1371, 1522  
Goldring SR, 836  
Goldschmidt LP, 646  
Goldstein CS, 227  
Goldstein R, 426, 1440  
Goldstine J, 897  
Golombek SJ, 1090  
Gómez JM, 1171  
Gomez-Reino J, 932  
Gordon TP, 1172  
Gorevic PD, 944, 1170  
Gottfredsen A, 694  
Gran JT, 303  
Grand Ø, 715  
Granier F, 189  
Graus F, 1090  
Greenblatt DJ, 971  
Greenfield DI, 296  
Greenwald R, 1039  
Griffiths MM, 1263  
Groff G, 902  
Gross KR, 997  
Gross L, 926  
Gross RH, 1301  
Gruber B, 944  
Gunnarsson K, 1405  
Günther R, 1063  
Guy H, 933  
Guyton JM, 151

## H

Haapasaari J, 47  
Haber E, 207  
Hacbarth E, 1334  
Hadler NM, 1410  
Häfner R, 801  
Hahn BH, 1139  
Hakim FT, 114  
Hamilton JA, 1397  
Hanly JG, 16, 480  
Hanna N, 1122  
Hanson V, 274  
Harboe M, 715  
Hardin JA, 457  
Hardin JG, 455  
Harley JB, 196  
Harmatz JS, 971  
Harpel PC, 1467  
Harris CC, 755  
Harris ED Jr, 1297  
Harris NE, 1292, 1535  
Harris WH, 836  
Hassan J, 16, 480  
Hausen A, 1063  
Hazelton RA, 964  
Healey LA, 149  
Heck LW, 75  
Hedfors E, 986  
Helfrich D, 124  
Henke CJ, 1322  
Henochowicz S, 565  
Henriksson KG, 817  
Hepburn B, 1427  
Herrera GA, 1173  
Hiermaux P, 453  
Hindin L, 1203  
Hirakata M, 1343  
Hirohata S, 793  
Hirose S, 242  
Ho G Jr, 136  
Hochberg M, 1039  
Hoffman RW, 1057  
Holmdahl R, 106, 400, 730, 1501  
Holmes EW, 880  
Holt DA, 286  
Hom D, 1269  
Homma M, 1216, 1343  
Hopkins P, 1085  
Horn J, 986  
Horowitz J, 1026  
Hørslev-Petersen K, 592  
Hoshino T, 371  
Hosono O, 1216  
Hough AJ Jr, 1010  
Housset E, 189  
Houtman NM, 451  
Howard RG, 926  
Howell D, 1039  
Howell FV, 577  
Huaux J-P, 693, 918

Huebsch LB, 426  
Hughes GRV, 1292, 1535  
Hughes WS, 296  
Hulth A, 730  
Hungerford DS, 1177  
Husson BJ, 153  
Husby G, 207, 303  
Husson JM, 1054  
Hyatt RE, 556

## I

Ichikawa Y, 1518  
Iguchi T, 600  
Ike RW, 913  
Inman RD, 910  
Intrator L, 1294  
Irani A-M, 956  
Iyer R, 926

## J

Jacob JR, 10, 431  
Jacobs JC, 274  
Jacoby RK, 814  
Jaeger P, 688  
Jansson L, 106, 1501  
Jasty M, 836  
Jean F, 1054  
Jerdan MS, 1223  
Jimenez SA, 851, 1160  
Johnell O, 730  
Johnson WJ, 1122  
Jones JG, 1413  
Jones MM, 1402  
Jones VE, 814  
Joosten LAB, 532  
Jordan JM, 1527  
Jouquan J, 147  
Jump AA, 344  
Junker P, 592

## K

Kahl LE, 1269  
Kajdacsy-Balla A, 1334  
Kallenberg CGM, 451  
Kallio P, 1232  
Kamen B, 832  
Kammer GM, 646  
Kanayama Y, 748  
Kane RL, 628  
Kano T, 680, 1050  
Kant JA, 770  
Kaplan AP, 944  
Kaplan D, 1039  
Kaplan F, 1032  
Kaplan HB, 1085  
Kaplan JE, 394  
Kaplan SB, 1427  
Kapoor WN, 1166  
Karakaya AE, 1412



Karsh J, 1440  
 Kater L, 695, 1295  
 Katz RS, 775  
 Kaufman JL, 1291  
 Kernodle GW Jr, 570  
 Khaw BA, 207  
 Khoury MI, 450  
 Kiljan E, 1485  
 Kinsella TD, 358  
 Kishore V, 411  
 Klareskog L, 106, 400, 730  
 Kleesiek K, 319  
 Klein KA, 1023  
 Klein M, 1026  
 Kleinheksel SM, 614  
 Klein-Nulend J, 1002  
 Klinkhoff AV, 1152  
 Klinman DM, 697  
 Klipple GL, 39  
 Knight PJ, 1052  
 Koch AE, 471  
 Kohashi O, 547  
 Kohashi Y, 547  
 Kohno A, 242  
 Koide J, 1216  
 Kolin A, 1284  
 Komar R, 1351  
 Kontinen YT, 47  
 Koopman WJ, 151, 1039, 1194  
 Koster JF, 1187  
 Kozin F, 577  
 Kremer JM, 822, 832  
 Kresina TF, 646, 863  
 Krueger GG, 782  
 Kuijter R, 1239, 1248  
 Kumagai N, 680  
 Kunnamo I, 47, 1232  
 Kuntz D, 453  
 Kurihara J, 680  
 Kurosaka M, 600  
 Kursunoglu S, 10  
 Kushner I, 303

## L

LaFeber GJM, 166  
 Lakhanpal S, 1414  
 Lambrey G, 301  
 Landsverk J, 1203  
 Lanken PA Jr, 153  
 LaPorte RE, 1269  
 Larson MG, 937, 1057  
 Larsson E, 106, 400  
 Larsson J, 817  
 Latman NS, 411  
 Lavaud S, 1170  
 Lawson JG, 1427  
 Laxer RM, 439, 997  
 Layfer LF, 775  
 Lea T, 175

Leake B, 628  
 Leavitt F, 775  
 LeClerc S, 1510  
 Lee JK, 822  
 Lee LA, 782  
 Lefrere JJ, 575  
 Legars D, 301  
 le Hoang P, 574  
 Leibovich SJ, 471, 573  
 Leijh PCJ, 166  
 Le Menn G, 147  
 le Minh H, 574  
 Lens JW, 665  
 Lentz D, 1023  
 Leon-Ponte M, 1446  
 LeRoy EC, 525, 816  
 Leroy JP, 147  
 Lessels AM, 337  
 Levine JD, 897, 1017  
 Levinson DJ, 880  
 Levinson JE, 274  
 Lewkonia RM, 358  
 Liang MH, 937  
 Lidsky MD, 1402  
 Lijewski JE, 1223  
 Linares L, 932  
 Lindholm L, 1405  
 Ling N, 65  
 Lionberger DR, 153  
 Lluberas G, 1480  
 Lockshin MD, 1467  
 Longhi M, 1532  
 Longley S III, 1039  
 Lorenzen I, 592  
 Lorish CD, 906  
 Losman MJ, 880  
 Lubeck DP, 488, 614  
 Lucas P, 453  
 Ludewig R, 1085  
 Luthra HS, 556

## M

Macartney HW, 379  
 Mackay IR, 174  
 Mahieu P, 300  
 Maisiak R, 906  
 Major P, 65  
 Makoul GT, 539  
 Malaise M, 300  
 Maldague B, 918  
 Malemud CJ, 863  
 Malghem J, 918  
 Malleson PN, 997  
 Malone DG, 956  
 Mankin HJ, 292, 1039  
 Mann DL, 185, 755  
 Manning M, 1527  
 Manoussakis MN, 1098  
 Manthorpe R, 857  
 Marcoux C, 1177

Maricic M, 133  
 Maricq HR, 452  
 Marie A, 301  
 Mark GE, 755  
 Martel-Pelletier J, 1112  
 Martin L, 65  
 Martin-Villa M, 932  
 Maruyama N, 242  
 Massi AT, 274, 453  
 Masuho Y, 1216  
 Matlis R, 971  
 Mayes M, 897  
 McAllister CB, 843  
 McCain GA, 655  
 McCallum RM, 448  
 McCarty DJ, 454  
 McCombs CC, 586  
 McCormick MC, 872  
 McGehee W, 808  
 McKendry RJR, 426  
 McKiernan FE, 304  
 McShane DJ, 1, 274, 706, 1039  
 Medcalf RL, 1397  
 Medsger TA Jr, 124, 515, 586, 1039, 1166, 1269  
 Meenan R, 1039  
 Mehlman I, 880  
 Meijon LV, 1387  
 Melin J-P, 1170  
 Mellbye OJ, 715  
 Ménard H-A, 1147  
 Menninger H, 379  
 Mertani EB, 574  
 Messner RP, 638  
 Metcalf JF, 525  
 Metcalfe DD, 956  
 Metzger AL, 431  
 Meunier PC, 1122  
 Meyling FHJG, 1295  
 Michalski JP, 586  
 Mielens Z, 394  
 Mikkelsen W, 1039  
 Mink JH, 431  
 Miossec P, 461  
 Mitchell DM, 488, 494, 614, 620, 706  
 Miyamoto T, 560, 793  
 Moatamed F, 128  
 Mochan BS, 770  
 Mochan E, 1078  
 Mol MJT, 813  
 Molden DP, 39  
 Mollnes TE, 715, 1359  
 Molony J, 16  
 Monsees B, 454  
 Montecucco C, 1532  
 Moore SE, 344  
 Moore TL, 142  
 Morales-Piga A, 1278  
 Moriarty M, 16

Morimoto C, 1216  
 Moriuchi J, 1518  
 Moskowitz MA, 897  
 Moskowitz RW, 863, 1039  
 Mottier D, 147  
 Moutsopoulos HM, 1098  
 Muirhead KA, 1122  
 Murakawa Y, 371  
 Murphy WA, 454, 1039

## N

Nagant de Deuxchaisnes C, 693, 918  
 Nakamura RM, 39  
 Neuss MN, 448  
 Newton P, 337  
 Newton R, 1078  
 Nicholas JJ, 934, 1176  
 Nielsen H, 857  
 Nilsson L-Å, 1405  
 Niwa Y, 371  
 Noel LH, 453  
 Nojima T, 292  
 Nomura S, 680  
 Norris DA, 782  
 Nussenblatt RB, 574

## O

Ochs HR, 971  
 O'Duffy JD, 556, 1414  
 Oen KG, 65, 797  
 Ogata T, 560  
 Oh SJ, 1173  
 Ohosone Y, 1343  
 Ohta K, 242  
 Okada H, 1050  
 Okudaira H, 560  
 Olsson N-O, 933  
 Oppenheim JJ, 114  
 Oppenheimer-Marks N, 789  
 Osborn TG, 142  
 Otterness IG, 1131  
 Owens GR, 515  
 Owens TR, 501  
 Oxholm A, 1052  
 Oxholm P, 857, 1052  
 Ozawa A, 547  
 Özdoğan H, 436

## P

Pachman LM, 1365  
 Page DL, 1170  
 Pahle J, 715  
 Palestine AG, 574  
 Palmoski MJ, 1256  
 Panush RS, 220  
 Papadopoulos NM, 1098  
 Partin J, 944  
 Pate D, 10

Patel DC, 1365  
 Paulus HE, 628, 1157, 1289  
 Paus A, 1359  
 Peebles CL, 39, 748  
 Pelkonen P, 1232  
 Pelletier JP, 1112  
 Pennec Y, 147  
 Pepys MB, 1131  
 Pereira RS, 1274  
 Perry RF, 452  
 Peter JB, 148, 1052  
 Petersen RA, 1057  
 Petite JP, 1054  
 Pettersson I, 986  
 Petty RE, 997  
 Phillips B, 174  
 Phillips TM, 296  
 Pierce L, 565  
 Piette JC, 574  
 Piferrer JM, 1387  
 Pinals RS, 1427  
 Pincus T, 508, 843, 1456  
 Pineda CJ, 10  
 Pisetsky DS, 1417  
 Pisko EJ, 286, 455  
 Polverini PJ, 471  
 Pope JH, 964  
 Pope RM, 1435  
 Pelkonen P, 1232  
 Popovic M, 185  
 Postl B, 65  
 Poznansky M, 944  
 Prickett JD, 539  
 Prince RK, 54  
 Prins APA, 1485  
 Priollet P, 189, 1054  
 Provost TT, 196  
 Pruzanski W, 1534  
 Puttick AH, 814

## Q

Qamar T, 1467  
 Quismorio FP Jr, 808

## R

Rakic M, 926  
 Ramadan F, 926  
 Ramirez F, 326  
 Rampon S, 1413  
 Ramsey-Goldman R, 1269  
 Ratnoff WD, 739  
 Redecha P, 1467  
 Reed M, 65  
 Reekers P, 415  
 Reginato AJ, 1387  
 Reibnegger G, 1063  
 Reichlin M, 196, 782  
 Resnick D, 10, 431  
 Riccardi A, 1532  
 Rich SA, 501

Richman S, 1  
 Riddle JM, 149  
 Rivera ER, 1387  
 Robaays G, 305  
 Robbins DL, 722  
 Roberts WN, 937  
 Roberts-Thomson PJ, 32, 1172  
 Robinson CA, 577  
 Robinson DR, 539  
 Rocamora-Ripoll A, 1278  
 Rodnan GP, 54, 515  
 Rodriguez MA, 1446  
 Roelke MS, 836  
 Rola-Pleszczynski M, 1147  
 Rook AH, 1210  
 Rose HA, 153  
 Rosen MS, 1473  
 Rosenberg AL, 880  
 Rosenberg AM, 797  
 Rosenbloom J, 851  
 Rosso R, 1532  
 Rostand KS, 95  
 Roth SH, 488, 614, 620, 1175  
 Rothfuss MS, 770, 889, 1387  
 Rothschild B, 1039  
 Rottembourg J, 574  
 Roujouleh H, 1170  
 Rourke CM, 836  
 Rowley M, 174  
 Roy-Byrne P, 1203  
 Rubenstein JD, 233  
 Rubin K, 106, 400, 730  
 Rubin RL, 39  
 Rubinow A, 445  
 Russell AS, 1510  
 Ryerse JS, 142

## S

Saelens JK, 394  
 Sakane T, 212, 371  
 Sany J, 675  
 Sardas OS, 1412  
 Sardas S, 1412  
 Sartoris D, 10  
 Sato K, 1518  
 Satoh M, 1343  
 Sauvezie B, 1413  
 Schalkwijk J, 532  
 Schaller JG, 274  
 Schiffman G, 26  
 Schmitt TC, 1122  
 Schneiderman R, 1365  
 Schreiber R, 1105  
 Schreuder I, 436  
 Schroeder ML, 65  
 Schrohenloher RE, 1194  
 Schumacher HR Jr, 770, 889, 1032, 1166, 1473, 1480  
 Schur PH, 419, 739, 1023

Schurman DJ, 1378

Schwartz JA, 937  
 Schwartz LB, 956  
 Schwingel M, 379  
 Scopelitis E, 586  
 Sculley TB, 964  
 Searles RP, 326  
 Sebert J-L, 301  
 Segal M, 1039  
 Seibold JR, 1052  
 Seidman JG, 1023  
 Semble EL, 286  
 Seoane JLF, 1387  
 Seror P, 152  
 Shader RI, 971  
 Sharp GC, 986  
 Sharp JT, 1  
 Shaw S, 1057  
 Sheehan NJ, 1296  
 Sherrer YS, 494  
 Sheth KJ, 450  
 Shigematsu N, 547  
 Shimizu H, 1518  
 Shimizu S, 150  
 Shiozawa S, 150  
 Shirai T, 242  
 Shortkroff S, 153  
 Sibbitt WL Jr, 326  
 Sieck MS, 770, 889  
 Sigal LH, 761  
 Silberman HR, 448  
 Silis M, 1098  
 Silver RM, 525  
 Singer JZ, 82  
 Skilling J, 722  
 Slade J, 1291  
 Sledge CB, 153, 937  
 Slowman SD, 88  
 Smajda A, 301  
 Smeltzer D, 363  
 Smiley JD, 344  
 Smith CB, 1263  
 Smith CR, 439  
 Smith EI, 986  
 Smith MD, 32  
 Smith PL, 1210  
 Smith RL, 1378  
 Sobel A, 1294  
 Sokoloff L, 660, 1039  
 Solary E, 933  
 Sontheimer RD, 421  
 Spalding DM, 75, 1173  
 Spiegel JS, 628, 1203  
 Spiegel TM, 628, 1203  
 Spitz PW, 1, 488, 614, 620, 706  
 Srolovitz H, 282  
 Stachura I, 54  
 Stalenhoef AFH, 813  
 Stålhandske T, 1405  
 Stanescu R, 573

Stastny P, 421  
 Stecher VJ, 394  
 Stechschulte DJ, 1029  
 Steen VD, 515, 1269  
 Steere AC, 761  
 Stein LD, 439  
 Steinberg AD, 539, 697  
 Stemmler MM, 872  
 Steven MM, 812  
 Stevens JO, 782  
 Stevens MB, 1177  
 Stone WJ, 1170  
 Strauss GD, 1203  
 Streckfuss A, 832  
 Strober S, 26  
 Stroud RM, 220  
 Stupi AM, 515  
 Sturrock RD, 812  
 Suarez-Almazor ME, 1510  
 Sukeinik S, 1026  
 Surbrugg SK, 782  
 Suzuki N, 212, 371  
 Swaak AJG, 1187  
 Szegedi G, 1053

## T

Tait B, 174  
 Takada S, 371  
 Takahash K, 560  
 Takahashi T, 547  
 Takano M, 1216  
 Takaya M, 1518  
 Takeuchi A, 793  
 Takeuchi T, 1216  
 Talal N, 1435  
 Tan EM, 39, 748  
 Tanay A, 26  
 Tanter Y, 933  
 Tarkowski A, 1405  
 Taylor DJ, 160  
 Taylor FH, 934  
 Taylor RP, 1417  
 Terkeltaub R, 363  
 Thakker S, 808  
 Thevenet JP, 1413  
 Thomas TJ, 638  
 Thompson MS, 937  
 Thomsen BS, 857  
 Toupance O, 1170  
 Tovar Z, 1435  
 Towle CA, 292  
 Townes AS, 1316  
 Treadwell BV, 292  
 Trostle DC, 124, 1166  
 Truckenbrodt H, 801  
 Tsao M, 1071  
 Tschesche H, 379  
 Tsokos GC, 185, 755, 1210  
 Tsuji K, 1518  
 Tsunematsu T, 212, 371

Turner R, 1056  
 Turon RP, 1387  
 Tuzi T, 1533  
 Tzioufas AG, 1098

## U

Uchino H, 680  
 Uchiyama M, 1518  
 Udell J, 1032  
 Ueda Y, 212, 371  
 Uhl J, 1078  
 Unni KK, 556  
 Urhahn JM, 142

## V

van den Barselaar MT, 166  
 van den Berg WB, 532, 665  
 van de Putte LBA, 415, 532, 665  
 van der Korst JK, 1239, 1248, 1485  
 van de Stadt RJ, 1239, 1248, 1485  
 van de Voorde-Vissers E, 1239, 1248  
 van Dissel JT, 166  
 van Eijk HG, 1187

van Houten Sauter S, 388  
 van Kampen GPJ, 1239, 1248  
 Vantelon J, 453  
 Varga J, 1160  
 Vasconez F, 1387  
 Vasil A, 782  
 Vaughn WK, 1456  
 Vayssairat M, 189  
 Veldhuijzen JP, 1002  
 Verdickt W, 305  
 Vernay D, 1413  
 Vertessen S, 305  
 Villena AA, 932  
 Votta BJ, 1122

## W

Wachter H, 1063  
 Wahl SM, 262  
 Wallace SL, 82  
 Wang G, 986  
 Ward NB, 628  
 Watson WC, 1316  
 Webber RJ, 1010  
 Webster EM, 220  
 Wechsler B, 574  
 Wei LS, 1263  
 Wei X, 660  
 Weiner SR, 1157

Weisbart RH, 1157  
 Weisman MH, 10, 431  
 Weissman B, 1  
 Weissmann G, 1085  
 Welsh K, 1274  
 Werner ER, 1063  
 Weston WL, 782  
 Whelan A, 16, 480  
 Whiteside TL, 54, 1071  
 Wigzell H, 400, 986  
 Wilder RL, 262  
 Wilkinson GR, 843  
 Williams RC Jr, 207, 326  
 Williamson PK, 227  
 Williamson WD, 1402  
 Wilson JG, 739  
 Wistar R Jr, 72  
 Withofs H, 918  
 Wolfe F, 1, 488, 614, 620, 1039, 1456  
 Woodruff TG, 32  
 Wooley PH, 1131, 1316  
 Woolley DE, 160  
 Woosley RL, 508, 843  
 Worrall JG, 54  
 Wortmann DW, 450  
 Wouda AA, 451  
 Wouters JMGW, 415  
 Wright GC Jr, 660

## Y

Yamagata H, 196, 1343  
 Yazici H, 436  
 Yelin EH, 1322  
 Yocum DE, 262  
 Yoffe JR, 160  
 Yoshida H, 242  
 Yoshinoya S, 560  
 Yoshizawa H, 560  
 Youinou P, 147  
 Young DY, 274, 494, 614, 706  
 Yow MD, 1402  
 Yunus MB, 453

## Z

Zackler L, 1203  
 Zalutsky MR, 153  
 Zea-Mendoza AC, 1278  
 Zeevi A, 1071  
 Ziegler GC, 1269  
 Ziff M, 352, 461, 600, 789  
 Zingraff J, 453  
 Zitaglio T, 1010  
 Zizic TM, 1177  
 Zuckerman JD, 153  
 Zurier RB, 312  
 Zwarts WA, 665

## SUBJECT INDEX

*Arthritis and Rheumatism*, Volume 29, Number 1 through 12, 1986

### A

- Abdomen, pain in fibromyalgia and, 775
- Acetylator phenotype in SLE, 508, 1412
- Acinar salivary gland epithelial cells, HLA-DR antigen on, in Sjögren's syndrome, 1105
- Acquired immunodeficiency syndrome (AIDS)
  - human T cell leukemia virus and, 185
  - Sjögren's syndrome and, 577
- Acroosteolysis, idiopathic familial, 1032
- Activities of daily living in childhood rheumatic disease, patient's family and, 872
- Acute-phase reactants, orosomucoid and haptoglobin, 1413
- Acute-phase response, in murine type II collagen arthritis, 1131
- Acute rheumatic fever, neutrophils in, 1334
- Adenosine creatine, muscle energy metabolism in primary fibromyalgia and, 817
- Adenosine diphosphate, muscle energy metabolism in primary fibromyalgia and, 817
- Adenosine induced-T4 → T8 phenotype switch in SLE, 646
- Adenosine monophosphate, muscle energy metabolism in primary fibromyalgia and, 817
- Adenosine triphosphate, muscle energy metabolism in primary fibromyalgia and, 817
- Adenylate cyclase stimulators, IL-1 induction of synovial cell plasminogen activator and, 1078
- Adherent cells, autoantibodies to U1 RNP in connective tissue disease and, 1343
- Adipose tissue, scleroderma in Raynaud's phenomenon, immobilization and, 1160
- Adjuvant arthritis
  - Escherichia coli* in germ-free rats and, 547
  - fibronectin in inflammation and, 394
  - macrophage activation in, 1122
  - neurotoxic effect of gold in rats and, 897
  - pain and disability in, 1017
  - progesterone secretion in rats in, 411
- Ads-1, Ads-3, Ads-4, gp70, anti-dsDNA and, in autoimmune New Zealand mice, 242
- Adult-onset gout, phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880
- Adult-onset Still's disease, HLA associations in, 415
- Adult sporadic hypophosphatemic osteomalacia, presenting as regional migratory osteoporosis, 688
- Adult-type osteopetrosis, presenting as carpal tunnel syndrome, 926
- Adverse drug reactions
  - monitoring of, 1175
  - to sulfasalazine in RA, 1427
- Age
  - proteoglycan, collagenase and, in cartilage, 1239, 1248
  - proteoglycan synthesis of fibrochondrocytes and, 1010 in RA
    - disability and, 494
    - mortality and, 706
  - salicylate kinetics and, 971
  - work disability in musculoskeletal disease and, 1322, 1410
- Agp-1, Agp-3, gp70, anti-dsDNA and, in autoimmune New Zealand mice, 242
- Airways obstruction in bronchiolitis in RA, auranofin and, 556
- AL amyloidosis, melphalan, prednisone, and colchicine in, 683
- Alcohol abuse, MSU crystals in knee joint in gout and, 1480
- Algorithms, ARA criteria for OA and, 1039
- Alleles, Bf, in SLE, 932
- Allergy, eosinophilic synovitis and, 1147
- Allied health professionals, cost of, in RA, 488
- Allopurinol hypersensitivity syndrome, 82
- $\alpha$ -interferon
  - scleroderma fibroblast collagen production by, 851 in SLE, 501
- $\alpha_1$ -antitrypsin phenotypes, in RA and systemic sclerosis, 586
- $\alpha_2$ -macroglobulin-proteinase in synovial fluid, in RA, 319
- $\alpha_2$ -proteinase inhibitor-elastase in synovial fluid, in RA, 319
- Ambulatory medical care, cost of, in RA, 488
- American Rheumatism Association
  - classification criteria of OA of knee, 1039
  - Presidential Address, 1986, 1297
  - Subcommittee for Classification for a Diagnosis of JRA, 274
- Amino-terminal type III procollagen peptide in RA, 592
- Amitriptyline
  - in fibromyalgia, 1371
  - in primary fibrositis, 655
- Amyloid
  - lymphadenopathy, in mixed (type II) cryoglobulinemia, 1050
  - polyneuropathy, familial, scalloped pupils in, 445
  - serum P, murine type II collagen arthritis and, 1131
  - SLE and, 680
- Amyloidosis
  - AL, melphalan, prednisone, and colchicine in, 683
  - destructive spondylarthropathy in hemodialysis and, 301
  - pulmonary, associated with SLE, 680
  - synovial,  $\beta_2$ -microglobulin and, in hemodialysis, 453
- Anaphylatoxins, complement, in SLE, 1085
- Anemia
  - aplastic, gold in bone marrow in, in JRA, 128



**Anemia (cont'd)**

- microangiopathic hemolytic, in Wegener's granulomatosis, 1515
- Anesthetic, spray coolant, in joint aspiration, 576
- Angiography, fluorescein, retinopathy, disease activity and, in SLE, 1152
- Animal studies. *See also* Bovine, Calf; Canine; Guinea Pig; Mouse; Rat
  - antibody binding in cutaneous lupus and, 782
- Ankle, hemarthrosis of, factor XIII deficiency and, 808
- Ankylosing spondylitis
  - anti-*Klebsiella* lymphocytotoxicity in, 358
  - familial, HLA-B27 haplotype in, 1510
- Ankylosis, hereditary joint disorder in ank/ank mice and, 114
- Anserine bursitis, 812
- Anterior cruciate ligament
  - canine, glycoprotein in OA cartilage in, 1256
  - of knee, in cartilage matrix glycoprotein in canine OA, 1493
- Antibodies
  - anticardiolipin, 1052, 1295
  - anticentriole, 142
  - anti-collagen (type II), 400, 730
  - anti-DNA, 26, 242, 1216, 1351
  - anti-EBNA-2, 964
  - anti- $\gamma$ -interferon, 1105
  - antigranulocyte, 26
  - antihistone, 148, 748
  - anti-HLA-B27, 352
  - anti-La, 981
  - antineuronal, in CNS lupus, 1090
  - antinuclear. *See* Antinuclear antibodies
  - anti-P, 981
  - antiphospholipid, 695, 1535
  - antiribosomal P protein, 981, 1090
  - anti-Ro, 981
  - anti-Ro (SS-A), 782
  - anti-SS-A, 1269
  - aseptic arthritis in toxic shock syndrome and, 910
  - autoantibodies in CNS lupus and, 1090
  - binding of, in cutaneous lupus, animal model of, 782
  - collagen, 174, 1131
  - coxsackie B virus, 365
  - cytoskeletal, 1351
  - effects of total lymphoid irradiation on, in SLE and RA, 26
  - human T cell leukemia virus in SLE and, 185
  - idiotype, autoimmunity and, 697
  - IgM anti-histone H-3, 39
  - lymphocytotoxic, 326
  - monoclonal, 32, 400, 471, 600, 730, 863, 1105, 1194, 1351, 1417
  - OKM1, OKM5, 471
- Anticardiolipin
  - antibodies, 1052, 1295
  - vascular complications, oral contraceptives and, 1294

- Anticentriole antibody in progressive systemic sclerosis, 142
- Anticentromere, complement activation and, 748
- Anticoagulant, lupus
  - anticardiolipin antibodies, prednisone and, 1295
  - fetal loss in SLE and, 695
- Anticollagen antibodies, murine type II collagen arthritis and, 1131
- Anti-CR1, Anti-CR2 complement receptors in SLE and, 739
- Anti-denatured DNA (dDNA), in (NZB  $\times$  NZW) $F_1$  mice, 1139
- Anti-DNA
  - antibodies
    - DNA-daunorubicin complexes and, in SLE, 1216
    - effect of total lymphoid irradiation on, 16
    - monoclonal, cytoskeletal binding of, 1351
    - complement activation and, 748
    - in SLE, 1417
- Anti-double-stranded DNA
  - antibodies, gp70 and in autoimmune New Zealand mice, 242
  - anti-P antibody in SLE and, 981
  - complement activation and, 748
- Anti-EBNA-2 in RA, 964
- Anti- $\gamma$ -interferon antibody, HLA-DR on salivary gland epithelial cells in SS and, 1105
- Antigen cytotoxic-drug conjugates, DNA-daunorubicin, anti-DNA antibodies and, in SLE, 1216
- Antigen-induced arthritis in mice, 665
- Antigens
  - anti-P antibody and, 981
  - anti-type II collagen monoclonals and, in RA and OA, 730
  - autoantibodies in CNS lupus and, 1090
  - B1, 739
  - Borrelia burgdorferi*, 761
  - cardiac myosin-heavy chain, 107
  - EBNA-2, 964
  - environmental, 220
  - histocompatibility, 1105
  - HLA. *See* HLA antigens
  - Ia, 1122
  - Ia-like, 32
  - microbial, 352
  - in monarticular JRA, 47
  - monoclonal antibody analysis of OA cartilage and, 863
  - nucleic acid, 1351
  - RANA, 964
  - response of, mononuclear cells in Lyme disease and, 761
  - schistosomal, 296
  - Sm, 986
  - streptococcal cell wall, 262
  - T3, T4, T8 surface, 646
- Antigranulocyte antibodies, effects of total lymphoid irradiation on, in SLE and RA, 26
- Antihistone
  - antibodies, 39, 148, 748
  - complement activation and, 748

- Anti-HLA-B27 antibodies in gram-negative bacterial infections, 352
- Anti-HLA-DR  
monoclonal antibodies, in staining of RA synovium, 600  
neovascularization in RA and, 471
- Anti-human IgE, histamine in synovial fluid mast cells and, 956
- Antihypertensive drugs, debrisoquine oxidation phenotypes in SLE and, 843
- Anti-Ia  
Aschoff lesions in rheumatic myocarditis and, 207  
monoclonal antibodies, in HLA-DR staining in RA synovium, 600
- Antiidiotypy, autoimmunity and, 697
- Anti-IgE, synovial mast cells and, 944, 956
- Antiinflammatory actions of gold, neurotoxic effect of, on peripheral nerves in rats, 897
- Antiinflammatory drugs, FDA Arthritis Advisory Committee Meeting on, 1289
- Anti-*Klebsiella* lymphocytotoxicity, in ankylosing spondylitis, 358
- Anti-La antibodies, anti-P in SLE and, 981
- Anti-La (SS-B) in Sjögren's syndrome, 196
- Anti-Leu-11b, Ig production, natural killer cells and, in RA, 1435
- Anti-Leu M-3  
Aschoff lesions in rheumatic myocarditis and, 207  
neovascularization in RA and, 471
- Antilymphocyte antibodies, immunoglobulin and interferon release in SLE and, 326
- Anti-monocyte/macrophage (63D3) monoclonal antibodies, HLA-DR staining in RA synovium and, 600
- Anti-native DNA (Anti-nDNA)  
IgM anti-histone H-3 antibody and, 42  
mouse model of antibody binding in cutaneous lupus and, 782  
in (NZB  $\times$  NZW)F<sub>1</sub> mice, 1139
- Antineuronal antibodies, autoantibodies in CNS lupus and, 1090
- Antinuclear antibodies  
anti-Ro (SS-A), anti-nRNP (Sm) and, in SS, 196  
autoantibodies to U1 RNP in connective tissue disease and, 1343  
classification of Sjögren's syndrome and, 577  
complement activation by, 748  
effects of total lymphoid irradiation on, in SLE and RA, 26  
IgM anti-histone H-3, in rheumatic diseases, 39  
in SLE, 457
- Antinuclear histone, complement activation and, 748
- Antinuclear ribonucleoprotein (Anti-nRNP)  
complement activation and, 748  
in Sjögren's syndrome, 196
- Anti-P antibody in SLE, 981
- Antiparasitic drugs  
in *Schistosoma mansoni* infection with arthritis, 296
- Antiphospholipid antibodies in SLE  
chorea, oral contraceptives and, 1535  
fetal loss, lupus anticoagulant and, 695
- Anti-RANA in RA, 964
- Antirheumatic drugs, patients' knowledge of, 934
- Antiribonucleoprotein (Anti-RNP) in mixed connective tissue disease and SLE, 986
- Antiribosomal P protein antibody  
autoantibodies in CNS lupus and, 1090  
in SLE, 981
- Anti-Ro antibodies, anti-P in SLE and, 981
- Anti-Ro (SS-A)  
cryoglobulinemia in autoimmune rheumatic diseases and, 1098  
mouse model of antibody binding in cutaneous lupus and, 782  
in Sjögren's syndrome, 196
- Anti-single-stranded DNA (Anti-ssDNA), IgM anti-histone H-3 antibody and, 42
- Anti-Sm antigen, complement activation and, 748
- Anti-SS-A, fetal outcome in maternal SLE and, 1269
- Anti-SS-B/La, complement activation and, 748
- Anti-T cell autoantibodies in SLE, 646
- Anti-Tac, immunoglobulin and interferon release in SLE and, 333
- Anti-type II collagen  
autoantibodies, collagen (type II) arthritis in mice and, 106  
monoclonal antibodies in RA and OA, 730
- Anti-U1 ribonucleoprotein (Anti-U1 RNP) in connective tissue diseases, 1343
- Anti-vimentin antibody B11.5.1, mouse monoclonal, monoclonal cytoskeletal antibodies and, 1351
- Apatite deposition disease, crystal-associated arthropathy in hemodialysis and, 1387
- Aplasia, bone marrow, in gold-induced neutropenia, 1515
- Aplastic anemia, gold in bone marrow in, in JRA, 128
- Apophyseal joint cyst, in back pain and sciatica in RA, 431
- Arachidonic acid  
histamine-stimulated PGE and, 160  
phospholipase activity in RA and, 312
- Arteries  
calcification of, crystal arthropathy, hemodialysis and, 1387  
tibial, thrombosis of, gangrene, lupus vasculitis and, 1291  
vertebral, pseudoaneurysm of, in cervical spine in RA, 136
- Arthralgia, IgM anti-histone H-3 antibody and, 39
- Arthritis  
acute, 889, 1232, 1278  
adjuvant, 394, 411, 547, 897, 1017, 1122  
allergic, 220  
antigen-induced, in mice, 665  
aseptic, in toxic shock syndrome, 910  
autoimmune, rat cytomegalovirus infection and, 1263  
bacterial, staphylococcal PG-releasing factor and, 1378  
childhood, 997, 1232

### Arthritis (*cont'd*)

- chronic, 889, 997, 1232
- collagen-induced, 106, 400, 1131, 1263, 1501
- destructive, 812
- experimental, 106, 1017, 1263
- food-induced, 220
- immune complex, 296
- infectious, 227
- inflammatory, 220
- liposome-induced synovitis in rabbits and, 889
- manubriosternal joint, 1029
- methyated bovine serum albumin-induced, 665
- monarticular, 1147, 1166
- MSU crystals in knee in gout and, 1480
- pericarditis, camptodactyly, coxa vara and, 436
- psoriatic, 1029
- self-management courses and exercise, evaluation of, 388
- streptococcal cell wall-induced, 262
- terminology and, 1232
- in urban Finnish children, 1232

### Arthritis self-management courses, 388

### Arthropathy

- camptodactyly-arthropathy-pericarditis syndrome, 439
- cutaneous calcinosis and, in hemodialysis oxalosis, 1387
- factor XIII deficiency and, 808
- human parvovirus, 575

### Arthroplasty, total joint, cost-effectiveness of, in OA, 937

### Articular bone, cytomegalovirus infection, collagen arthritis and, 1263

### Articular chondrocytes

- human, histamine-stimulated PGE and, 160
- inorganic pyrophosphate release by, in rabbits, 1485

### Articular disease, diagnosis of, in RA, 614

### Articular involvement, in JRA and uveitis, 797

### Articular tissue, OA in metacarpophalangeal joint and, 1284

### Aschoff lesions, florid rheumatic, immunofluorescence studies of, 207

### Aseptic arthritis in toxic shock syndrome, 910

### Aseptic necrosis of bone, diagnosis of, 1177

### Aspirin

- phospholipase activity in RA and, 312
- salicylate kinetics and, 971

### Assistive devices, cost of, in RA, 488

### Ataxia, phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880

### Auranofin, bronchiolitis in RA and, 556

### Auricles, Aschoff lesions in rheumatic myocarditis and, 207

### Autoantibodies

- anticentriole, in progressive systemic sclerosis, 142
- anti-Ro (SS-A) and anti-La (SS-B) in SS, 196
- anti-T cell, 646
- anti-type II collagen, 106
- in cerebrospinal fluid in SLE, 1090
- classification of Sjögren's syndrome and, 577
- collagen, type II, in RA, 1316

### Autoantibodies (*cont'd*)

- effects of total lymphoid irradiation in SLE and RA on, 26
- gp70, anti-dsDNA and, in New Zealand mice, 242
- monoclonal cytoskeletal antibodies and, 1351
- U1 RNP, in connective tissue disease, 1343

### Autoantigens, lupus, in SLE, 457

### Autoimmune arthritis, rat cytomegalovirus infection and, 1263

### Autoimmune disease

- anti-P antibody in, 981
- female sex hormones in collagen arthritis and, 1501
- proto-oncogenes in, 755
- rheumatic, cryoglobulinemia in, 1098
- Sjögren's syndrome and, 577

### Autoimmunity

- gp70, anti-dsDNA and, in New Zealand mice, 242
- idiotypy and, 697
- in MRL/l mice, LS-2616 therapy in, 1405
- nDNA and dDNA detection by ELISPOT in mice and, 1139

### Avascular necrosis of bone, diagnosis of, 1177

### Axial skeleton, human parvovirus arthropathy and, 575

### Axons, neurotoxic effect of gold in rats and, 897

### Azathioprine, amino-terminal type III procollagen peptide in RA and, 592

## B

### B cells

- autoantibodies to U1 RNP in connective tissue disease and, 1343
- in Behçet's disease, 212
- IgM rheumatoid factor, *Staphylococcus aureus* Cowan I and, 1440
- immune deficiency of, in Sjögren-like syndrome, 1532
- interleukin-1 chemotactic activity in RA and, 461
- proto-oncogenes in SLE and autoimmune diseases and, 755
- in recent-onset monarticular JRA, 47
- in Sjögren's syndrome
- hyperreactivity of, 1098
- immunoglobulin and rheumatoid factor synthesis by, 1446
- in SLE, 501
- complement receptors and, 739
- DNA-daunorubicin, anti-DNA antibodies and, 1216
- B1 antigen, complement receptors in SLE and, 739
- B27 haplotypes, ankylosing spondylitis in families and, 1510
- Back pain
- in fibromyalgia, 775
- in RA, 431, 775
- Bacteria, *Escherichia coli* in adjuvant arthritis in rats, 547
- Bacterial arthritis, staphylococcal proteoglycan-releasing factor and, 1378

## Bacterial infections

- after renal transplantation, 227
- gram-negative, anti-HLA-B27 antibodies in, 352

## Beans, food-induced arthritis and, 220

## Beck test in diagnosis of xerostomia, 936

## Behçet's disease

- B cell functions in, 212
- CNS and cerebrospinal fluid IgM index in, 793
- cyclosporin A in, 574
- interleukin-2 in, 371

## Benign monoclonal gammopathy, in scleromyxedema, 913

## $\beta$ -2-microglobulin, dialysis-related amyloid and, 1170

## Bf polymorphisms, in SLE patients of Spanish descent, 932

## Biomechanics

- growth plate cartilage calcification and, 1002
- in myectomy and tendotomy-induced OA, 251

## Biopsy, in recent monarticular JRA, 47

## Birefringent spherulites, liposome-induced synovitis in rabbits and, 889

## Bleeding factor XIII deficiency in hemarthrosis and, 808

## Blood urea nitrogen, nDNA and dDNA detection by ELI-SPOT in mice and, 1139

## Blood vessels

- binding of human mononuclear cells to, in RA, 789
- in idiopathic familial acroosteolysis, 1032
- macrophage activation in adjuvant arthritis and, 1122

## Bone

- articular, cytomegalovirus infection and, 1263
- biopsy of, 926, 1032
- cement-interface, total hip replacement and, 836
- cysts, subchondral, in rheumatoid nodulosis, 1278
- erosions, crystal arthropathy, hemodialysis and, 1387
- fragments, in synovium in metacarpophalangeal OA, 1284
- growth plate cartilage calcification and, 1002
- idiopathic familial acroosteolysis and, 1032
- innominate, Paget's disease of, OA and, 1414
- ischemic necrosis of, diagnosis of, 1177
- lysis of, prosthetic loosening after hip replacement and, 836
- marrow
  - aplasia of, in gold-induced neutropenia, 1515
  - gold and, in aplastic anemia in JRA, 128
  - lymphocytosis and, 675
- mass, menopause, glucocorticoids and, in RA, 693
- proteoglycan synthesis of meniscal fibrochondrocytes and, 1010
- resorption of, after total hip replacement, 836
- small, of hand, rheumatoid nodulosis and, 1278
- spicules, in adult-type osteopetrosis, 926

## Book Reviews

- Arthritis and Allied Conditions*, 10th ed (McCarty, ed), 455
- Arthritis and the Elderly* (Moskowitz and Haug, eds), 1416
- Autoantibodies to Nuclear Antigens* (Nakamura et al), 816
- Psoriatic Arthritis*, (Gerber and Espinoza), 455

## Book Reviews (cont'd)

- Rehabilitation Management of Rheumatic Conditions* (Ehrlich, ed), 1176
- Rheumatismo, Artritis y Otros Males* (Alarcón-Segovia), 936
- Rheumatoid Arthritis* (Gordon, ed), 1056
- Systemic Sclerosis (Scleroderma): Current Topics in Rheumatology* (Black and Myers, eds), 816
- Textbook of Rheumatology*, 2nd ed (Kelley et al, eds), 455
- Borrelia burgdorferi* antigens, mononuclear cells in Lyme disease and, 761
- Bovine studies
  - effect of sodium selenite on chondrocytes in, 660
  - oxygen radicals and cartilage destruction in, 379
  - proteoglycanase from human OA chondrocytes in, 292
- Breast mass, in Wegener's granulomatosis, 1515
- Bronchiolitis, in RA, auranofin and, 556
- Bronchoalveolar lavage fluid, interstitial lung disease in scleroderma and, 525
- Bursitis
  - anserine, 812
  - olecranon, crystal arthropathy, hemodialysis and, 1387
  - septic, toxic shock syndrome and, 910
- BXSB mice, dietary fish oil and renal disease in lupus and, 539

## C

## Calcifications

- articular, in cartilage in metacarpophalangeal OA, 1284
- in growth plate cartilage, 1002
- Calcinosis cutaneous, arthropathy and, in hemodialysis oxalosis, 1387
- Calcitriol, in osteomalacia, 918
- Calcium
  - hydroxyapatite, joint disorder in ank/ank mice and, 114
  - ionophore A23187, rheumatoid synovial mast cells and, 944
  - warfarin sodium and, in rheumatic diseases, 344
- Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease, pressure erosions in, 454
- Calf studies, lupus-inducing drugs and B to Z DNA transition, 638
- cAMP, IL-1 induction of synovial cell plasminogen activator and, 1078
- Camptodactyly, pericarditis, arthritis, coxa vara and, 436
- Camptodactyly-arthropathy-pericarditis syndrome, 439
- Campylobacter jejuni*, anti-HLA-B27 antibodies and, 352
- Canine studies
  - cartilage matrix glycoprotein in OA, 1493
  - glycoprotein in articular cartilage, 1256
  - glycosaminoglycan metabolism of articular cartilage, 88
  - 4-carboxy-L-glutamic acid, warfarin sodium and, in rheumatic diseases, 344
- Cardiac involvement, Aschoff lesions and, in rheumatic myocarditis, 207



- Cardiolipin, monoclonal cytoskeletal antibodies and, 1351
- Cardiomyopathy, amyloid, in AL amyloidosis, 683
- Carpal tunnel syndrome
- adult-type osteopetrosis presenting as, 926
  - dialysis membrane in hemodialysis and, 1170
- Carrageenan-induced inflammation, fibronectin and, 394
- Cartilage
- in adult-type osteopetrosis, 926
  - anti-type II collagen monoclonals and, in RA and OA, 730
  - articular
    - collagenase and, 1239, 1248
    - fibrillation in, in metacarpophalangeal OA, 1284
    - glycosaminoglycan metabolism in, 88
    - human, 292, 379, 1239, 1248, 1316
    - proteoglycanase from OA chondrocytes of, 292
    - proteoglycans in, 95, 292, 1239, 1248
    - surface, negative charge of, 573
  - bacterial arthritis and, *Staphylococcus aureus* in, 1378
  - collagen-induced arthritis and, 400
  - damage to, hydrogen peroxide-induced tissue damage and, 532
  - degradation of, 379, 1112
  - fragments of, PPI release by rabbit chondrocytes and, 1485
  - growth plate, calcification of, 1002
  - hypertrophic, 1002
  - matrix glycoprotein, in canine studies, 1256, 1493
  - OA, monoclonal antibody analysis of, 863
  - oxygen radicals and, 379
  - rat cytomegalovirus infection, collagen arthritis and, 1263
  - water content of, in myectomy and tendotomy-induced OA, 251
- Catalase
- cartilage destruction and, 379
  - hydrogen peroxide-induced tissue damage and, 532
- Catalytic defects, phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880
- Cationized ferritin, negative charge of articular cartilage surface and, 573
- Cell lysate, polymorphonuclear cells, MSU-induced superoxides and, 1473
- Cell membranes, lipoprotein, crystals, inflammation and, 363
- Cellular immunity, urinary neopterin in RA and, 1063
- Central nervous system
- anti-P antibody in SLE and, 981
  - cerebrospinal fluid and, in Behçet's disease, 793
  - disease of
    - autoantibodies in, in SLE, 1090
    - in primary Sjögren's syndrome, 1223
- Central nervous system lupus. *See also* Cutaneous lupus; Drug-induced lupus erythematosus; Idiopathic systemic lupus erythematosus; Lupus; Maternal systemic lupus erythematosus; Neonatal lupus; Systemic lupus erythematosus
- autoantibodies in, 1090
- Cerebrospinal fluid
- autoantibodies in, in SLE, 1090
  - CNS disease in primary Sjögren's syndrome and, 1223
  - IgM, CNS involvement in Behçet's disease and, 793
- Cervical spine, pseudoaneurysm of vertebral artery in RA in, 136
- Charcot-Leyden crystals, eosinophilic synovitis and, 1147
- Chemotactic activity, interleukin-1, in RA, 461
- Childhood arthritis, in urban Finnish, 1232
- Childhood rheumatic diseases, impact of, on family, 872
- Chloroquine, retinopathy and disease activity in SLE and, 1152
- Chondrocalcinosis, crystal-associated arthropathy in hemodialysis and, 1387
- Chondrocytes
- articular, 160, 1485
  - effect of sodium selenite on, 660
  - hydrogen peroxide-induced tissue damage and, 532
  - hypertrophic, growth plate cartilage calcification and, 1002
- Chondroitin sulfate
- articular cartilage proteoglycans in OA mice and, 95
  - proteoglycan, collagenase and, in cartilage, 1239, 1248
- Chondrosarcoma, dermatomyositis and, 813
- Chorea, antiphospholipid antibodies, contraceptives and, in SLE, 1535
- Chorée fibrillaire, followed by Guillain-Barré syndrome after gold in RA, 1413
- Chromosome 17, gp70, anti-dsDNA and, in autoimmune New Zealand mice, 242
- Chronic disease, work disability in musculoskeletal disease and, 1322, 1410
- Churg-Strauss vasculitis
- eosinophilic vasculitic neuropathy in, 1173
  - necrotizing systemic vasculitis and, 565
- <sup>14</sup>C-hydroxyproline production, scleroderma fibroblast collagen,  $\gamma$ -interferon and, 851
- Circulating immune complexes
- C3b and, in primary Sjögren's syndrome, 857
  - IgG-milk, food-induced arthritis and, 220
- Coagulopathy, consumptive, in Wegener's granulomatosis, 1527
- Colchicine
- in AL amyloidosis, 683
  - in lipid microspherule-associated monarticular arthritis, 1166
  - toxicity and death due to, 448
- Collagen
- arthritis, type II, 400, 1131, 1263, 1501
  - biosynthesis, scleroderma in Raynaud's phenomenon and, 1160
  - collagenase, proteoglycans and, in articular cartilage, 1239
  - deposition, scleroderma in Raynaud's phenomenon and, 1160
  - fibroblasts, scleroderma,  $\gamma$ -interferon and, 851

### Collagen (*cont'd*)

- homologous type II, arthritis induced in mice and, 106
- monoclonal anti-type II antibodies, in RA and OA, 730
- neutral proteases in human OA synovium and, 1112
- in RA
  - denatured, antibodies to, 174
  - neovascularization and, 471
  - type II, autoantibodies in, 1316

### Collagenase

- $\alpha_2$ -macroglobulin-proteinase in RA and, 319
- in macrophages, gold sodium thiomalate-induced, 75
- oxygen radicals, cartilage destruction and, 379
- proteoglycans and, in human articular cartilage, 1239, 1248
- pyrophosphate release by rabbit chondrocytes and, 1485
- synovial cell, rabbit genes for, 1301

### Color vision, retinopathy, disease activity and, in SLE, 1152

### Comorbidity, work disability in musculoskeletal disease and, 1322, 1410

### Complement

- activation of
  - in antinuclear antibodies, 748
  - in aseptic arthritis in toxic shock syndrome, 910
  - in JRA, 1359
  - in RA, 715
  - in SLE, 739, 1085, 1467
- anti-HLA-B27 antibodies in gram-negative infections and, 355
- coxsackie B virus in juvenile dermatomyositis and, 1365
- neutrophils and, in SLE, RA, and acute rheumatic fever, 1334

### Complement C1s-C1, inhibitor complex, hypocomplementemia and, in SLE, 1467

### Complement C3

- activation of, in JRA, 1359
- antinuclear antibodies and, 748
- aseptic arthritis in toxic shock syndrome and, 910
- C1s-C1 inhibitor complex in SLE and, 1467
- neovascularization in RA and, 471
- phagocytosis and intracellular killing by SF PMN and, 166
- in primary Sjögren's syndrome, 857

### Complement C3a, anaphylatoxins, in SLE, 1085

### Complement C3b

- in primary Sjögren's syndrome, 857
- receptors, HLA-DR3 antigen and, 300

### Complement C3b/C4b, receptors, in SLE, 739

### Complement C3c, in primary Sjögren's syndrome, 857

### Complement C3d

- in primary Sjögren's syndrome, 857
- receptors, in SLE, 739

### Complement C3dg

- complement activation in JRA and, 1359
- in RA, 715

### Complement C4

- antinuclear antibodies and, 748
- aseptic arthritis in toxic shock syndrome and, 910

### Complement C4 (*cont'd*)

- C1s-C1 inhibitor complex in SLE and, 1467
- cryoglobulinemia in Sjögren's syndrome and, 1098

### Complement C4a, in systemic sclerosis, 1274

### Complement C4a desarg, C1s-C1 inhibitor complex in SLE and, 1467

### Complement C5, type II collagen autoantibodies in RA and, 1316

### Complement C5a

- anaphylatoxins, in SLE, 1085
- type II collagen autoantibodies in RA and, 1316

### Complement CH50, C1s-C1 inhibitor complex in SLE and, 1467

### Compliance, patients' knowledge of antirheumatic drugs and, 934

### Compound 48/80, histamine in synovial fluid mast cells and, 956

### Compressive force, growth plate cartilage calcification as a result of, 1002

### Concanavalin A

- DNA-daunorubicin, anti-DNA antibodies and, in SLE, 1216
- lymphoblasts, IL-2, T cells and, in Behçet's disease, 371
- scleroderma-like phenotypes from mononuclear cells and, 54

### Congenital cytomegalovirus infection, maternal SLE and, 1402

### Congenital heart block, fetal, anti-SS-A antibodies and, in maternal SLE, 1269

### Connective tissue

- effect of sodium selenite on chondrocytes and, 660
- histamine in synovial fluid mast cells and, 956
- monoclonal antibody analysis of OA cartilage and, 863
- rheumatoid synovial mast cells and, 944

### Connective tissue disease. *See also* Mixed connective tissue disease

- autoantibodies to U1 RNP in, 1343
- Sjögren's syndrome and, HLA antigens in, 1518
- undifferentiated, IgM anti-histone H-3 antibody and, 39

### Contraceptives, oral

- anticardiolipin and vascular complications in, 1294
- antiphospholipid antibodies, chorea and, in SLE, 1535

### Cornea, rat, neovascularization in RA and, 471

### Coronary heart disease, MSU crystals in knee joint in gout and, 1480

### Cortical neurons, human, autoantibodies in CNS lupus and, 1090

### Corticosteroid drugs. *See also* Glucocorticoid drugs; Steroid drugs

- CNS disease in primary Sjögren's syndrome and, 1228
- methotrexate and, in JRA, 801
- necrotizing systemic vasculitis and, 565
- progressive multifocal leukoencephalopathy in SLE and, 337
- type II muscle atrophy and, 555

### Cost-effectiveness, of total joint arthroplasty in OA, 937

Cotton-wool spots, retinopathy, disease activity and, in SLE, 1152

Coxa vara, pericarditis, arthritis, camptodactyly and, 436

Coxsackie B virus antibodies, in juvenile dermatomyositis, 1365

C-reactive protein  
in JRA  
complement activation and, 1359  
methotrexate and, 801  
murine type II collagen arthritis and, 1131  
in RA  
intractable, total lymphoid irradiation and, 23  
methyprednisolone infusion therapy and, 32  
in Wegener's granulomatosis, 1527

Creatine, muscle energy metabolism in primary fibromyalgia and, 817

Creatinine, serum, MSU crystals in knee joint in gout and, 1480

Cruciate ligament, anterior, matrix glycoprotein in canine OA and, 1493

Cryoglobulinemia  
in autoimmune rheumatic diseases, 1098  
mixed (type II), amyloid lymphadenopathy in, 1050  
in Raynaud's disease, 1026

Cryoglobulins, primary monoclonal, in Sjögren's syndrome, 1098

Cryoprecipitate infusions, arthropathy, factor XIII deficiency and, 808

Crystals  
calcium oxalate, arthropathy and, in hemodialysis, 1387  
Charcot-Leyden, eosinophilic synovitis and, 1147  
monosodium urate, 1172, 1473  
synovial fluid analysis and, 770

Cutaneous calcinosis, arthropathy and, in hemodialysis oxalosis, 1387

Cutaneous dermatographism, eosinophilic synovitis and, 1147

Cutaneous lupus. *See also* Central nervous system lupus; Drug-induced lupus erythematosus; Idiopathic systemic lupus erythematosus; Lupus; Maternal systemic lupus erythematosus; Neonatal lupus; Systemic lupus erythematosus  
animal model of antibody binding in, 782  
erythematosus, subacute, concurrent RA and, 421

Cutaneous polyarteritis nodosa, destructive arthritis and, 812

Cyanine dyes, fluorescent, macrophage activation in adjuvant arthritis and, 1122

Cycloheximide  
autoantibodies to U1 RNP in connective tissue disease and, 1343  
glycoprotein and, in OA cartilage, 1256

Cyclooxygenase inhibitors, IL-1 induction of synovial cell plasminogen activator and, 1078

Cyclophosphamide  
LS-2616 therapy of autoimmunity in MRL/l mice and, 1405  
in necrotizing systemic vasculitis, 565  
in Wegener's granulomatosis in elderly, 1157

Cyclosporin A  
in Behçet's disease, 574  
in streptococcal cell wall-induced arthritis, 262

Cystic lesions, subchondral, in rheumatoid nodulosis, 1278

Cysts, apophyseal joint, back pain and sciatica in RA and, 431

Cytochrome P-450, debrisoquine oxidation phenotypes in SLE and, 843

Cytodiagnostic urinalysis, in necrotizing systemic vasculitis, 565

Cytomegalovirus infection  
congenital, maternal SLE and, 1402  
type II collagen arthritis and, in rats, 1263

Cytoplasmic esterase, monarticular JRA and, 47

Cytoskeletal antibodies, in tonsillar lymphoid cells, 1351

Cytotoxicity, effect of sodium selenite on chondrocytes and, 660

## D

DA rats, cytomegalovirus infection and collagen arthritis in, 1263

Darier's disease, coexistent primary Sjögren's syndrome and, 1052

Daudi cell line in SLE, 501

Daunorubicin hydrochloride, anti-DNA antibodies in SLE and, 1216

DBA/1 mice, collagen-induced arthritis in, 106, 1501

Deafness, sensorineural, PRPP synthetase activity and, 880

Debrisoquine oxidation phenotypes, in SLE, 843

Denatured DNA (dDNA), detection of, by ELISPOT, 1139

Deoxyribonucleic acid (DNA)  
anti-native. *See* Anti-native DNA  
antibody response to, in autoimmune New Zealand mice, 242  
denatured. *See* Denatured DNA  
double-stranded. *See* Double-stranded DNA  
effect of sodium selenite on chondrocytes and, 660  
glycosaminoglycan metabolism of articular cartilage and, 88  
human T cell leukemia virus in SLE and, 185  
lupus-inducing drugs and, 638  
monoclonal cytoskeletal antibodies and, 1351  
nDNA and dDNA in (NZB × NZW)<sub>F</sub><sub>1</sub> mice and, 1139  
neutral proteases in OA synovium and, 1116  
scleroderma fibroblast collagen,  $\gamma$ -interferon and, 851  
single-stranded. *See* Single-stranded DNA  
T cells in SLE and, 1023

Depression  
arthritis self-management courses and, 388  
MMPI and, in RA, 1456

- Dermal fibroblasts**  
glycosaminoglycan stimulatory factor, cloned T cells and, 1071  
scleroderma in Raynaud's phenomenon, immobilization and, 1160  
scleroderma-like phenotypes from mononuclear cells and, 54
- Dermatomyositis**  
chondrosarcoma and, 813  
D-penicillamine-induced polymyositis in RA and, 560  
effect of warfarin sodium on glutamic acid excretion in, 344  
juvenile, coxsackie B virus antibodies in, 1365
- Dermis, scleromyxedema and, 913**
- Destructive arthritis, cutaneous polyarteritis nodosa and, 812**
- Destructive spondylarthropathy, in hemodialysis, 1171**
- Diabetes**  
mellitus, retinopathy, disease activity and, in SLE, 1152  
renal phosphate, regional migratory osteoporosis and, 688
- Dialysis, peritoneal, in gold toxicity, 450**
- Dialysis membrane, carpal tunnel syndrome and, in hemodialysis, 1170**
- Dialysis-related amyloid,  $\beta$ -2-microglobulin and, 1170**
- Dibutyl cAMP, IL-1 induction of synovial cell plasminogen activator and, 1078**
- Dietary fish oil, renal disease in murine lupus and, 539**
- Digital ulceration, pentoxifylline in Raynaud's phenomenon in SLE and, 1055**
- Diltiazem, esophageal sphincter pressure in PSS and, 1054**
- Dimethyl sulfoxide (DMSO)**  
FDA Arthritis Advisory Committee and, 1289  
in scleroderma, 1289
- Diphtheria toxoid, effects of TLI on autoantibodies in SLE and RA and, 26**
- Disability**  
development of, in RA, 494  
impact of specific therapy on, in RA, 620  
pain and, in experimental arthritis, 1017  
work, in musculoskeletal conditions, 1322, 1410
- Disease activity**  
in adult-onset Still's disease, 415  
in JRA, complement activation and, 1359  
in RA  
amino-terminal type III procollagen peptide and, 592  
group therapy and, 1203  
intractable, total lymphoid irradiation and, 16  
methylprednisolone infusion therapy and, 32  
MMPI scores and, 1456  
murine type II collagen arthritis and, 1131  
rehabilitation and, 628  
urinary neopterin and, 1063  
in Sjögren's syndrome, C3b and, 857  
in SLE, 501, 1152  
in Wegener's granulomatosis, 1527
- Disease duration**  
effect of intraarticular triamcinolone hexacetonide in knee and, 997  
in RA, erosion of distal interphalangeal joints in, 10
- Disease exacerbation, complement activation during, in SLE, 1085**
- Disease modifying antirheumatic drugs (DMARD), guidelines for clinical evaluation of, 1289**
- Disease onset, disability in RA and, 494**
- Disease severity**  
in adjuvant arthritis, 1017  
in RA  
MMPI scores and, 1456  
mortality and, 706
- DNA-anti-DNA, immune complexes, in SLE, 1417**
- DNA-daunorubicin complexes, anti-DNA antibodies in SLE and, 1216**
- Double-stranded DNA (dsDNA), anti-P antibodies in SLE and, 981**
- Drug-induced lupus erythematosus. *See also* Central nervous system lupus; Cutaneous lupus; Idiopathic systemic lupus erythematosus; Lupus; Maternal systemic lupus erythematosus; Neonatal lupus; Systemic lupus erythematosus**  
antihistone antibodies in, 148
- Drug reactions, adverse, monitoring of, 1175**
- Drugs. *See also* Gold**  
allopurinol, 82  
amitriptyline, 1371  
antigen-cytotoxic conjugates, 1216  
antihypertensive, 843  
antiinflammatory, 1289  
antirheumatic, 934  
aspirin, 312, 971  
auranofin, 556  
azathioprine, 592  
calcitriol, 918  
chloroquine, 1152  
colchicine, 448, 683, 1166  
corticosteroid, 337, 555, 565, 801, 1228  
cost of, in RA, 488  
cycloheximide, 1343  
cyclophosphamide, 565, 1157, 1405  
daunorubicin hydrochloride, 1216  
debrisoquine, 843  
diltiazem, 1054  
disease-modifying antirheumatic (DMARD), 1289  
DMSO, 1289  
folinic acid, 832  
forskolin, 1078  
glucocorticoid, 32, 693  
hydralazine, 638  
hydroxychloroquine, 620  
ibuprofen, 620  
immunosuppressive, 337



## Drugs (cont'd)

- indomethacin, 305, 532, 620, 839, 1078
  - isoniazid, 638
  - L-canavanine, 638
  - lupus-inducing, 638
  - meclofenamate, 620
  - melphalan, 680
  - methotrexate, 133, 151, 620, 801, 822, 832, 902, 1289
  - N-acetyl procainamide, 638
  - naproxen, 305, 620, 1371
  - nifedipine, 1053, 1054
  - NSAID, 620, 1289
  - penicillamine, 450, 592, 620, 638
  - pentoxifylline, 1055
  - piroxicam, 532, 620
  - prednisone, 620, 683, 706, 822, 1295, 1402
  - procainamide, 638
  - steroid, 680, 902, 1112
  - sulfasalazine, 1427
  - sulindac, 620
  - tetracycline, 1032
  - thalidomide, 1296
  - theophylline, 1078
  - tolmetin, 620
  - triamcinolone hexacetonide, 997
  - tunicamycin, 1485
  - Vivonex, 220
  - warfarin sodium, 344
- Ductal salivary gland epithelial cells, HLA-DR antigen on, in Sjögren's syndrome, 1105
- Dyscrasia, plasma cell, 233, 1534
- Dysesthesia, pentoxifylline in Raynaud's phenomenon in SLE and, 1055
- Dysphagia, in scleromyxedema, 913
- Dysprosium 165, in rheumatoid synovitis of knee, 153

## E

- Ebselen, hydrogen peroxide-induced tissue damage and, 532
- Ectopic calcifications, warfarin, glutamic acid and, in rheumatic diseases, 344
- Edema, adjuvant arthritis and  
macrophage activation in, 1127  
progesterone secretion in, 411
- Effusions, intraarticular triamcinolone hexacetonide in knee and, 997
- Elastase, oxygen radicals, cartilage destruction and, 379
- Elbow, joint, OA in, in jackhammer operator, 1284
- Elderly  
salicylate kinetics and, 971  
Wegener's granulomatosis in, 1157
- End-stage renal failure, crystal-associated arthropathy in, 1387
- Endocrine-exocrine diseases, autoimmune, HLA-DR and epithelial cells in, 1105
- Endothelial cells  
bovine, effect of sodium selenite on chondrocytes and, 660  
interleukin-1 chemotactic activity in RA and, 461
- Endothelial vessels, binding of mononuclear cells to, in RA synovial membrane, 789
- Enteropathic arthritis, in urban Finnish children, 1232
- Environmental antigens, food-induced arthritis and, 220
- Enzyme immunoassay, IgM anti-histone H-3 antibodies and, 39
- Enzyme-linked immunosorbent assay (ELISA)  
autoantibodies to U1 RNP in connective tissue disease and, 1343  
nDNA and dDNA detection by ELISPOT in mice and, 1139
- Enzyme-linked immunospot assay (ELISPOT), detection of nDNA and dDNA in (NZB  $\times$  NZW) $F_1$  mice by, 1139
- Enzymes  
liver, methotrexate and, in JRA, 801  
macrophage collagenase, gold sodium thiomalate and, 75  
phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880  
proteoglycan-degrading, neutral proteases in human OA and, 1112
- Eosinophilia, allopurinol hypersensitivity syndrome, 82
- Eosinophilic synovitis, dermatographism and, 1147
- Eosinophilic vasculitis  
necrotizing systemic vasculitis and, 565  
neuropathy in, in Churg-Strauss syndrome, 1173
- Epithelial cells  
autoantibodies in CNS lupus and, 1090  
human, monoclonal cytoskeletal antibodies and, 1351  
salivary gland, HLA-DR on, in Sjögren's syndrome, 1105
- Epstein-Barr virus  
complement receptors in SLE and, 739  
nuclear antigen, type II, in RA, 964
- Erosions  
bone, crystal-associated arthropathy in hemodialysis and, 1387  
chest, in manubriosternal synovitis in psoriasis, 1029  
in RA  
amino-terminal type III procollagen peptide and, 592  
methotrexate and, 822  
subchondral, hydrogen peroxide-induced tissue damage and, 532
- Erosive arthropathy, calcium crystals, hemodialysis and, 1387
- Erosive synovitis, cyclosporin A and, in streptococcal cell wall arthritis, 262
- Erythrocyte sedimentation rate  
methotrexate and, in JRA, 801  
pleurisy, IgM anti-histone H-3 antibody and, 39  
total lymphoid irradiation in intractable RA and, 23  
in Wegener's granulomatosis, 1527

Erythrocytes  
 complement C3b and  
 receptors, HLA-DR3 antigen and, 300  
 in Sjögren's syndrome, 857  
 complement receptors in SLE and, 739  
 phosphoribosylpyrophosphate (PRPP) synthetase activity  
 and, 880

*Escherichia coli*  
 adjuvant arthritis in germ-free rats and, 547  
*Klebsiella* lymphocytotoxicity in AS and, 358

Esophageal spincter pressure, in PSS, diltiazem versus  
 nifedipine in, 1054

Esterase, neovascularization in RA and, 471

Estrogen, glucocorticoid and, in RA, 694

Euglobulins, immunoglobulin and interferon release in SLE  
 and, 326

European League Against Rheumatism, 929

Exercise, arthritis self-management courses and, 388

Exertional dyspnea, steroid-resistant, pulmonary amyloid-  
 osis, SLE and, 680

Experimental arthritis  
 homologous type II collagen-induced arthritis in mice, 106  
 pain and disability in, 1017  
 rat cytomegalovirus infection and collagen arthritis, 1263

Experimental osteoarthritis  
 induced by myectomy and tendotomy, 251  
 monoclonal antibody analysis of cartilage in, 863

Extracellular matrix, glycosaminoglycan metabolism of ar-  
 ticular cartilage and, 88

Extraglandular disease, cryoglobulinemia in Sjögren's syn-  
 drome and, 1098

Extremities, pain and disability in, in experimental arthritis,  
 1017

Eye, neovascularization in rat cornea in RA, 471

## F

F344 rats, *Escherichia coli* in adjuvant arthritis in, 547

Face Scale, nonverbal method for assessing patient mood,  
 906

Factor XIII, deficiency, arthropathy and, 808

Factor B  
 aseptic arthritis in toxic shock syndrome and, 910  
 null alleles, C4A and, in systemic sclerosis, 1274

Familial acroosteolysis, idiopathic, 1032

Familial amyloid polyneuropathy, scalloped pupils in, 445

Familial disease, phosphoribosylpyrophosphate (PRPP) syn-  
 thetase activity and, 880

Familial syndrome, pericarditis, arthritis, camptodactyly,  
 and coxa vara, 436

Family, impact of childhood rheumatic disease on, 872

Fatigue, amitriptyline and naproxen in fibromyalgia and,  
 1371

Fatty acids  
 phospholipase activity in RA and, 312

Fatty acids (*cont'd*)  
 renal disease in mice and, 539

Fc receptors  
 neovascularization in RA and, 471  
 phagocytosis by synovial fluid polymorphonuclear cells  
 and, 166

FDA Arthritis Advisory Committee discussions  
 adverse drug reactions and, 1175  
 antiinflammatory drugs, clinical evaluation of, 1289  
 methotrexate, 1289

Feet  
 in osteomalacia, 918  
 in RA  
 pain in, 775  
 surgery in, 614  
 in rheumatoid nodulosis, 1278

Felty's syndrome, low-dose oral methotrexate in, 902

Female sex hormones, in collagen-induced arthritis in mice,  
 1501

Femoral cartilage, OA, monoclonal antibody analysis of, 863

Femoral condyle, canine, GAG metabolism of articular  
 cartilage and, 88

Femoral head  
 in myectomy and tendotomy-induced OA, 254  
 negative charge of articular cartilage surface of, 573

Ferric hydroxide, dysprosium 165 and, in rheumatoid syno-  
 vitis of knee, 153

Ferritin, cationized, negative charge of articular cartilage  
 and, 573

Ferritin-bound iron, intraarticular, in RA, 1187

Fertility, anti-SS-A antibodies and, in SLE, 1269

Fetal outcome  
 anti-SS-A antibodies and, in maternal SLE, 1269  
 lupus anticoagulant and, in SLE, 695

Fever, allopurinol hypersensitivity syndrome and, 82

Fibrillar cytoplasmic staining, by monoclonal cytoskeletal  
 antibodies, 1351

Fibrillation, in articular cartilage in metacarpophalangeal  
 OA, 1284

Fibroblasts  
 collagen production of, scleroderma,  $\gamma$ -interferon and, 851  
 dermal, GAG stimulatory factor, cloned T cells and, 1071  
 effect of sodium selenite on chondrocytes and, 660  
 HLA-DR staining in RA synovium and, 600  
 neovascularization in RA and, 471  
 phosphoribosylpyrophosphate (PRPP) synthetase activity  
 and, 880  
 proto-oncogenes in SLE and autoimmune diseases and,  
 755  
 scleroderma in Raynaud's phenomenon, immobilization  
 and, 1160  
 scleroderma-like phenotypes from mononuclear cells and,  
 54  
 synovial  
 histamine-stimulated PGE and, 160  
 human, urokinase-type plasminogen activator and, 1397

#### Fibroblasts (*cont'd*)

rabbit genes, synovial cell collagenase and, 1301

Fibrochondrocytes, rabbit meniscal, proteoglycan synthesis of, 1010

#### Fibromyalgia

natural history of, 1522

pain in, 775

primary, phosphates and muscle energy metabolism in, 817

syndrome, juvenile primary, 452

#### Fibronectin

in inflammation, 394

neovascularization in RA and, 471

#### Fibrosis

interstitial, pulmonary hypertension in CREST syndrome and, 515

pulmonary interstitial,  $\alpha_1$ -antitrypsin and, 586

scleroderma in Raynaud's phenomenon, immobilization and, 1160

Fibrositis, primary, amitriptyline in, 655

#### Fingers

in idiopathic familial acroosteolysis, 1032

joints of, crystal arthropathy in hemodialysis and, 1387

pain in, in RA, 775

pentoxifylline in Raynaud's phenomenon and, 1055

Fish oil, dietary, renal disease in murine lupus and, 539

Fluorescein angiography, retinopathy, disease activity and, in SLE, 1152

Fluorescent cyanine dyes, macrophage activation in adjuvant arthritis and, 1122

Folate, methotrexate metabolism in RA and, 832

Folic acid antagonist, megaloblastic pancytopenia after administration of, in RA, 133

Folinic acid, methotrexate and, in RA, 832

Food-induced arthritis, 220

Force, compressive, growth plate cartilage calcification and, 1002

Forskolin, IL-1 induction of synovial cell plasminogen activator and, 1078

Fractures, dialysis-related amyloid,  $\beta_2$ -microglobulin and, 1170

#### Functional ability

disability in RA and, 494

work disability in musculoskeletal disease and, 1322, 1410

#### Functional status

in OA, cost-effectiveness of total joint arthroplasty and, 937

in RA

group therapy and, 1203

rehabilitation and, 628

### G

Gait abnormalities, in myectomy and tendotomy-induced OA, 251

#### Gamma globulin

anti-Ro (SS-A), anti-La (SS-B) and, in SS, 196

#### Gamma globulin (*cont'd*)

intravenous, in gold-induced thrombocytopenia, 426

neutrophils and, in SLE, RA, and acute rheumatic fever, 1334

#### $\gamma$ -interferon

deficiency of, in SLE, 1210

HLA-DR on salivary gland epithelial cells in SS and, 1105

Gastrointestinal complications, methotrexate and, in JRA, 801

#### Gastrointestinal involvement in RA

mortality and, 706

reactions to sulfasalazine and, 1427

Gender, salicylate kinetics and, 971

#### Genetics

B27 haplotypes in ankylosing spondylitis and, 1510

complement receptors in SLE and, 739

gp70 and anti-dsDNA in autoimmune New Zealand mice and, 242

hereditary joint disease in ank/ank mice and, 114

HLA antigens and, in Sjögren's syndrome, 1518

idiopathic familial acroosteolysis and, 1032

polymorphism, debrisoquine oxidation phenotypes in SLE and, 843

rabbit genes for synovial cell collagenase and, 1301

T cells and, in SLE, 1023

Genomic clones, rabbit genes for synovial cell collagenase and, 1301

Genotoxicity, methotrexate and, 1289

Giant cell reaction, prosthetic loosening after total hip replacement and, 836

Global assessment, amitriptyline and naproxen in fibromyalgia and, 1371

Global health, cost-effectiveness of total joint arthroplasty in OA and, 937

Glomerular podocytes, complement receptors in SLE and, 739

#### Glomerulonephritis

dietary fish oil and, in renal disease in murine lupus, 539

LS-2616 therapy of autoimmunity in MRL/l mice and, 1405

necrotizing, necrotizing systemic vasculitis and, 565

Glomerulopathy, microangiopathic, in POEMS syndrome, 233

Glucocorticoid drugs. *See also* Corticosteroid drugs; Steroid drugs

menopause, bone mass and, in RA, 693

Glucose oxidase, hydrogen peroxide-induced tissue damage and, 532

Glutamic acid, warfarin sodium and, in rheumatic diseases, 344

Glutathione peroxidase, hydrogen peroxide-induced tissue damage and, 532

#### Glycoprotein

$\alpha_1$ -antitrypsin and, in RA and systemic sclerosis, 586

cartilage and, in canine studies, 1256, 1493

fibronectin in inflammation and, 394

## Glycosaminoglycans

- articular cartilage and, 88, 95
- scleroderma-like phenotype in fibroblasts and, 54
- Staphylococcus aureus* in bacterial arthritis and, 1378
- stimulatory factor of, cloned T cells and, 1071
- Gm allotyping type II collagen autoantibodies in RA and, 1316
- Gold. *See also* Auranofin
  - in bone marrow in aplastic anemia and JRA, 128
  - toxicity of, peritoneal dialysis in, 450
  - in RA
    - intramuscular, 620
    - mortality and, 706
    - mucocutaneous toxicity and HLA-Bw35 after, 303
- Gold-induced neutropenia, HLA-DR antigens in, 1515
- Gold-induced thrombocytopenia, intravenous gamma globulin in, 426
- Gold salts, rheumatoid factor synthesis in RA and, 480
- Gold sodium thiomalate
  - neurotoxic effect of, in rats, 897
  - rheumatoid factor synthesis in RA and, 480
- Gold therapy
  - aplastic anemia secondary to, in JRA, 128
  - impact of, in RA, 620
  - neurotoxic effect of, on peripheral nerves in rats, 897
  - rheumatoid factor synthesis and, in RA, 480
- Gold toxicity
  - penicillamine in, 450
  - peritoneal dialysis in, 450
- Gout
  - acute
    - in manubriosternal joint, 570
    - polymorphonuclear cells, MSU, superoxides and, 1473
  - asymptomatic nontophaceous, MSU crystals in knee joint in, 1480
  - crystal-associated arthropathy in hemodialysis and, 1387
  - inflammation, crystals, lipoprotein and, 363
  - monosodium urate crystals in, 1172
  - phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880
- gp70 immune complexes, retroviral, in autoimmune New Zealand mice, 242
- Graft-versus-host disease, Sjögren's syndrome and, 577
- Gram-negative bacterial infections, anti-HLA-B27 antibodies in, 352
- Granular lymphocytes in RA, 675
- Granulocytes
  - antigen-induced arthritis in mice and, 665
  - ferritin-bound iron in RA and, 1187
  - low-dose oral methotrexate in Felty's syndrome and, 902
- Granuloma
  - hepatic, cyclosporin A and, 262
  - intraosseous rheumatoid, in rheumatoid nodulosis, 1278
- Granulomatosis
  - allergic (Churg-Strauss syndrome), 565, 1173
  - Wegener's, 565, 1157

- Grip strength, sulfasalazine in RA and, 1427
- Group therapy, in RA, 1203
- Growth factor, T cells, GAG stimulatory factor and, 1071
- Growth plate cartilage, calcification of, 1002
- Guillain-Barré syndrome, Chorée fibrillaire before, after gold in RA, 1413
- Guinea pig studies, myectomy and tendotomy-induced OA, 251

## H

- <sup>3</sup>H-glucosamine, scleroderma-like phenotypes from mononuclear cells and, 54
- <sup>3</sup>H-leucine, glycoprotein and, in OA cartilage, 1256
- <sup>3</sup>H-mannose, glycoprotein and, in OA articular cartilage, 1256
- H-2 complex, gp70, anti-dsDNA and, in New Zealand mice, 242
- Hajdu-Cheney syndrome, histomorphometric study of, 1032
- Hand
  - crystal-associated arthropathy in hemodialysis and, 1387
  - in idiopathic familial acroosteolysis, 1032
  - OA of, in an Inuit population, 69
  - in osteomalacia, 918
  - in RA
    - assessment of radiologic progression in, 1
    - distal interphalangeal joint involvement in, 10
  - scleroderma in Raynaud's phenomenon, immobilization and, 1160
  - small bone of, rheumatoid nodulosis and, 1278
- Handedness, in SLE, 419
- Haplotypes, B27 in ankylosing spondylitis, 1510
- Haptoglobin, acute-phase reactant, 1413
- Head, pain in fibromyalgia and, 775
- Health Assessment Questionnaire Disability Index, cost in RA and, 488
- Health behavior, arthritis self-management course and, 388
- Health care utilization and costs, in RA, 488
- Health status
  - cost-effectiveness of total joint arthroplasty in OA and, 937
  - work disability in musculoskeletal disease and, 1322, 1410
- Heart
  - Aschoff lesions in rheumatic myocarditis, 207
  - coronary heart disease and MSU crystals in knee in gout, 1480
- Helper cells
  - Ig and RF synthesis in Sjögren's syndrome and, 1446
  - IgM-RF, *Staphylococcus aureus* Cowan I and, 1440
- Hemarthrosis, ankle, factor XIII deficiency and, 808
- Hemodialysis
  - carpal tunnel syndrome, dialysis membrane and, 1170
  - destructive spondylarthropathy in, 301, 1171
  - oxalosis, arthropathy and cutaneous calcinosis in, 1387
  - synovial amyloidosis and  $\beta_2$ -microglobulin in, 453



- Hemodynamic studies, in diagnosis of ischemic necrosis of bone, 1177
- Hemoglobin, methotrexate and, in JRA, 801
- Hemolytic anemia, microangiopathic, in Wegener's granulomatosis, 1527
- Hemophilia, arthropathy, factor XIII deficiency and, 808
- Hemorrhage, complication of warfarin sodium, 344
- Hepatic folate deficiency, methotrexate metabolism in RA and, 832
- Hepatic granuloma, cyclosporin A and, 262
- Hepatitis B
- in Raynaud's disease, 1026
  - surface antigen, in juvenile dermatomyositis, 1365
- Hepatocellular injury, allopurinol hypersensitivity syndrome and, 82
- Hepatotoxicity, methotrexate and, 822, 832, 1289
- Hereditary joint disorder, in ank/ank mice, 114
- Herpes zoster infection, methotrexate and, in JRA, 801
- Hip
- OA, Paget's disease and, 1414
  - pain in, in fibromyalgia, 775
  - proteoglycan after collagenase in cartilage and, 1248
  - total replacement of, prosthetic loosening after, 836
  - transient synovitis of, in urban Finnish children, 1232
- Histamine
- lymphokines, rheumatoid synovial mast cells and, 944
  - synovial fluid mast cells and, 956
- Histamine-stimulated prostaglandin E, 160
- Histiocytes
- HLA-DR staining in RA synovium and, 600
  - interleukin-1 chemotactic activity in RA and, 461
- Histomorphometric studies, idiopathic familial acroosteolysis, 1032
- HLA
- antigens
    - in adult-onset Still's disease, 415
    - null alleles, C4A and, in systemic sclerosis, 1274
    - in rheumatic diseases in an Inuit population, 65
    - in Sjögren's syndrome in Japanese, 1518
  - haplotypes, in JRA, 1059
- HLA-B8, null alleles, C4A and, in systemic sclerosis, 1274
- HLA-B27
- in ankylosing spondylitis, 1510
  - gram-negative bacterial infections and, 352
  - Klebsiella* lymphocytotoxicity in AS and, 358
  - in rheumatic diseases in an Inuit population, 65
- HLA-Bw35
- in adult-onset Still's disease, 415
  - antigen, mucocutaneous toxicity after gold in RA and, 303
- HLA-DP antigens, in pauciarticular JRA, 1057
- HLA-DR
- allorecognition, GAG stimulatory factor, T cells and, 1071
  - antigens
    - in gold-induced neutropenia, 1515
    - methylprednisolone infusion therapy in RA and, 32
    - salivary gland in Sjögren's syndrome and, 1105
  - HLA-DR (*cont'd*)
    - staining, in RA synovium, 600
  - HLA-DR1, adult-onset Still's disease and, 415
  - HLA-DR2, positivity, methotrexate and, in RA, 151
  - HLA-DR3
    - antigens, C3b receptor (CR1) on erythrocytes and, 300
    - anti-Ro (SS-A), anti-La (SS-B) and, in SS, 196
    - in gold-induced neutropenia, 1515
    - null alleles, C4A and, in systemic sclerosis, 1274
  - HLA-DR4
    - in adult-onset Still's disease, 415
    - antigen, in gold-induced neutropenia, 1515
    - collagen antibodies in RA and, 174
    - in an Inuit population, 65
  - HLA-DR5
    - null alleles, C4A and, in systemic sclerosis, 1274
    - pauciarticular JRA and, 1057
  - HLA-DR6, in adult-onset Still's disease, 415
  - HLA-DRw8, pauciarticular JRA and, 1057
  - HLA-DRw52 (MT2), HLA-DRw53 (MT3), in Sjögren's syndrome, 1518
  - Homologous type II collagen-induced arthritis in mice, 106
  - Hormones
    - sex
      - female, in collagen-induced arthritis in mice, 1501
      - steroids, debrisoquine oxidation phenotypes in SLE and, 343
  - Hospitalization, in RA, 488, 614
  - Hue discrimination, retinopathy, disease activity and, in SLE, 1152
  - Human studies
    - articular chondrocytes and histamine-stimulated PGE, 160
    - B lymphoblastoid cell line in SLE, 501
    - binding of mononuclear cells to blood vessels in RA, 789
    - cartilage
      - articular, proteoglycans, collagenase and, 1239, 1248
      - type II collagen autoantibodies in RA and, 1316
    - cortical neurons and autoantibodies in CNS lupus, 1090
    - epithelial cells and monoclonal cytoskeletal antibodies, 1351
    - IgG and 19S rheumatoid factor avidity, 722
    - neovascularization in RA synovial tissue macrophages, 571
    - neutral proteases in OA synovium, 1112
    - parvovirus arthropathy, 575
    - proteoglycanase in OA chondrocytes, 292
    - T cell lymphotropic retroviruses in RA, 1533
    - type C retrovirus and T cell leukemia virus in SLE, 185
    - urokinase plasminogen activator in synovial fibroblasts, 1397
  - Hyaluronic acid, in scleromyxedema, 913
  - Hybridoma supernatants, monoclonal cytoskeletal antibodies and, 1351
  - Hydralazine, B to Z DNA transition and, 638
  - Hydrocortisone, in hereditary joint disorder in ank/ank mice, 114

Hydrogen peroxide  
 in experimental model of tissue damage, 532  
 ferritin-bound iron in RA and, 1187  
 Hydroxychloroquine in RA, 620  
 Hydroxyl radicals, ferritin-bound iron in RA and, 1187  
 Hydroxyproline, cartilage destruction and, 379  
 Hyperplasia, rheumatoid synovial mast cells and, 944  
 Hyperreactivity  
 antigen-induced arthritis in mice and, 665  
 B cell, cryoglobulinemia in Sjögren's syndrome and, 1098  
 Hypersensitivity, milk, food-induced arthritis and, 220  
 Hypertension  
 MSU crystals in knee joint in gout and, 1480  
 pulmonary, in CREST syndrome, 515  
 in SLE  
 lupus anticoagulant, veno-occlusive disease and, 147  
 retinopathy, disease activity and, 1152  
 Hypertrophic cartilage, growth plate, calcifications and, 1002  
 Hypertrophy, synovial, neutral proteases in human OA synovium and, 1112  
 Hyperuricemia, phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880  
 Hypochondriasis, MMPI and, in RA, 1456  
 Hypocomplementemia, C1s-C1 inhibitor complex in SLE and, 1467  
 Hypophosphatemic osteomalacia, regional migratory osteoporosis and, 688  
 Hyposelenosis, effect of sodium selenite on chondrocytes and, 660  
 Hypoxanthine, cartilage destruction and, 379  
 Hysteria, MMPI and, in RA, 1456

## I

Ia antigen, macrophage activation in adjuvant arthritis and, 1122  
 Ia cells, recent monarticular JRA and, 47  
 Ia-like antigens, methylprednisolone infusion therapy in RA and, 32  
 Ibuprofen in RA, 620  
 Idiopathic familial acroosteolysis, pentoxifylline in Raynaud's phenomenon in SLE and, 1055  
 Idiopathic osteoarthritis, ARA criteria for, 1039  
 Idiopathic systemic lupus erythematosus. *See also* Central nervous system lupus; Cutaneous lupus; Drug-induced lupus erythematosus; Lupus; Maternal systemic lupus erythematosus; Neonatal lupus; Systemic lupus erythematosus  
 acetylator phenotype and, 508  
 debrisoquine oxidation phenotypes in, 843  
 Idiotype, autoimmunity and, 697  
 IgA  
 anti-Ro (SS-A), anti-La (SS-B) and, in SS, 196  
 CNS involvement in Behçet's disease and, 793

## IgA (cont'd)

rheumatoid factor  
 molecular forms of, in RA, 1194  
 synthesis of, gold therapy and, 480

## IgE

anti-milk, food-induced arthritis and, 220  
 in peripheral blood in eosinophilic synovitis, 1147  
 rheumatoid synovial mast cells and, 944

## IgG

antibodies  
 binding of, in mouse cutaneous lupus, 782  
 type II collagen autoantibodies in RA and, 1316  
 anti-Ro (SS-A), anti-La (SS-B) and, in SS, 196  
 anti-T cell autoantibodies and, in SLE, 646  
 autoantibodies to U1 RNP in connective tissue disease and, 1343  
 CNS disease in primary Sjögren's syndrome and, 1223  
 CNS involvement in Behçet's disease and, 793  
 collagen autoantibodies (type II) in RA and, 1316  
 complement activation by antinuclear antibodies and, 748  
 DNA-daunorubicin, anti-DNA antibodies and, in SLE, 1216  
 food-induced arthritis and, 220  
 human, 19S IgM rheumatoid factor avidity and, 722  
 IgM anti-histone H-3 antibody and, 39  
 interferon release and, in SLE, 326  
 mouse, monoclonal antibody analysis of OA cartilage and, 863  
 nDNA and dDNA detection by ELISPOT and, 1139  
 polymorphonuclear cell lysis, MSU, superoxides and, 1473  
 production of, natural killer cells and, in RA, 1435  
 rheumatoid factor, synthesis of, gold therapy and, 480  
 synthesis of  
 intrathecal, autoantibodies in CNS lupus and, 1090  
 in Sjögren's syndrome, 1446

## IgM

anti-histone H-3 antibody, rheumatic disease syndromes and, 39  
 anti-Ro (SS-A), anti-La (SS-B) and, in SS, 196  
 anti-T cell autoantibodies and, in SLE, 646  
 cerebrospinal fluid, CNS and, in Behçet's disease, 793  
 interferon release and, in SLE, 326  
 monoclonal cytoskeletal antibodies and, 1351  
 nDNA and dDNA detection by ELISPOT and, 1139  
 production of, natural killer cells and, in RA, 1435  
 rheumatoid factor  
 in Sjögren's syndrome, 1446  
*Staphylococcus aureus* Cowan I and, 1440  
 synthesis of, gold therapy and, 480  
 total lymphoid irradiation in RA and, 23  
 in Sjögren's syndrome, 1446  
 cryoglobulinemia in, 1098  
 Iliac crest bone in idiopathic familial acroosteolysis, 1032  
 Immobilization of limb, scleroderma in Raynaud's phenomenon after, 1160

- Immune complex arthritis, in *Schistosoma mansoni* infection, 296
- Immune complexes
  - aseptic arthritis in toxic shock syndrome and, 910
  - C1s-C1 inhibitor complex in SLE and, 1467
  - cryoglobulinemia in Sjögren's syndrome and, 1098
  - DNA-anti-DNA, in SLE, 1417
  - gp70, anti-dsDNA and, in autoimmune New Zealand mice, 242
  - interstitial lung disease in scleroderma and, 525
  - methylprednisolone infusion therapy in RA and, 32
- Immune deficiency, primary B cell, in Sjögren-like syndrome, 1532
- Immune response,
  - HLA-DR staining in RA synovium and, 600
  - monarticular JRA and, 47
- Immune system, idiotype, autoimmunity and, 697
- Immunoblotting
  - autoantibodies to U1 RNP in connective tissue disease and, 1343
  - snRNP in mixed connective tissue disease and SLE and, 986
- Immunocompetent cells, CNS disease in primary Sjögren's syndrome and, 1223
- Immunofixation, cryoglobulinemia in autoimmune rheumatic diseases and, 1098
- Immunofluorescence
  - monoclonal cytoskeletal antibodies and, 1351
  - rheumatic Aschoff lesions and, 207
- Immunogenetics
  - HLA-DP antigens in pauciarticular JRA and, 1057
  - HLA-DR antigens in gold-induced neutropenia and, 1515
- Immunoglobulins
  - in Behçet's disease
    - B cell function in, 212
    - CNS involvement in, 793
  - chemotherapy in type AL amyloidosis and, 683
  - in cryoglobulinemia in rheumatic diseases, 1098
  - IgM anti-histone H-3 antibodies and, 39
  - production of, natural killer cells and, in RA, 1435
  - rheumatoid factor synthesis and
    - in gold therapy, 480
    - in Sjögren's syndrome, 1446
  - in SLE sera, 326
  - total lymphoid irradiation in intractable RA and, 23
- Immunohistology, macrophage activation in adjuvant arthritis and, 1126
- Immunomodulation, naproxen and, 305
- Immunomodulators, LS-2616 therapy of autoimmunity in MRL/l mice and, 1405
- Immunopathogenesis, for CNS disease in primary Sjögren's syndrome, 1223
- Immunoperoxidase, HLA-DR on salivary gland epithelial cells in SS and, 1105
- Immunoprecipitation, snRNP and, in mixed connective tissue disease and SLE, 986
- Immunoreactive enzymes, phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880
- Immunosuppression in maternal SLE, congenital cytomegalovirus infection and, 1402
- Immunosuppressive therapy, progressive multifocal leukoencephalopathy in SLE and, 337
- Implant loosening after total hip replacement, 836
- Index of Well-Being, cost-effectiveness of total joint arthroplasty in OA and, 937
- Indomethacin
  - bone resorption after total hip replacement and, 839
  - hydrogen peroxide-induced tissue damage and, 532
  - IL-1 induction of synovial cell plasminogen activator and, 1078
  - immunomodulation and, 305
- Infection
  - cytomegalovirus
    - congenital, maternal SLE and, 1402
    - type II collagen arthritis in rats and, 1263
  - gram-negative bacterial, anti-HLA-B27 antibodies in, 352
  - herpes zoster, methotrexate and, in JRA, 801
  - in RA
    - low-dose oral methotrexate in, 902
    - mortality and, 706
- Infectious arthritis in renal transplant patients, 227
- Inflammation
  - acute, 363, 394
  - antigen-induced arthritis in mice and, 665
  - aseptic arthritis in toxic shock syndrome and, 910
  - chronic, fibronectin in, 394
  - crystal-associated arthropathy in hemodialysis and, 1387
  - eosinophilic synovitis and, 1147
  - hereditary joint disorder in ank/ank mice and, 114
  - HLA-DR staining in RA synovium and, 600
  - hydrogen peroxide-induced tissue damage and, 532
  - in interstitial lung disease in scleroderma, 525
  - intraarticular triamcinolone hexacetonide in knee and, 997
  - lipoprotein, phlogistic crystals and, 363
  - macrophage activation in adjuvant arthritis and, 1122
  - methylprednisolone infusion therapy in RA and, 32
  - in monarticular JRA, 47
  - mononuclear cell response in Lyme disease and, 761
  - monosodium urate crystals in gout and, 1172
  - neurotoxic effect of gold in rats and, 897
  - neutral proteases in human OA synovium and, 1112
  - progesterone in adjuvant arthritis and, 411
  - scleroderma in Raynaud's phenomenon, immobilization and, 1160
  - synovial fluid analysis and, 770
- Inflammatory arthritis, milk and, 220
- Inflammatory joint disease
  - aseptic arthritis in toxic shock syndrome and, 910
  - food-induced arthritis and, 220
- Inflammatory polyarthritis, IgM anti-histone H-3 antibody and, 39

Inguinal lymph nodes, dysprosium 165 in rheumatoid synovitis of the knee and, 165

Inorganic pyrophosphate, release of, by rabbit articular chondrocytes, 1485

Interdigitating cells, HLA-DR staining in RA synovium and, 600

Interferon

- $\alpha$ , lupus inclusions in SLE and, 501
- $\gamma$ 
  - HLA-DR on salivary gland epithelial cells in SS, 1105
  - scleroderma fibroblast production and, 851
  - in SLE, 1210
  - immunoglobulin in SLE sera and, 326

Interleukin-1

- chemotactic activity of, in RA, 461
- induction of synovial cell plasminogen activator by, 1078
- macrophage activation in adjuvant arthritis and, 1122

Interleukin-2

- in Behçet's disease, 371
- in SLE,  $\gamma$ -interferon and, 1210

International League Against Rheumatism, history and update, 929

Interstitial fibrosis, pulmonary

- $\alpha_1$ -antitrypsin and, in RA and SSc, 586
- predictor of pulmonary hypertension in CREST syndrome and, 515

Interstitial lung disease in scleroderma, 525

Intraarticular calcium hydroxyapatite, hereditary joint disorder in ank/ank mice and, 114

Intraarticular ferritin-bound iron in RA, 1187

Intraarticular triamcinolone hexacetonide in chronic arthritis in children, 997

Intracellular killing by polymorphonuclear cells from synovial fluid in RA, 166

Intractable rheumatoid arthritis, total lymphoid irradiation in, 16

Intramuscular gold in RA, 620

Intraosseous rheumatoid granuloma, rheumatoid nodulosis in, 1278

Intraosseous venography, in diagnosis of ischemic necrosis of bone, 1177

Intrathecal IgG synthesis, autoantibodies in CNS lupus and, 1090

Intravenous gamma globulin in gold-induced thrombocytopenia, 426

Iridocyclitis, HLA-DP antigens and, in pauciarticular JRA, 1057

Iron, intraarticular ferritin-bound, in RA, 1187

Ischemic necrosis of bone, 1177

Isoniazid, B to Z DNA transition and, 638

Isozymes, debrisoquine oxidation phenotypes in SLE and, 843

## J

### Joints

anti-type II collagen monoclonals in RA and OA and, 730

### Joints (*cont'd*)

antigen-induced arthritis in, in mice, 665

apophyseal, cysts of, causing back pain and sciatica in RA, 431

aspiration of, spray coolant anesthetics in, 576

cavity of, in rheumatoid nodulosis, 1278

complement activation in JRA and, 1359

destruction of

- in adult-onset Still's disease, 415
- cytomegalovirus infection and, 1263
- hydrogen peroxide-induced tissue damage and, 532
- radiologic assessment of, 1

diseases of

- adjuvant arthritis in rats and, 547
- food-induced arthritis and, 220
- inflammatory, 394, 910

distal interphalangeal, in RA, 10

elbow, OA in, in jackhammer operator, 1284

erosions of, in RA, 1, 10, 592

ferritin-bound iron in RA and, 1187

finger, crystal-associated arthropathy, hemodialysis and, 1387

fluid in, mononuclear cells in Lyme disease and, 761

hip, prosthetic loosening after total replacement of, 836

infection of, after renal transplantation, 227

inflammation of, 761, 910

intraarticular, in myectomy and tendotomy-induced OA, 251

involvement of, in RA, 10, 706

knee

- arthritis in, after renal transplantation, 227
- intraarticular triamcinolone hexacetonide in, 997
- liposome-induced synovitis, in rabbits, 889
- in mice, hydrogen peroxide-induced tissue damage and, 532
- MSU crystals in, in nontophaceous gout, 1480

large, crystal-associated arthropathy in hemodialysis and, 1387

manubriosternal, 570, 1029

metacarpophalangeal, OA in, in jackhammer operator, 1284

metatarsophalangeal, in rheumatoid nodulosis, 1278

methotrexate and, in JRA, 801

pain in, in fibromyalgia and RA, 775

rat cytomegalovirus infection and collagen arthritis in, 1263

replacement of, 614, 836

rheumatoid, 32, 1435

space

- narrowing of, in RA, 1, 10
- in rheumatoid nodulosis, 1278
- widening of, in psoriatic arthritis, 1029

structure of, factor XIII deficiency and, 808

swelling of

- acute gout in manubriosternal joint and, 570
- food-induced arthritis and, 220



## Joints (cont'd)

- sulfasalazine in RA and, 1427
- tenderness of
  - food-induced arthritis and, 220
  - sulfasalazine in RA and, 1427
- tissue of, cytomegalovirus infection and, 1263
- total arthroplasty of, cost-effectiveness of, in OA, 937
- Juvenile dermatomyositis, coxsackie B virus antibodies in, 1365
- Juvenile primary fibromyalgia syndrome, 452
- Juvenile rheumatoid arthritis
  - aplastic anemia secondary to gold therapy in, 128
  - camptodactyly-arthritis-pericarditis syndrome and, 439
  - classification criteria for, 274
  - complement activation in, 1359
  - coxsackie B virus antibodies and, 1365
  - in an Inuit population, 65
  - methotrexate in, 801
  - monarticular, biopsy in, 47
  - oligoarticular disease in, in urban Finnish children, 1232
  - pauciarticular, HLA-DP antigens in, 1057
  - peritoneal dialysis for gold toxicity in, 450
  - uveitis and, ocular and articular disease in, 797
- Juxtaarticular osteoporosis, 149

## K

- Kappa chain deficiency in Sjögren-like syndrome, 1532
- Kashin-Beck disease, effect of sodium selenite on chondrocytes in, 660
- Keratoconjunctivitis sicca
  - classification of Sjögren's syndrome and, 577
  - HLA-DR on salivary gland epithelial cells in, 1105
- Klebsiella* lymphocytotoxicity, in ankylosing spondylitis, 348
- Knee
  - acute monarticular arthritis and lipid microspherules in, 1166
  - cartilage of, 1248, 1493
  - chondrosarcoma, dermatomyositis and, 813
  - hydrogen peroxide-induced tissue damage of, in mice, 532
  - infectious arthritis in, after renal transplantation, 227
  - joint
    - intraarticular triamcinolone hexacetonide in, 997
    - methyalted bovine serum albumin-induced arthritis in, 665
    - in monarticular JRA, 47
    - monoclonal antibody analysis of OA rabbit cartilage in, 665
  - MSU crystals in, in nontophaceous gout, 1480
- OA of
  - anserine bursitis and, 812
  - ARA criteria for, 1039
  - pain, anserine bursitis and, 812
  - rabbit, liposome-induced synovitis in, 889
  - total replacement of, in RA, 614

## L

- Laboratory studies, cost of, in RA, 488
- Lactobacillus*, adjuvant arthritis in rats and, 547
- L-canavanine, B to Z DNA transition and, 638
- Leg aches in juvenile primary fibromyalgia syndrome, 452
- Lesions, subchondral cystic, in rheumatoid nodulosis, 1278
- Leu-3a+ lymphocytes, total lymphoid irradiation in intractable RA and, 16
- Leu-11b, Ig production, natural killer cells and, in RA, 1435
- Leukemia virus, human T cell, 185
- Leukocytes
  - complement receptors in SLE and, 739
  - fibronectin in inflammation and, 394
  - induction of lupus-type inclusions by SLE sera and, 501
  - low-dose methotrexate in Felty's syndrome and, 902
  - polymorphonuclear, 32, 379
  - synovial fluid analysis and, 770
- Leukocytosis
  - allopurinol hypersensitivity syndrome and, 82
  - liposome-induced synovitis in rabbits and, 889
- Leukoencephalopathy, progressive multifocal, complicating SLE, 337
- Leukopenia, anti-Ro (SS-A), anti-La (SS-B) and, in SS, 196
- LEW/N rats, CsA in streptococcal cell wall-induced arthritis in, 262
- Ligaments
  - cruciate, glycoprotein in OA and, 1256, 1493
  - myectomy and tendotomy-induced OA and, 251
- Limb immobilization, development of scleroderma after, 1160
- Linear scleroderma, 555
- Linoleic acid, phospholipase activity in RA and, 312
- Lipid microspherule-associated acute monarticular arthritis, 1166
- Lipids, renal disease in mice and, 539
- Lipopolysaccharides, adjuvant arthritis in rats and, 547
- Lipoprotein, crystal-inflammatory cell interactions and, 363
- Liposome-induced synovitis in rabbits, 889
- Liver
  - CsA in streptococcal cell wall-induced arthritis and, 262
  - enzymes, methotrexate and, in JRA, 801
  - function of, in AL amyloidosis, 683
  - leakage of intraarticular <sup>165</sup>Dy in synovitis and, 153
  - lymphocytosis and, 675
  - methotrexate and, in RA, 822, 832
- Loosening of prosthesis after total hip replacement, 836
- LS-2616 therapy for autoimmunity in MRL/l mice, 1405
- Lung volume
  - interstitial lung disease in scleroderma and, 525
  - pulmonary hypertension in CREST syndrome and, 515
- Lupus. *See also* Central nervous system lupus; Cutaneous lupus; Drug-induced lupus erythematosus; Idiopathic systemic lupus erythematosus; Maternal systemic lupus erythematosus; Neonatal lupus; Systemic lupus erythematosus



### Lupus (cont'd)

- autoantigens, in SLE, 457
- cutaneous, animal model of antibody binding in, 782
- inclusions, induction of, in SLE, 501
- nephritis, effects of TLI on autoantibodies in, 26
- psychosis, antiribosomal P protein antibody in, 1090
- retinitis, 555
- therapy of autoimmunity with LS-2616 in MRL/l mice and, 1405
- vasculitis, tibial artery thrombosis and gangrene in, 1291
- Lupus anticoagulant
  - prednisone, anticardiolipin antibodies and, 1295
  - in SLE
    - fetal loss and, 695
    - hypertension, veno-occlusive disease and, 147
- Lupus erythematosus
  - animal model of antibody binding in, 782
  - drug-induced, antihistone antibodies and, 148
  - subacute cutaneous, concurrent RA and, 421
- Lupus-inducing drugs, synthetic DNA transition and, 638
- Lupus-like disease, myocardial infarction in, 1292
- Lyme disease, proliferative response of mononuclear cells in, 761
- Lymph nodes
  - binding of mononuclear cells to blood vessels in RA and, 789
  - intraarticular  $^{165}\text{Dy}$  in rheumatoid synovitis and, 153
- Lymphadenopathy
  - amyloid, in mixed (type II) cryoglobulinemia, 1050
  - LS-2616 therapy of autoimmunity in MRL/l mice and, 1405
- Lymphoblastoid cells
  - CNS disease in primary Sjögren's syndrome and, 1223
  - human B, in SLE, 501
- Lymphoblasts, Con A-activated, IL-2 and, in Behçet's disease, 371
- Lymphocytes
  - B cell function in Behçet's disease and, 212
  - binding of mononuclear cells to blood vessels in RA and, 789
  - blood, Ig and RF synthesis in Sjögren's syndrome and, 1446
  - cyclosporin A in streptococcal cell wall-induced arthritis and, 262
  - DNA-daunorubicin, anti-DNA antibodies and, in SLE, 1216
  - glycosaminoglycan stimulatory factor, cloned T cells and, 1071
  - granular, in RA, 675
  - HLA-DR and
    - on salivary gland epithelial cells in SS, 1105
    - staining in RA synovium, 600
  - IgM-RF, *Staphylococcus aureus* Cowan I and, 1440
  - immunoglobulin and interferon release in SLE and, 326
  - interleukin-1 chemotactic activity in RA and, 461

### Lymphocytes (cont'd)

- methylprednisolone infusion therapy in RA and, 32
- neutrophils and, in SLE, RA, and acute rheumatic fever, 1334
- peripheral blood
  - Klebsiella* cytotoxicity in, in AS, 358
  - oncogenes in, in autoimmune diseases, 755
  - phytohemagglutinin-induced proliferation of, naproxen and, 305
  - Sjögren-like syndrome in  $\kappa$  chain deficiency and, 1532
- Lymphocytosis, chronic T cell, in RA, 675
- Lymphocytotoxic antibodies, immunoglobulin and interferon release in SLE and, 326
- Lymphocytotoxicity, anti-*Klebsiella*, in ankylosing spondylitis, 358
- Lymphoid aggregates, rheumatoid synovial mast cells and, 944
- Lymphoid cells, tonsillar, monoclonal cytoskeletal antibodies from, 1351
- Lymphoid neoplasia, cryoglobulinemia in Sjögren's syndrome and, 1098
- Lymphokines, histamine-releasing, rheumatoid synovial mast cells and, 944
- Lymphoma
  - human T cell leukemia virus and, 185
  - Sjögren's syndrome and, 577
- Lymphopenia
  - anti-Ro (SS-A), anti-La (SS-B) and, in SS, 196
  - total lymphoid irradiation in intractable RA and, 16
- Lymphotropic retroviruses, human T cell, RA and, 1533
- Lyophilized food, in food-induced arthritis, 220
- Lysozymes
  - macrophage collagenase, gold sodium thiomalate and, 75
  - nDNA and dDNA detection by ELISPOT in mice and, 1139

## M

### Macrophages

- activation of, in rat models of adjuvant arthritis, 1122
- collagenase, gold sodium thiomalate and, 75
- in RA
  - interleukin-1 chemotactic activity and, 461
  - neovascularization and, 471
  - staining by, in RA synovium, 600
- Major histocompatibility complex
  - ankylosing spondylitis in families and, 1510
  - null alleles, C4A and, in systemic sclerosis, 1274
- Manubriosternal joint
  - acute gout presenting in, 570
  - psoriatic arthritis affecting, 1029
- Mast cells
  - in idiopathic familial acroosteolysis, 1032
  - rheumatoid synovial, 944
  - synovial fluid, histamine and, 956

- Mastocytosis, systemic, histamine in synovial fluid mast cells and, 956
- Maternal systemic lupus erythematosus. *See also* Central nervous system lupus; Cutaneous lupus; Drug-induced lupus erythematosus; Idiopathic systemic lupus erythematosus; Lupus; Neonatal lupus; Systemic lupus erythematosus
- anti-SS-A antibodies and fetal outcome in, 1269
  - congenital cytomegalovirus infection and, 1402
- Matrix glycoprotein, cartilage, in canine articular cartilage, 1256
- Meat, food-induced arthritis and, 220
- Meclofenamate in RA, 620
- Median nerve entrapment in adult-type osteopetrosis, 926
- Medical care use, impact of childhood rheumatic disease on family and, 872
- Megaloblastic pancytopenia, methotrexate, trimethoprim-sulfamethoxazole and, in RA, 133
- Melphalan in AL amyloidosis, 683
- Melzack's general pain model, 777
- Menhaden oil, renal disease in murine lupus and, 539
- Meniscal fibrochondrocytes, rabbit, proteoglycan synthesis of, 1010
- Menopause, glucocorticoids, bone mass and, in RA, 693
- Mental health, rehabilitation in RA and, 628
- Messenger ribonucleic acid (mRNA), collagenase, synovial cells, rabbit genes and, 1301
- Metacarpophalangeal joint, OA in, in jackhammer operator, 1284
- Metalloproteoglycan-degrading enzyme, neutral proteases in OA synovium and, 1112
- Metatarsal bone, growth plate cartilage calcification and, 1002
- Metatarsophalangeal joint in rheumatoid nodulosis, 1278
- Methotrexate
- FDA Arthritis Advisory Committee on, 1289
  - genotoxicity, hepatotoxicity and, 1289
  - in JRA, 801
  - low-dose oral, in Felty's syndrome, 902
  - in RA
    - HLA-DR2 positivity and, 151
    - impact of, 620
    - metabolism of, 832
    - safety and efficacy of, 822
    - trimethoprim-sulfamethoxazole and pancytopenia and, 133
- Methylprednisolone infusion therapy in RA, 32
- Microaneurysms, retinopathy, disease activity and, in SLE, 1152
- Microangiopathic glomerulopathy in POEMS syndrome, 233
- Microangiopathic hemolytic anemia in Wegener's granulomatosis, 1527
- Microangiopathy, nailfold capillary microscopy and, 189
- Microbial antigens, anti-HLA-B27 antibodies in gram-negative infections and, 352
- Microflora, adjuvant arthritis in rats and, 547
- Miliary calcified deposits in skin, crystal-associated arthropathy, hemodialysis and, 1387
- Milk, inflammatory arthritis and, 220
- Minnesota Multiphasic Personality Inventory (MMPI) in RA, 1456
- Mitogens
- glycosaminoglycan stimulatory factor, cloned T cells and, 1071
  - immunoglobulin synthesis in Sjögren's syndrome and, 1446
  - pokeweed, mononuclear cell response in Lyme disease and, 761
  - proto-oncogenes in SLE and autoimmune diseases and, 755
  - in SLE,  $\gamma$ -interferon and, 1210
  - total lymphoid irradiation in intractable RA and, 16
- Mixed connective tissue disease
- nailfold capillary microscopy in, 189
  - Sm antigen in, 986
  - snRNP in, 986
- Mixed cryoglobulinemia
- in Raynaud's disease, 1026
  - type II, amyloid lymphadenopathy in, 1050
- Mixed polyclonal IgM in cryoglobulinemia in SLE and RA, 1098
- Molecular forms of IgA rheumatoid factor in RA, 1194
- Monarticular arthritis
- eosinophilic synovitis and, 1147
  - lipid microspherule-associated acute, 1166
- Monarticular juvenile rheumatoid arthritis, biopsy in, 47
- Monoclonal antibodies
- analysis of OA cartilage with, 863
  - anti-DNA
    - in tonsillar lymphoid cells, 1351
    - in SLE, 1417
  - anti-type II collagen antibodies and, 400, 730
  - HLA-DR
    - on salivary gland epithelial cells in SS, 1105
    - staining in RA synovium, 600
  - in RA
    - methylprednisolone infusion therapy and, 32
    - neovascularization and, 471
- Monoclonal anti-human  $\alpha$  chain antibody, IgA rheumatoid factor in RA and, 1194
- Monoclonal anti-type II collagen antibodies in collagen-induced arthritis, 400
- Monoclonal cryoglobulins, circulating, in primary Sjögren's syndrome, 1098
- Monoclonal gammopathy
- benign, in scleromyxedema, 913
  - POEMS syndrome and, 233, 1534
- Monoclonal IgM in cryoglobulinemia in Sjögren's syndrome, 1098
- Monoclonal (M)-protein in POEMS syndrome, 233, 1534

## Monocytes

- $\gamma$ -interferon and, in SLE, 1210
- peripheral blood, phospholipase activity in, in RA, 312
- staining by, in RA synovium, 600
- synovial fibroblasts, urokinase plasminogen activator and, 1397

## Monocytoid cells, Aschoff lesions in rheumatic myocarditis and, 207

## Monomeric IgA rheumatoid factor in RA, 1194

## Mononuclear cells

- binding of, to blood vessels in RA synovial membrane, 789
- CNS disease in primary Sjögren's syndrome and, 1223
- glycosaminoglycan stimulatory factor, cloned T cells and, 1071
- gold therapy, rheumatoid factor synthesis and, 480
- IgM-RF, *Staphylococcus aureus* Cowan I and, 1440
- immunoglobulin and interferon release in SLE and, 326
- liposome-induced synovitis in rabbits and, 889
- peripheral,  $\gamma$ -interferon and, in SLE, 1210
- peripheral blood
  - autoantibodies to U1 RNP and, 1343
  - naproxen and, 305
  - neutrophils in, 1334
- proliferative response of, in Lyme disease, 761
- proto-oncogenes in SLE and autoimmune diseases and, 755
- recent onset monarticular JRA and, 47
- scleroderma in Raynaud's phenomenon, immobilization and, 1160
- scleroderma-like phenotypes in fibroblasts and, 54
- synovial fluid, Ig and, in RA, 1435

## Monosodium urate (MSU) crystals

- in gout, 1172
- inflammatory cell interaction, lipoprotein and, 363
- in knee joint in nontophaceous gout, 1480
- polymorphonuclear cell lysis, superoxide production and, 1473

## Morbidity

- in adjuvant arthritis, 1017
- allopurinol hypersensitivity syndrome and, 82
- Wegener's granulomatosis in elderly and, 1157

## Morning stiffness

- amitriptyline in primary fibrositis and, 655
- food-induced arthritis and, 220
- sulfasalazine in RA and, 1427

## Mortality

- allopurinol hypersensitivity syndrome and, 82
- in RA, 706
- Wegener's granulomatosis in elderly and, 1157

## Mouse studies. See also ank/ank mice; BXSB mice; DBA/1 mice; MRL/l mice; New Zealand mice; (NZB $\times$ NZW)F<sub>1</sub> mice; STR/IN mice

- antigen-induced arthritis, 665
- articular cartilage proteoglycans in OA, 95
- growth plate cartilage calcification, 1002
- hereditary joint disorder, 114

## Mouse studies (cont'd)

- homologous type II collagen-induced arthritis, 106
- hydrogen peroxide-induced tissue damage, 532
- IgA rheumatoid factor in RA, 1194
- IgM anti-histone H-3 antibody in rheumatic diseases, 39
- monoclonal antibodies
  - anti-type II collagen, 400
  - cytoskeletal, 1351
- nude, antibody binding in cutaneous lupus, 782

## MRL/1 mice

- dietary fish oil and renal disease in lupus in, 539
- LS-2616 therapy of autoimmunity in, 1405

## Mucocutaneous toxicity in RA after gold, HLA-Bw35 and, 303

## Multiple myeloma, coexistent SLE and, 933

## Multiple sclerosis, systemic sclerosis and, 124

## Murine collagen arthritis, type II, 1131

## Muscle

- Aschoff lesions in rheumatic myocarditis and, 207
- energy metabolism, phosphates and, in primary fibromyalgia, 817
- gluteal, in myectomy and tendotomy-induced OA, 251
- necrosis, hydrogen peroxide-induced tissue damage and, 532
- skeletal, in POEMS syndrome, 286
- weakness of, in scleromyxedema, 913

## Muscle atrophy, corticosteroid type II, 555

## Musculoskeletal complaints in an Inuit population, 65

## Musculoskeletal disease, work disability and, 1322, 1410

## Myalgia, IgM anti-histone H-3 antibody and, 39

## Mycoplasma pneumoniae in juvenile dermatomyositis, 1365

## Myectomy-induced osteoarthritis, 251

## Myelotoxicity, HLA-DR antigens in gold-induced neutropenia and, 1515

## Myocardial infarction in SLE and lupus-like disease, 1292

## Myocarditis, rheumatic, Aschoff lesions in, 207

## Myopathy in scleromyxedema, 916

## Myositis, IgM anti-histone H-3 antibody and, 39

## Myositis ossificans progressiva, effect of warfarin on glutamic acid excretion in, 344

## N

## Nailfold capillaries

- abnormalities in scleroderma, 451
- in mixed connective tissue disease, 189
- narrowfield, water-soluble gels in, 304

## Naproxen

- in fibromyalgia, 1371
- immunomodulatory effects of, 305

## Native DNA (nDNA), detection of, by ELISPOT, 1139

## Native type II collagen monoclonal antibodies and, in RA and OA, 730

## Natural killer cells, immunoglobulin in production by, in RA, 1435

## Necrosis

- bone, ischemic, diagnosis of, 1177

## Necrosis (*cont'd*)

- joint space and, in rheumatoid nodulosis, 1278
- muscle, hydrogen peroxide-induced tissue damage and, 532
- Necrotizing glomerulonephritis, necrotizing systemic vasculitis and, 565
- Necrotizing vasculitis
  - dietary fish oil in renal disease in murine lupus and, 539
  - granulomatous, Wegener's granulomatosis in elderly and, 1157
  - systemic, 565
- Neonatal lupus. *See also* Central nervous system lupus; Cutaneous lupus; Drug-induced lupus erythematosus; Idiopathic systemic lupus erythematosus; Lupus; Maternal systemic lupus erythematosus; Systemic lupus erythematosus
  - mouse model of antibody binding in, 782
- Neoplasia, lymphoid, cryoglobulinemia in Sjögren's syndrome and, 1098
- Neopterin, urinary, in RA, 1063
- Neovascularization in RA synovial tissue macrophages, 471
- Nephritis
  - lupus, effects of TLI on autoantibodies in, 26
  - nDNA and dDNA detection by ELISPOT in mice and, 1139
  - proliferative, complement receptors in SLE and, 739
- Nephrotic syndrome
  - in AL amyloidosis, 683
  - pulmonary amyloidosis associated with SLE and, 680
- Nerves, median, entrapment of, in adult-type osteopetrosis, 926
- Nervous system, peripheral, neurotoxic effect of gold on, in rats, 897
- Neuro-Behçet's syndrome, cerebrospinal fluid IgM index in, 793
- Neurogenic inflammation, neurotoxic effect of gold in rats and, 897
- Neurologic involvement
  - cerebrospinal IgM index in Behçet's disease and, 793
  - CNS disease in primary Sjögren's syndrome, 1223
  - phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880
  - progressive multifocal leukoencephalopathy in SLE, 337
- Neurons, human cortical, autoantibodies in CNS lupus and, 1090
- Neuropathy
  - eosinophilic vasculitic, in Churg-Strauss syndrome, 1173
  - POEMS syndrome and, 233, 286
- Neurotoxic effects of gold sodium thiomalate in rats, 897
- Neutral protease in human OA synovium, 1112
- Neutropenia
  - gold-induced, HLA-DR antigens in, 1515
  - low-dose oral methotrexate and, 902
  - in RA, 675
- Neutrophils
  - $\alpha_2$ -macroglobulin-proteinase in RA and, 319

## Neutrophils (*cont'd*)

- complement receptors in SLE and, 739
- crystal-inflammatory cell interactions, lipoproteins and, 363
- interstitial lung disease in scleroderma and, 525
- MSU crystals in gout and, 1172
- polymorphonuclear, liposome-induced synovitis and, 889
- in SLE, RA and acute rheumatic fever, 1334
- synovial fluid analyses and, 770
- New Zealand mouse studies, gp70 and anti-dsDNA in, 242
- New Zealand white rabbit studies
  - monoclonal antibody analysis of OA cartilage, 863
  - proteoglycan synthesis of meniscal fibrochondrocytes, 1010
- Nifedipine in progressive systemic sclerosis, 1053, 1054
- 19S IgM rheumatoid factor, avidity of, 722
- Nodular pulmonary infiltrates in necrotizing systemic vasculitis, 565
- Nodules, subcutaneous rheumatoid, in rheumatoid nodulosis, 1278
- Noninflammatory rheumatic diseases, naproxen in, 305
- Nonsteroidal antiinflammatory drugs (NSAID)
  - chronic arthritis in children and, 997
  - crystal-associated arthropathy in hemodialysis and, 1387
  - guidelines for clinical evaluation of, 1289
  - immunomodulatory effects of naproxen, 305
  - in RA, 620
  - increased phospholipase activity in RA and, 312
- Nonthoraceous gout, asymptomatic, MSU crystals in knee joint in, 1480
- Nontraditional therapy, cost of, in RA, 488
- Nuclear antigens, complement activation and, 748
- Nuclear ribonucleoprotein (nRNP)
  - in Sjögren's syndrome, 196
  - small (snRNP), in MCTD and SLE, 986
- Nucleic acid antigens, monoclonal cytoskeletal antibodies and, 1351
- Nucleotides, purine, PRPP synthetase activity and, 880
- Null alleles in systemic sclerosis, 1274
- (NZB  $\times$  NZW) $F_1$  mice
  - detection of nDNA and dDNA by ELISPOT in, 1139
  - dietary fish oil in renal disease in, 539
  - gp70 and anti-dsDNA in, 242

## O

### Obesity

- lipid microspherules, acute monarticular arthritis and, 1166
- salicylate kinetics and, 971
- Ocular disease in JRA and uveitis, 797
- OKM1, OKM3, Aschoff lesions in rheumatic myocarditis and, 207
- OKM1, OKM5 monoclonal antibodies, neovascularization in RA and, 471
- OKT8 cells, immunoglobulin synthesis in Sjögren's syndrome and, 1446

- Olecranon bursitis, crystal-associated arthropathy in hemodialysis and, 1387
- Oligoarticular disease in JRA in urban Finnish children, 1232
- Oligoclonal bands, CNS disease in primary Sjögren's syndrome and, 1223
- Oncogenes in SLE and autoimmune diseases, 755
- Oophorectomy, female sex hormones in collagen-induced arthritis and, 1501
- Oral contraceptives
- anticardiolipin, vascular complications and, 1294
  - antiphospholipid antibodies, chorea and, in SLE, 1535
- Organomegaly in POEMS syndrome, 233
- Orosomucoid, acute-phase reactant, 1413
- Orthophosphate, pyrophosphate release by rabbit chondrocytes and, 1485
- Osteoarthritis
- $\alpha_2$ -macroglobulin proteinase in, 319
  - anti-type II collagen monoclonal antibodies in, 730
  - ARA criteria for, 1039
  - articular cartilage proteoglycans in mice with, 95
  - canine, cartilage matrix protein in, 1256, 1493
  - cartilage, monoclonal antibody analysis of, 863
  - cost-effectiveness of total joint arthroplasty in, 937
  - distal interphalangeal joints involvement in RA and, 10
  - HLA-DR staining in, 600
  - human, synovium in, neutral proteases in, 1112
  - idiopathic, ARA criteria for, 1039
  - in an Inuit population, 65
  - knee, anserine bursitis and, 812
  - metacarpophalangeal, in jackhammer operator, 1284
  - myectomy and tendotomy-induced, 251
  - Paget's disease and, 1414
  - primary, ARA criteria for, 1039
  - proteoglycanase in human chondrocytes in, 292
  - secondary, ARA criteria for, 1039
  - selenite and chondrocytes in Kashin-Beck disease and, 660
  - synovial mast cells in, 944
  - urinary neopterin in, 1063
- Osteomalacia
- hypophosphatemic, regional migratory osteoporosis and, 688
  - reflex sympathetic dystrophy syndrome and, 918
- Osteopetrosis, adult-type, presenting as carpal tunnel syndrome, 926
- Osteophytes, hereditary joint disorder in ank/ank mice and, 114
- Osteophytosis, distal interphalangeal joint involvement in RA and, 10
- Osteoporosis
- juxtaarticular, 149
  - regional migratory, hypophosphatemic osteomalacia and, 688
- Outcome data of group therapy in RA, 1203
- Oxalosis, hemodialysis, arthropathy and cutaneous calcinosis in, 1387
- Oxidation phenotypes, debrisoquine, in SLE, 843
- Oxygen radicals
- cartilage destruction and, 379
  - tissue destruction, ferritin-bound iron and, in RA, 1187
- P**
- Paget's disease, OA and, 1414
- Pain
- in acute gout presenting in manubriosternal joint, 570
  - amitriptyline and
    - in fibromyalgia, 1371
    - in primary fibrositis, 655
  - arthritis self-management courses and, 388
  - aseptic arthritis in toxic shock syndrome and, 910
  - disability in experimental arthritis and, 1017
  - in fibromyalgia, 775, 1371
  - in knee
    - anserine bursitis and, 812
    - ARA criteria for OA and, 1039
  - muscle, phosphates and, in primary fibromyalgia, 817
  - in RA
    - cost and, 488
    - use of gold treatment and, 620
- Pan American League Against Rheumatism, 929
- Pancytopenia, methotrexate, trimethoprim-sulfamethoxazole and, in RA, 133
- Pannus, synovial, neovascularization in RA and, 471
- Paraarticular pain, ARA criteria for OA and, 1039
- Paracortical lymph nodes, binding of mononuclear cells to blood vessels in RA and, 789
- Parotid salivary gland in Sjögren's syndrome, 577
- Parvovirus arthropathy, human, 575
- Patient education
- about antirheumatic drugs, 934
  - evaluation of, 388
- Patient global assessment
- amitriptyline in primary fibrositis and, 655
  - in RA, 620
- Patient mood, Face Scale in assessment of, 906
- Pauciarticular juvenile rheumatoid arthritis, HLA-DP antigens in, 1057
- Penicillamine
- B to Z-DNA transition and, 638
  - in gold toxicity, 450
  - in RA, 620
    - amino-terminal type III procollagen peptide and, 592
    - polymyositis induced by, 560
- Pentoxifylline in Raynaud's phenomenon, 1055
- Peptides, amino-terminal type III procollagen, in RA, 592
- Periarticular tissue, hydrogen peroxide-induced damage in, 532
- Pericarditis
- arthritis, camptodactyly, coxa vara and, in the familial syndrome, 436



- Pericarditis (*con'd*)  
 camptodactyly-arthropathy-pericarditis syndrome, 439
- Peripheral arthritis, manubriosternal synovitis in psoriatic arthritis and, 1029
- Peripheral blood  
 eosinophilic synovitis and, 1147
- B cells  
 complement receptors in SLE and, 739  
 GAG stimulatory factor, cloned T cells and, 1071  
 Ig and RF synthesis in Sjögren's syndrome and, 1446
- lymphocytes  
 lymphocytosis and, 675  
 proto-oncogenes in, in SLE and autoimmune diseases, 755
- lymphopenia, total lymphoid irradiation in intractable RA and, 16
- monocytes  
 phospholipase activity in, in RA, 312
- mononuclear cells  
 autoantibodies to U1 RNP in CTD and, 1343  
 human T cell leukemia virus in SLE and, 185  
 IgM-RF, *Staphylococcus aureus* Cowan I and, 1440  
 immunoglobulin and interferon release in SLE and, 326  
 naproxen and, 305  
 neutrophils in, in SLE, RA and acute rheumatic fever, 1334  
 proliferative response of, in Lyme disease, 761  
 in SLE,  $\gamma$ -interferon and, 1210
- T cells  
 glycosaminoglycan stimulatory factor and, 1071
- Peripheral nerves  
 neurotoxic effect of gold on, in rats, 897  
 in POEMS syndrome, 286
- Peritoneal cavity, macrophage activation in adjuvant arthritis and, 1122
- Peritoneal dialysis in gold toxicity, 450
- Perivascular region, rheumatoid synovial mast cells in, 944
- Peroxidase, neovascularization in RA and, 471
- Phagocytes  
 HLA-DR staining in RA synovium and, 600
- Phagocytosis  
 lipoprotein, crystal-inflammatory cell interactions and, 363  
 in polymorphonuclear cells from synovial fluid in RA, 166
- Phlogistic crystal-inflammatory cell interactions, lipoprotein and, 363
- Phosphate  
 diabetes, regional migratory osteoporosis and, 688  
 glycoprotein and, in OA articular cartilage, 1256  
 growth plate cartilage calcification and, 1002  
 muscle energy metabolism in primary fibromyalgia and, 817
- Phosphatidylcholine, phospholipase activity in RA and, 312
- Phosphatidylethanolamine, phospholipase activity in RA and, 312
- Phosphatidylinositol, phospholipase activity in RA and, 312
- Phosphodiesterase inhibitors, IL-1 induction of synovial cell plasminogen activator and, 1078
- Phospholipase in RA, 312
- Phosphoribosylpyrophosphate (PRPP) synthetase, 880
- Phosphorus, warfarin sodium and, in rheumatic diseases, 344
- Phosphoryl creatine, muscle energy metabolism in primary fibromyalgia and, 817
- Physical limitations, work disability in musculoskeletal disease and, 1322, 1410
- Physician global assessment, amitriptyline in primary fibrositis and, 655
- Physician services, cost of, in RA, 488
- Phytohemagglutinin  
 interleukin-2, T cells and, in Behçet's disease, 371  
 lymphocyte proliferation induced by, naproxen and, 305  
 mononuclear cell response in Lyme disease and, 761  
 in SLE  
 DNA-daunorubicin, anti-DNA antibodies and, 1216  
 $\gamma$ -interferon and, 1210
- Piroxicam, hydrogen peroxide-induced tissue damage and, 532
- Plasma cells  
 CNS disease in primary Sjögren's syndrome and, 1223  
 dyscrasia of  
 in POEMS syndrome, 233  
 in Takatsuki syndrome, 1534  
 HLA-DR staining in RA synovium and, 600
- Plasma infusions, arthropathy, factor XIII deficiency and, 808
- Plasminogen activator  
 synovial cell, IL-1 induction of, 1078  
 urokinase-type, human synovial fibroblast production of, 1397
- Platelets, lipoprotein, crystal-inflammatory cell interactions and, 363
- Pleocytosis, CSF, CNS disease in Sjögren's syndrome and, 1223
- Pleural cavity, fibronectin in inflammation and, 394
- Pleurisy, IgM anti-histone H-3 antibody and, 39
- Pneumococcal polysaccharides, effects of total lymphoid irradiation on autoantibodies in SLE and RA and, 26
- Pneumococci, type II collagen autoantibodies in RA and, 1316
- Podagra, crystal-associated arthropathy in hemodialysis and, 1387
- POEMS syndrome  
 endocrinopathy in, 233  
 light and electron microscopy in, 286  
 unusual features of, 233
- Point tenderness, amitriptyline in primary fibrositis and, 655
- Pokeweed mitogen  
 B cell function in Behçet's disease and, 212

Pokeweed mitogen (*cont'd*)

- IgM-rheumatoid factor, *Staphylococcus aureus* Cowan 1 and, 1440
- mononuclear cell response in Lyme disease and, 761
- Polyarteritis nodosa, cutaneous, destructive arthritis and, 812
- Polyarthralgia, *Schistosoma mansoni* infection and, 296
- Polyarthritis
  - inflammatory, IgM anti-histone H-3 antibody and, 39
  - seronegative, anti-HLA-B27 antibodies and, 352
- Polyclonal B cell hyperreactivity, cryoglobulinemia in Sjögren's syndrome and, 1098
- Polyclonal IgM in cryoglobulinemia in Sjögren's syndrome, 1098
- Poly(dA:dT), monoclonal cytoskeletal antibodies and, 1351
- Poly(dG) · poly(dC), monoclonal cytoskeletal antibodies and, 1351
- Poly(dG-me<sup>5</sup>dC) · poly(dG-me<sup>5</sup>dC), DNA, lupus-inducing drugs and, 638
- Polyethylene, prosthetic loosening after total hip replacement and, 836
- Polyglutamates, methotrexate metabolism in RA and, 832
- Polymeric IgA rheumatoid factor in RA, 1194
- Polymethyl methacrylate cement, prosthetic loosening after total hip replacement and, 836
- Polymorphisms
  - Bf, in SLE patients of Spanish descent, 932
  - DNA, T cells and, in SLE, 1023
- Polymorphonuclear cells
  - injury, IgG, monosodium urate, superoxide production and, 1473
  - synovial fluid, phagocytosis and intracellular killing by, 166
- Polymorphonuclear leukocytes
  - methylprednisolone infusion therapy in RA and, 32
  - oxygen radicals, cartilage destruction and, 379
- Polymorphonuclear neutrophils, liposome-induced synovitis in rabbits and, 889
- Polymyositis, penicillamine-induced, in RA, 560
- Polyneuropathy
  - familial amyloid, scalloped pupils in, 445
  - neurotoxic effect of gold in rats and, 897
  - in POEMS syndrome, 233
- Polysaccharides, type II collagen autoantibodies in RA and, 1316
- Prednisone
  - in AL amyloidosis, 683
  - anticardiolipin, lupus anticoagulant and, 1295
  - congenital cytomegalovirus infection in maternal SLE and, 1402
  - in RA
    - methotrexate and, 822
    - mortality and, 706
- Pregnancy, anti-SS-A antibodies and fetal outcome in maternal SLE, 1269
- Pressure erosions, RA, CPPD disease and, 454
- Primary B cell immune deficiency in Sjögren-like syndrome, 1532
- Primary fibromyalgia
  - juvenile, 452
  - phosphates and muscle energy metabolism in, 817
- Primary fibrositis, amitriptyline in, 655
- Primary osteoarthritis, ARA criteria for, 1039
- Primary Sjögren's syndrome
  - C3b in, 857
  - central nervous system disease in, 1223
  - circulating monoclonal cryoglobulins in, 1098
  - Darier's disease and, 1052
  - HLA-DR on salivary gland epithelial cells in, 1105
  - immunoglobulin and rheumatoid factor synthesis in, 1446
- Procainamide, B to Z DNA transition and, 638
- Procollagen
  - messenger RNA, scleroderma, fibroblasts, interferon and, 851
  - peptide, amino-terminal type III, in RA, 592
- Progesterone, adjuvant arthritis in rats and, 411
- Progestogen, glucocorticoids and, in RA, 694
- Progressive ankylosis, hereditary joint disorder in ank/ank mice and, 114
- Progressive multifocal leukoencephalopathy complicating SLE, 337
- Progressive systemic sclerosis
  - anticentriole antibody in, 142
  - colonic telangiectasias in, 282
  - diltiazem, nifedipine and esophageal sphincter in, 1054
  - fibroblast collagen production by  $\gamma$ -interferon and, 851
  - nifedipine in, 1053, 1054
- Proliferative nephritis, complement receptors in SLE and, 739
- Propeptides in RA, 592
- Properdin, complement activation by antinuclear antibodies and, 748
- Prostaglandin E, histamine stimulation by rheumatoid synovial cells, 160
- Prostaglandin E<sub>2</sub>
  - IL-1 induction of synovial cell plasminogen activator and, 1078
  - macrophage activation in adjuvant arthritis and, 1122
  - naproxen and, 305
  - prosthetic loosening after total hip replacement and, 836
- Prostaglandins, phospholipase activity in RA and, 312
- Prosthetic loosening after total hip replacement, 836
- Protease
  - $\alpha_1$ -antitrypsin in RA and systemic sclerosis and, 586
  - histamine in synovial fluid mast cells and, 956
  - neutral, in human OA synovium, 1112
- Protein
  - $\alpha_2$ -macroglobulin in RA synovial fluid and, 319
  - antiribosomal P, autoantibodies and, in CNS lupus, 1090
  - cartilage and, in canine studies, 1256, 1493

**Protein (cont'd)**

- CNS disease in primary Sjögren's syndrome and, 1223
- EBNA-2, RANA and, in RA, 964
- link, articular cartilage proteoglycans in OA mice and, 95
- macrophage collagenase, gold sodium thiomalate and, 75
- monoclonal (M), in POEMS syndrome, 233
- proteoglycan after collagenase in cartilage and, 1248
- snRNP and, in mixed connective tissue disease and SLE, 986
- warfarin sodium, glutamic acid and, in rheumatic diseases, 344

Protein A, C1s-C1 inhibitor complex in SLE and, 1467

**Proteinase**

- $\alpha_2$ -macroglobulin in RA, 319
- synovial fibroblasts, urokinase plasminogen activator and, 1397

**Proteinuria**

- dietary fish oil and, in renal disease in murine lupus, 539
- gp70, anti-dsDNA and, in New Zealand mice, 247
- nDNA and dDNA detection by ELISPOT in mice and, 1139
- in POEMS syndrome, 233
- pulmonary amyloidosis associated with SLE and, 680

Proteoglycanase in human OA chondrocytes, 292

Proteoglycan-degrading enzymes, neutral proteases in human OA synovium and, 1112

**Proteoglycans**

- articular cartilage in OA mice and, 95
- collagenase and, in human articular cartilage, 1239, 1248
- in human OA chondrocytes, 292
- myectomy and tendotomy-induced OA and, 251
- pyrophosphate release by rabbit chondrocytes and, 1485
- rabbit, monoclonal antibody analysis of OA cartilage with, 863
- Staphylococcus aureus* and, in bacterial arthritis, 1378
- synthesis of
  - effect of selenite on chondrocytes and, 660
  - hydrogen peroxide-induced tissue damage and, 532
  - rabbit meniscal fibrochondrocytes and, 1010

Proteolytic enzymes, macrophage collagenase, gold sodium thiomalate and, 75

Proto-oncogenes in SLE and autoimmune disease, 755

Pseudoaneurysm, vertebral artery, cervical spine disease in RA and, 136

Pseudogout, crystal-associated arthropathy in hemodialysis and, 1387

Psoriasis, pustular, manubriosternal synovitis in, 1029

Psoriatic arthritis in manubriosternal joint, 1029

Psychological status in RA, 1203, 1456

Psychosis, anti-P antibody in SLE and, 981

Pulmonary amyloidosis, SLE and, 680

Pulmonary disease,  $\alpha_1$ -antitrypsin phenotypes in, 586

Pulmonary hypertension in CREST syndrome, 515

Pulmonary infiltrates, nodular, necrotizing systemic vasculitis and, 565

Pulmonary interstitial fibrosis,  $\alpha_1$ -antitrypsin and, in RA and systemic sclerosis, 586

Pupils, scalloped, in familial amyloid polyneuropathy, 445

Purines, phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880

**Purpura**

- anti-Ro (SS-A), anti-La (SS-B) and, in SS, 196
- thrombocytopenic, prednisone in, 1295

Pustular psoriasis, manubriosternal synovitis in, 1029

Pyoderma gangrenosum, 554

Pyrophosphate, inorganic, release of, by rabbit articular chondrocytes, 1485

**R**

**Rabbit studies**

- effect of sodium selenite on chondrocytes, 660
- genes for synovial cell collagenase, 1301
- inorganic pyrophosphate release by articular chondrocytes, 1485
- liposome-induced synovitis, 889
- monoclonal antibody analysis of OA cartilage, 863
- proteoglycan synthesis of fibrochondrocytes, 1010
- Radiation synovectomy, dysprosium 165-ferric hydroxide macroaggregate in, 153
- Radiographs, cost of, in RA, 488
- Radiologic progression in RA, 1
- Rash, allopurinol hypersensitivity syndrome and, 82

**Rat studies**

- adjuvant arthritis, 411, 547, 1017, 1122
- cytomegalovirus infection and type II collagen arthritis, 1263
- fibronectin in inflammation, 394
- neovascularization in RA, 471
- neurotoxic effect of gold on peripheral nerves, 897
- Raynaud's disease, cryoglobulinemia and hepatitis B markers in, 1026

**Raynaud's phenomenon**

- pentoxifylline in, 1055
- in progressive systemic sclerosis, diltiazem in, 1054
- scleroderma in, after limb immobilization, 1157
- in scleromyxedema, 913

Reactive arthritis, anti-HLA-B27 antibodies, *Yersinia* infection and, 352

Red blood cells, methotrexate in RA and, 832

Referred pain, ARA criteria for OA and, 1039

Reflex sympathetic dystrophy syndrome, osteomalacia and, 918

Regional migratory osteoporosis, adult sporadic hypophosphatemic osteomalacia and, 688

Rehabilitation in RA, 628

**Reiter's syndrome**

- Doctor Yvan and, 152
- in an Inuit population, 65

Relaxation training/group assertion in RA, 1203

#### Renal disease

- anti-P antibody in SLE and, 981
- dietary fish oil and, in murine lupus, 539
- gp70, anti-dsDNA and, in New Zealand mice, 242
- in necrotizing systemic vasculitis, 565

Renal enlargement in POEMS syndrome, 233

Renal failure, end-stage, crystal-associated arthropathy in, 1387

#### Renal function

- allopurinol hypersensitivity syndrome and, 82
- in necrotizing systemic vasculitis, 565

Renal insufficiency, phosphoribosylpyrophosphate synthetase activity and, 880

Renal phosphate diabetes, 688

Renal tolerance, cyclosporin A in Behçet's disease and, 574

Renal transplantation, infectious arthritis after, 227

Renal tubular osteomalacia, reflex sympathetic dystrophy syndrome and, 918

Retinal dysfunction, retinopathy, disease activity and, in SLE, 1152

Retinoic acid, synovial fibroblasts, urokinase plasminogen activator and, 1397

Retroviral gp70 in autoimmune New Zealand mice, 242

#### Retroviruses

- human T cell lymphotropic, in RA, 1533
- type C, HTLV in SLE and, 185

#### Rheumatic diseases

- autoimmune, cryoglobulinemia in, 1098
- in an Inuit population, 65
- systemic scleromyxedema mimics, 913

Rheumatic fever, acute, low density neutrophils in, 1334

Rheumatic myocarditis, Aschoff lesions in, 207

#### Rheumatoid arthritis

- $\alpha_1$ -antitrypsin phenotypes in, 586
- $\alpha_2$ -macroglobulin-proteinase in, 319
- $\alpha_2$ -proteinase inhibitor-elastase in, 319
- anti-type II collagen monoclonal antibodies in, 730
- ARA criteria for OA and, 1039
- aspirin in, 620
- back pain in, apophyseal joint cyst and, 431
- bone mass in, 693, 694
- bronchiolitis in, auranofin and, 556
- Chorée fibrillaire and gold in, 1413
- clinical features of, 17
- collagen antibodies in, 174
- collagen arthritis and, 106
- collagen autoantibodies in, 1316
- complement activation in, 715
- complications of, 614
- cost of hospitalization for, 614
- cost study of, 488
- cryoglobulinemia in, 1098
- depression in, 1456
- disability in, 494

#### Rheumatoid Arthritis (*cont'd*)

- distal interphalangeal joint in, 10
- EBNA-2 in, 964
- effects of total lymphoid irradiation on autoantibodies in, 26
- in elderly, 149
- Face Scale in assessment of patient mood in, 906
- gamma globulin in gold-induced thrombocytopenia in, 426
- glucocorticoids in, 693, 694
- gold sodium thiomalate in, 75, 897
- gold therapy and rheumatoid factor synthesis in, 480
- granular lymphocytes in, 675
- group therapy in, 1203
- Guillain-Barré syndrome and gold in, 1413
- health service utilization in, 488
- homologous type II collagen-induced arthritis in mice and, 106
- hospitalization in, 614
- human T cell lymphotropic retroviruses in, 1533
- hydroxychloroquine in, 620
- hypochondriasis in, 1456
- hysteria in, 1456
- ibuprofen in, 620
- IgA rheumatoid factor in, 1194
- immunoglobulin production by natural killer cells in, 1435
- in an Inuit population, 65
- indomethacin in, 620
- interleukin-1 chemotactic activity in, 461
- intracellular killing by SF polymorphonuclear cells in, 166
- intractable, total lymphoid irradiation in, 16
- juvenile. *See* Juvenile rheumatoid arthritis
- juxtaarticular osteoporosis and, 149
- lymphocytosis in, 675
- macrophage collagenase, gold sodium thiomalate and, 75
- meclizolam in, 620
- menopause and, 693, 694
- methotrexate in, 151, 620, 822, 832, 902
- methylprednisolone infusion therapy in, 32
- mononuclear cells in, 789
- mortality in, 706
- mucocutaneous toxicity and HLA-Bw35 after gold in, 303
- murine type II collagen arthritis and, 113
- naproxen in, 305, 620
- neovascularization in, 471
- neurotoxic effect of gold sodium thiomalate in, 897
- neutropenia in, 675
- neutrophils in, 1334
- 19S IgM rheumatoid factor avidity in, 722
- NSAID in, 620
- oxygen radicals, cartilage destruction and, 379
- pain in, 775
- patients' knowledge of antirheumatic drugs in, 934
- penicillamine in, 610
- penicillamine-induced polymyositis in, 560
- phagocytosis by synovial fluid polymorphonuclear cells in, 166

### Rheumatoid Arthritis (*cont'd*)

- phospholipase activity in, 312
- piroxicam in, 620
- prednisone in, 620
- pressure erosions in, 454
- propeptides in, 592
- pseudoaneurysm of vertebral artery in cervical spine in, 136
- psychological adaptation and intervention in, 1203
- psychotherapy in, 1203
- rabbit genes for synovial cell collagenase and, 1301
- radiologic progression in, 1
- RANA in, 964
- rehabilitation in, 628
- relaxation training/group assertion in, 1203
- sciatica in, apophyseal joint cyst and, 431
- seropositive, 10, 814
- Sjögren's syndrome and, HLA in, 1518
- social adaptation in, 1203
- sulfasalazine in, 1427
- sulindac in, 620
- swan-neck deformity in, 555
- synovial fibroblasts, urokinase plasminogen activator and, 1397
- synovial mast cells in, 944
- synovial membrane, mononuclear cells, blood vessels and, 789
- synovitis of knee in, dysprosium 165 in, 153
- synovium in, HLA-DR staining in, 600
- thalidomide neurotoxicity in, 1296
- tolmetin in, 620
- total knee replacement in, 614
- urinary neopterin in, 1063
- wrist pain in, 775

### Rheumatoid arthritis nuclear antigen (RANA) in RA, 964

#### Rheumatoid factor

- anti-Ro (SS-A), anti-La (SS-B) and, in SS, 196
- classification of Sjögren's syndrome and, 577
- effects of total lymphoid irradiation on, in SLE and RA, 26
- IgA, in RA, 1194

#### IgM

- in cryoglobulinemia in autoimmune rheumatic diseases, 1098
- 19S, avidity of, 722
- Staphylococcus aureus* Cowan I stimulation of, 1440
- total lymphoid irradiation in intractable RA and, 23
- mortality in RA and, 706
- synthesis of, in Sjögren's syndrome, 1446

### Rheumatoid nodulosis, intraosseous rheumatoid granuloma in, 1278

#### Rheumatoid synovial cells

- histamine-stimulated prostaglandin E by, 160
- mast, 944

#### Rheumatoid synovitis

- knee, intraarticular dysprosium 165 in, 153

### Rheumatoid synovitis (*cont'd*)

- sulfasalazine in RA and, 1427

#### Rheumatology and rheumatologists

- International League Against Rheumatism and, 929
- need for mentors, ARA Presidential Address, 1986, 1297

#### Ribonucleic acid (RNA)

- messenger, rabbit genes for synovial cell collagenase and, 1301
- proto-oncogenes in SLE and autoimmune diseases and, 755
- scleroderma fibroblast collagen,  $\gamma$ -interferon and, 851
- in SLE,  $\gamma$ -interferon and, 1210

#### Ribonucleoprotein (RNP)

- nuclear, U small (snRNP), in MCTD and SLE, 986
- UI, autoantibodies to, in connective tissue disease, 1343

#### Ribosomes, anti-P antibody in SLE and, 981

#### Ro (SS-A)

- antigen, antibody binding in cutaneous lupus and, 782
- cryoglobulinemia in autoimmune rheumatic diseases and, 1098

## S

#### Salicylates

- absorption of, 971
- kinetics of, influence of age, gender, and obesity on, 971
- Saline stress test in diagnosis of ischemic necrosis of bone, 1177

#### Salivary gland

- classification of Sjögren's syndrome and, 577
- cytomegalovirus infection, rat collagen arthritis and, 1263
- epithelial cells, HLA-DR on, in Sjögren's syndrome, 1105
- Sarcoidosis, Sjögren's syndrome and, 577
- Scapulae, Paget's disease of, and OA, 1414

#### *Schistosoma mansoni* infection, immune complex arthritis in, 296

#### Sciatica in RA, apophyseal joint cyst in, 431

#### Sclerodactyly in scleromyxedema, 913

#### Scleroderma. *See also* Progressive systemic sclerosis; Systemic sclerosis

- DMSO and, 1289
- effect of warfarin sodium on glutamic acid excretion in, 344
- fibroblast collagen production,  $\gamma$ -interferon and, 851
- interstitial lung disease in, 525
- linear, 555
- multiple sclerosis and, 124
- naifold capillary abnormalities in, 451
- naifold capillary microscopy in, 189
- organ involvement in, 451
- POEMS syndrome and, 233
- in Raynaud's phenomenon after limb immobilization, 1160
- Scleroderma-like phenotypes, mononuclear cells and, 54
- Scleromyxedema, systemic, mimics rheumatic diseases, 913



## Sclerosis

- in adult-type osteopetrosis, 926
- chest, in manubriosternal synovitis in psoriasis, 1029

## Secondary osteoarthritis, ARA criteria for, 1039

## Secretagogues, rheumatoid synovial mast cells and, 944

## Sensorineural deafness, phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880

## Septic arthritis

- in renal transplant patients, 227
- in urban Finnish children, 1232

## Septic bursitis, toxic shock syndrome and, 910

## Serine proteases in human OA synovium, 1112

## Seronegative polyarthritis, anti-HLA-B27 antibodies and, 352

## Seronegative spondylarthropathy in an Inuit population, 65

## Seropositive rheumatoid arthritis

- distal interphalangeal joint in, 10
- synovitis of knee and, dysprosium 165 in, 153

## Serum

- amyloid P, murine type II collagen arthritis and, 1131
- creatinine, MSU crystals in knee joint in gout and, 1480
- uric acid, MSU crystals in knee joint in gout and, 1480
- Sex, proteoglycan synthesis of fibrochondrocytes and, 1010
- Sex hormones

- female, in collagen-induced arthritis in mice, 1501
- steroid, debrisoquine oxidation phenotypes in SLE and, 843

## *Shigella flexneri*, anti-HLA-B27 antibodies and, 352

## Shoulder, OA of, Paget's disease and, 1414

## Sicca symptoms

- bronchiolitis in RA, auranofin and, 556
- CNS disease in primary Sjögren's syndrome and, 1226

## Sicca syndrome

- classification of Sjögren's syndrome and, 577
- IgM anti-histone H-3 antibody and, 39

## Single-stranded DNA (ssDNA), monoclonal cytoskeletal antibodies and, 1351

## Sjögren-like syndrome, $\kappa$ chain deficiency in, 1532

## Sjögren's syndrome

- anti-Ro (SS-A) and anti-La (SS-B) in, 196
- Beck test in diagnosis of xerostomia in, 936
- cryoglobulinemia in, 1098
- HLA and, in Japanese, 1518
- HLA-DR on salivary gland epithelial cells in, 1105
- primary

- C3b in, 857
- central nervous system disease in, 1223
- circulating monoclonal cryoglobulins in, 1098
- Darier's syndrome and, 1052
- immunoglobulin and rheumatoid factor synthesis in, 1446
- proposed ARA criteria for classification of, 577

## Skeletal muscle in POEMS syndrome, 286

## Skeleton

- axial human parvovirus arthropathy and, 575

## Skeleton (*cont'd*)

- proteoglycan synthesis of meniscal fibrochondrocytes and, 1010

## Skin

- animal model of antibody binding in cutaneous lupus and, 782
- crystal-associated arthropathy in hemodialysis and, 1387
- fibroblasts, effect of sodium selenite on chondrocytes and, 660
- food-induced arthritis and, 220
- in POEMS syndrome, 233
- scleroderma in Raynaud's phenomenon, immobilization and, 1160
- scleromyxedema and, 913

## Sleep, amitriptyline in

- naproxen and, in fibromyalgia, 1371
- primary fibrositis and, 655

## Sm antigen in mixed connective tissue disease and SLE, 986

## Small nuclear ribonucleoprotein (snRNP) U, in mixed connective tissue disease and SLE, 986

## Smoking, salicylate kinetics and, 971

## Social adaptation in RA, 1203

## Social Security Administration Survey of Disabled and Non-Disabled Adults, 1322, 1410

## Social support systems, arthritis self-management courses and, 388

## Sodium selenite, effect of on chondrocytes, 660

## South East Asia Pacific Area League, 929

## Spherulites, liposome-induced synovitis in rabbits and, 889

## Spine

- in adult-type osteopetrosis, 926
- cervical, spondylarthropathy in hemodialysis and, 301
- Spleen, macrophage activation in adjuvant arthritis and, 1122

## Splenomegaly, LS-2616 therapy of autoimmunity in MRL/l mice and, 1405

## Spondylarthropathy

- destructive, in hemodialysis, 301, 1171
- seronegative, in an Inuit population, 65

## Spondylitis, manubriosternal synovitis in psoriatic arthritis and, 1029

## *Staphylococcus aureus*

- aseptic arthritis in toxic shock syndrome and, 910
- in bacterial arthritis, 1378
- Cl<sub>s</sub>-C1 inhibitor complex in SLE and, 1467
- Cowan 1, B cell function in Behçet's disease and, 212
- phagocytosis and intracellular killing by PMN in RA and, 166

## Steroid drugs. *See also* Corticosteroid drugs; Glucocorticoid drugs

- low-dose oral methotrexate in Felty's syndrome and, 902
- neutral proteases in human OA synovium and, 1112
- pulmonary amyloidosis associated with SLE and, 680
- Steroid-induced immunosuppression, progressive multifocal leukoencephalopathy in SLE and, 337

- Stiffness, fibromyalgia pain syndrome and, 775
- Still's disease, adult-onset, HLA associations in, 415
- Stimulator cells, glycosaminoglycan stimulatory factor, cloned T cells and, 1071
- STR/IN mice, articular cartilage proteoglycans in OA, 95
- Streptococcal cell wall-induced arthritis, cyclosporin A in, 262
- Subchondral bone erosions, crystal-associated arthropathy in hemodialysis and, 1387
- Subchondral cystic lesions in rheumatoid nodulosis, 1278
- Subcutaneous adipose tissue, scleroderma in Raynaud's phenomenon, immobilization and, 1160
- Subcutaneous rheumatoid nodules in rheumatoid nodulosis, 1278
- Sucrose, immunoglobulin and interferon release in SLE and, 326
- Sulfasalazine in RA, 1427
- Sulfates, glycoprotein and, in OA articular cartilage, 1256
- Sulindac in RA, 620
- Superoxide dismutase, cartilage destruction and, 379
- Superoxides  
ferritin-bound iron in RA and, 1187  
macrophage activation in adjuvant arthritis and, 1122  
MSU-induced, polymorphonuclear cell lysis and, 1473
- Suppressor cells, Ig and RF synthesis in Sjögren's syndrome and, 1446
- Surgery  
cost-effectiveness of total joint arthroplasty in OA and, 937  
myectomy and tendotomy-induced OA and, 251  
in RA, 614
- Swan-neck deformity in RA, 555
- Swelling  
aseptic arthritis in toxic shock syndrome and, 910  
fibronectin in inflammation and, 394  
joint, methotrexate and, in JRA, 801  
in murine type II collagen arthritis, 1131
- Synovial amyloidosis,  $\beta_2$ -microglobulin and, in hemodialysis, 453
- Synovial cell plasminogen activator, interleukin-1 induction of, 1078
- Synovial cells  
collagenase, rabbit genes for, 1301  
19S IgM rheumatoid factor avidity in, 722  
rheumatoid, histamine-stimulated PGE by, 160
- Synovial fibroblasts, human, urokinase-type plasminogen activator and, 1397
- Synovial fluid  
 $\alpha_2$ -macroglobulin-proteinase in, 319  
analysis of, 770  
aseptic arthritis in toxic shock syndrome and, 910  
complement activation and, 715, 1359  
crystal-associated arthropathy in hemodialysis and, 1387  
eosinophilia of, dermatographism and, 1147  
ferritin-bound iron in RA and, 1187  
IgA rheumatoid factor in, in RA, 1194
- Synovial fluid (*cont'd*)  
in infectious arthritis after renal transplantation, 227  
interleukin-1 chemotactic activity in, 461  
lipid microspherules, acute monarticular arthritis and, 1166  
liposome-induced synovitis in rabbits and, 889  
lymphocytes, methylprednisolone infusion therapy in RA and, 32  
mast cells in, histamine and, 956  
mononuclear cells and, 761, 1435  
MSU crystals in knee joint in gout and, 1480  
phagocytosis and intracellular killing by PMN by, in RA, 166  
RA, 319, 461  
rheumatoid factor synthesis of, gold therapy and, 480  
total lymphoid irradiation in intractable RA and, 16
- Synovial hypertrophy, neutral proteases in human OA synovium and, 1112
- Synovial-like membrane, formation of, after total hip replacement, 836
- Synovial lining, antigen-induced arthritis in mice and, 665
- Synovial mast cells in RA, 944
- Synovial membrane  
gold therapy, rheumatoid factor synthesis and, 480  
interleukin-1 lymphocyte chemotactic activity in RA and, 461  
liposome-induced synovitis in rabbits and, 889  
rheumatoid, HLA-DR staining of, 600  
synovial fluid, ferritin-bound iron in RA and, 1187
- Synovial pannus, neovascularization in RA and, 471
- Synovial stroma, antigen-induced arthritis in mice and, 665
- Synovial tissue  
anti-type II collagen monoclonals and, in RA and OA, 730  
complement activation in JRA and, 1359  
gold-induced macrophage collagenase and, 75  
neovascularization in RA and, 471
- Synovitis  
collagen-induced arthritis, type II, in mice and, 400  
crystal-associated arthropathy in hemodialysis and, 1387  
cyclosporin A in streptococcal cell wall arthritis and, 262  
eosinophilic, dermatographism and, 1147  
hereditary joint disorder in ank/ank mice and, 114  
hip, transient, in urban Finnish children, 1232  
liposome-induced, in rabbits, 889  
manubriosternal, in psoriatic arthritis, 1029  
in monarticular JRA, 47  
rheumatoid  
of knee, intraarticular dysprosium 165 in, 153  
sulfasalazine in, 1427  
in toxic shock syndrome, 910
- Synovium  
bony fragments in, in metacarpophalangeal OA, 1284  
crystal-associated arthropathy in hemodialysis and, 1387  
human OA, neutral proteases in, 1112  
macrophage activation in adjuvant arthritis and, 1122  
neovascularization in RA and, 471

### Synovium (*cont'd*)

- rheumatoid synovial mast cells and, 944
- Systemic lupus erythematosus. *See also* Central nervous system lupus; Cutaneous lupus; Drug-induced lupus erythematosus; Idiopathic systemic lupus erythematosus; Lupus; Maternal systemic lupus erythematosus; Neonatal lupus
- acetylator phenotype in, 508, 1412
- anticardiolipin antibodies in, 1295
- anti-DNA in, 1417
- anti-DNA antibody production by DNA-daunorubicin in, 1216
- antinuclear antibodies in, 457
- anti-P antibody in, 981
- antiphospholipid antibodies in, 1535
- antiribosomal P protein antibody in, 981
- anti-T cell autoantibodies in, 646
- autoantibodies in cerebrospinal fluid in, 1090
- Bf polymorphisms in, 932
- central nervous system disease in, 1223
- chorea in, 1535
- coexistent multiple myeloma and, 933
- complement activation during, 1085
- complement receptors in, 739
- concurrent subacute cutaneous LE, RA and, 421
- congenital cytomegalovirus infection and, 1402
- contraceptives, oral, in, 1535
- cryoglobulinemia in, 1098
- debrisoquine oxidation phenotypes in, 843
- disease activity in, 501
- DNA-anti-DNA immune complexes in, 1417
- DNA transition in, 638
- effects of total lymphoid irradiation on autoantibodies in, 26
- fetal loss and lupus anticoagulant in, 695
- $\gamma$ -interferon in, 1210
- handedness in, 419
- hypertension, lupus anticoagulant, and VDRL in, 147
- hypocomplementemia with low C1s-C1 inhibitor complex in, 1467
- immunoglobulin and interferon release in, 326
- lupus anticoagulant in, 695, 1295
- lupus autoantigens in, 457
- maternal, 1269, 1402
- multiple myeloma coexisting with, 933
- myocardial infarction in, 1292
- naifold capillary microscopy in, 189
- neutrophils in, 1334
- oncogenes in, 755
- oral contraceptives in, 1535
- pentoxifylline in Raynaud's phenomenon in, 1055
- progressive multifocal leukoencephalopathy complicating, 337
- proto-oncogenes in, 755
- pulmonary amyloidosis associated with, 680
- retinopathy and disease activity in, 1152

### Systemic lupus erythematosus (*cont'd*)

- Sm antigen in, 986
- snRNP in, 986
- T cells in, 185, 646, 1023
- type C retroviruses, T cell leukemia and, 185
- Systemic mastocytosis, histamine in synovial fluid mast cells and, 956
- Systemic necrotizing granulomatous vasculitis, Wegener's granulomatosis in elderly and, 1157
- Systemic onset juvenile rheumatoid arthritis, methotrexate in, 801
- Systemic scleromyxedema mimicking rheumatic diseases, 913
- Systemic sclerosis. *See also* Progressive systemic sclerosis; Scleroderma
- alpha<sub>1</sub>-antitrypsin phenotypes in, 586
- anticardiolipin antibodies in, 1052
- interstitial lung disease in, 525
- multiple sclerosis and, 124
- naifold capillary microscopy in, 189
- null alleles at C4A locus in, HLA antigens and, 1274
- pulmonary hypertension in CREST syndrome and, 515

### T

#### T cells

- activation of, methylprednisolone in RA and, 32
- Aschoff lesions in rheumatic myocarditis and, 207
- autoantibodies to U1 RNP in connective tissue disease and, 1343
- B cell function in Behçet's disease and, 212
- capping mechanism of, in SLE, 646
- cloned, glycosaminoglycan stimulatory factor and, 1071
- cyclosporin A, streptococcal cell wall arthritis and, 262
- DNA-daunorubicin, anti-DNA antibodies and, in SLE, 1216
- female sex hormones in collagen-induced arthritis and, 1501
- function of, in SLE, 646
- IgG synthesis in Sjögren's syndrome and, 1446
- IgM rheumatoid factor, *Staphylococcus aureus* Cowan I and, 1440
- interleukin-1 chemotactic activity in RA and, 461
- interleukin-2 in Behçet's disease and, 371
- lymphocytosis of, in RA, 675
- monarticular JRA and, 47
- proto-oncogenes in SLE and autoimmune diseases and, 755
- receptors for, in SLE, 1023
- total lymphoid irradiation in intractable RA and, 16
- T3, T4, T8 surface antigens in SLE, 646
- Takatsuki syndrome, reversible multisystem plasma cell dyscrasia, 1534
- Telangiectasias
- colonic, in progressive systemic sclerosis, 282
- in scleromyxedema, 913

- Tender points, amitriptyline and naproxen in fibromyalgia and, 1371
- Tenderness, joint, methotrexate and, in JRA, 801
- Tendotomy-induced osteoarthritis, 251
- Tenosynovitis, crystal-associated arthropathy in hemodialysis and, 1387
- Terminal complement complex  
complement activation in JRA and, 1359  
in RA, 715
- Tetanus toxoid  
protein, type II collagen autoantibodies in RA and, 1316  
total lymphoid irradiation in SLE and RA and, 26
- Tetracycline, deposition of, in idiopathic familial acroosteolysis, 1032
- Thalidomide, neurotoxicity of, in RA, 1296
- Theophylline, IL-1 induction of synovial cell plasminogen activator and, 1078
- Thigh, in fibromyalgia, 775
- Thioglycolate-elicited macrophages, gold sodium thiomalate and, 75
- Thrombocytopenia, gold-induced, intravenous gamma globulin in, 426
- Thrombocytopenic purpura, anticardiolipin antibodies, lupus anticoagulant and, 1295
- Thrombosis, tibial artery, gangrene and, in lupus vasculitis, 1291
- Thymocytes, interleukin-1 chemotactic activity in RA and, 461
- Thynäus, lupus-inducing drugs, B to Z DNA transition and, 638
- Tibia, in myectomy and tendotomy-induced OA, 255
- Tibial artery thrombosis, gangrene and, in lupus vasculitis, 1291
- Tibial cartilage, OA, monoclonal antibody analysis of, 863
- Tibial muscle, phosphates and, in primary fibromyalgia, 817
- Tissue  
articular, OA in metacarpophalangeal joint and, 1284  
damage to  
hydrogen peroxide-induced, 532  
oxygen radicals, cartilage destruction and, 379  
destruction of, oxygen free radicals, iron and, in RA, 1187  
eosinophilia, necrotizing systemic vasculitis and, 565  
human, proteoglycan after collagenase in cartilage and, 1248
- Tolmetin in RA, 620
- Tonsillar lymphoid cells, monoclonal cytoskeletal antibodies from, 1351
- Total joint arthroplasty, cost-effectiveness of, in OA, 937
- Total joint replacement  
cost of, 614  
of hip, prosthetic loosening after, 836  
of knee, in RA, 614
- Total lymphoid irradiation  
autoantibodies in SLE and RA and, 26  
in intractable RA, 16
- Toxic shock syndrome, aseptic arthritis in man with, 910
- Toxicity  
colchicine, 448  
gold, 450  
methotrexate, 822, 1289  
mucocutaneous, in RA after gold, HLA-Bw35 and, 303  
total lymphoid irradiation in intractable RA and, 16
- Transaminase, methotrexate in RA and, 822
- Trapezius muscle, phosphates and, in primary fibromyalgia, 817
- Trauma, monarthritis and, 1147, 1166
- Triamcinolone hexacetonide, intraarticular, in chronic arthritis in children, 997
- Trimethoprim-sulfamethoxazole, methotrexate in RA and, megaloblastic pancytopenia after, 133
- Trypsin, pyrophosphate release by rabbit chondrocytes and, 1485
- Tubular osteomalacia, renal, reflex sympathetic dystrophy syndrome and, 918
- Tumors  
amyloid, dialysis,  $\beta_2$ -microglobulin and, 1170  
cells of, macrophages in adjuvant arthritis and, 1122  
chondrosarcoma, dermatomyositis and, 813
- Tunicamycin, pyrophosphate release by rabbit chondrocytes and, 1485
- U
- U small nuclear ribonucleoproteins (U snRNP) in mixed connective diseases and SLE, 986
- U1 ribonucleoprotein (U1 RNP), autoantibodies to, in connective tissue disease, 1343
- Ulcerations, digital, pentoxifylline in Raynaud's phenomenon and, 1055
- Undifferentiated connective tissue disease. *See also* Connective tissue disease; Mixed connective tissue disease
- IgM anti-histone H-3 antibody and, 39
- Urate crystals  
lipoprotein, crystal-inflammatory cell interactions and, 363  
monosodium, in gout and, 1172
- Uric acid  
phosphoribosylpyrophosphate (PRPP) synthetase activity and, 880  
serum, MSU crystals in knee joint in gout and, 1480
- Urinary neopterin in RA, 1063
- Urine sediment in necrotizing systemic vasculitis, 565
- Urokinase-type plasminogen activator, human synovial fibroblasts and, 1397
- Uronic acid, cartilage and, 88, 379
- Uveitis, ocular and articular disease in JRA and, 797
- V
- Variable large speckles, IgM anti-histone H-3 antibody and, 39

Vascular complications, anticardiolipin, oral contraceptives and, 1294

Vascular damage, hydrogen peroxide-induced tissue damage and, 532

Vascular injury, complement activation during SLE and, 1085

Vascular tortuosity, retinopathy, disease activity and, in SLE, 1152

Vasculitis

- Churg-Strauss, 565, 1173
- eosinophilic, 565, 1173
- LS-2616 therapy of autoimmunity in MRL/l mice and, 1405
- lupus, tibial artery thrombosis and gangrene in, 1291
- necrotizing, 539, 565
- neuropathy in Churg-Strass syndrome and, 1173
- prednisone and, mortality in RA and, 706

Vasculopathy in PC  $\lambda$ MS syndrome, 286

Venography, intraosseous, in diagnosis of ischemic necrosis of bone, 1177

Venoocclusive disease, hypertension, lupus anticoagulant and, in SLE, 147

Ventricles, Aschoff lesions in rheumatic myocarditis and, 207

Vertebral artery, pseudoaneurysm of, cervical spine disease in RA and, 136

Viral arthritis after renal transplantation, 227

Viruses

- congenital cytomegalovirus infection in maternal SLE, 1402
- coxsackie B antibodies and, in juvenile dermatomyositis, 1365
- Epstein-Barr, complement receptors in SLE and, 739

Visual field testing, retinopathy, disease activity and, in SLE, 1152

Vivonex, food-induced arthritis and, 220

## W

Warfarin sodium, glutamic acid excretion in rheumatic diseases and, 344

Water-soluble gels in narrowfield nailfold capillary microscopy, 304

Wegener's granulomatosis

- in elderly, 1157
- necrotizing systemic vasculitis and, 565
- unusual manifestations of, 1527

Weight

- loss of, in scleromyxedema, 913
- salicylate kinetics and, 971

Western blot analysis

- to detect anti-P antibody in SLE, 981

White blood cells, complement activation in JRA and, 1359

Work

- cost-effectiveness of total joint arthroplasty in OA and, 937
- disability in musculoskeletal disease and, 1322, 1410

World Health Organization, 929

Wrist

- in adult-type osteopetrosis, 926
- OA in, in an Inuit population, 69
- in RA, 10, 614, 775

## X

Xanthine oxidase, cartilage destruction and, 379

Xenobiotics, debrisoquine oxidation phenotypes in SLE and, 843

Xerostomia

- classification of Sjögren's syndrome and, 577
- diagnosis of, Beck test and, 936

## Y

*Yersinia enterocolitica*, anti-HLA-B27 antibodies and, 352

Yvan, Doctor, father of Reiter's syndrome, 152



